淋巴瘤临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT04269902 / NCI-2020-00752

Testing Early Treatment for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

AI 简述这是一项III期试验，研究高危慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的早期治疗。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States，Canada
申办方: SWOG

正在招募 Phase 3

NCI NCT05675410 / NCI-2022-10845

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

AI 简述这是一项III期试验，比较标准疗法与Brentuximab Vedotin联合Nivolumab用于局限性霍奇金淋巴瘤。在美国和加拿大开展。

?

适用疾病: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
干预: 未列出
地点: United States，Canada
申办方: Children's Oncology Group

正在招募 Phase 3

NCI NCT05976763 / NCI-2023-03577

Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma

AI 简述这是一项III期试验，比较连续与间断使用泽布替尼用于老年未治套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3

NCI NCT06136559 / NCI-2024-01890

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

AI 简述这是一项III期试验，比较Nemtabrutinib与Ibrutinib或Acalabrutinib用于初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 3

NCI NCT06428019 / NCI-2024-09053

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项III期试验，评估Venetoclax联合Obinutuzumab或Acalabrutinib用于初治慢性淋巴细胞白血病患者的肿瘤溶解综合征风险，在美国、澳大利亚、法国、希腊等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 3

NCI NCT06615050 / NCI-2025-01040

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

AI 简述这是一项III期试验，比较他克莫司/甲氨蝶呤/芦可替尼与环磷酰胺/他克莫司/霉酚酸酯用于异基因造血干细胞移植后的移植物抗宿主病预防。

?

适用疾病: Chronic Myelogenous Leukemia (CML)；Chronic Myelomonocytic Leukemia (CMML)；Follicular Lymphoma
干预: 未列出
地点: United States
申办方: Incyte Corporation

正在招募 Phase 3

NCI NCT07220187 / NCI-2025-06717

Adding Pirtobrutinib to the Usual Treatment for People with Newly Diagnosed Richter Transformation, The PIRAMID Trial

AI 简述这是一项III期试验，在里氏转化患者中加用Pirtobrutinib至常规治疗。

?

适用疾病: Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma；Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma；Richter Syndrome
干预: 未列出
地点: United States
申办方: SWOG

正在招募 Phase 3

NCI NCT06846671 / NCI-2025-07449

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

AI 简述这是一项III期试验，比较BGB-16673与研究者选择的治疗方案用于既往经BTK和BCL2抑制剂治疗的CLL/SLL。

?

适用疾病: Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma；Recurrent Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: BeOne Medicines

正在招募 Phase 3

NCI NCT07321652 / NCI-2025-08923

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

AI 简述这是一项III期试验，研究Sonrotoclax联合Zanubrutinib用于未经治疗的CLL/SLL。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov NCT03647072

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

AI 简述这是一项III期试验，研究PPI和组胺拮抗剂作为化疗辅助用于淋巴瘤。

?

适用疾病: Lymphoma
干预: CHOP，CHOP Plus Lanzoprazole，CHOP Plus Famotidine
地点: Egypt
申办方: Sherief Abd-Elsalam

正在招募 Phase 3 生物制剂

ClinicalTrials.gov NCT04094311

Study of Out of Specification for Tisagenlecleucel

AI 简述这是一项III期试验，研究CTL019用于B细胞急性淋巴细胞白血病和弥漫大B细胞淋巴瘤。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Diffuse Large B-cell Lymphoma
干预: CTL019
地点: Canada，Japan
申办方: Novartis Pharmaceuticals

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04332822

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

AI 简述这是一项III期试验，比较R-mini-CHOP与R-pola-mini-CHP用于弥漫大B细胞淋巴瘤。

?

适用疾病: DLBCL；Diffuse Large B Cell Lymphoma
干预: R-pola-mini-CHP，R-mini-CHOP
地点: Australia，Denmark，Finland，Italy 等 3 个
申办方: Nordic Lymphoma Group

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04442412

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

AI 简述这是一项III期试验，研究泼尼松联合或不联合维生素D预处理用于老年弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma；Elderly Patients
干预: Vitamin D3 (Cholecalciferol)，RCHOP o R-miniCHOP at standard doses
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04638790

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

AI 简述这是一项III期试验，研究阿霉素、博来霉素、长春碱、达卡巴嗪化疗用于经典霍奇金淋巴瘤，在印度和俄罗斯等地开展。

?

适用疾病: Hodgkin Lymphoma, Adult
干预: Doxorubicin，Bleomycin，Vinblastine，Dacarbazine
地点: India，Russia
申办方: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

正在招募 Phase 3 药物放疗

ClinicalTrials.gov / NCI NCT04685616 / NCI-2023-06937

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

AI 简述这是一项III期试验，研究Brentuximab vedotin联合放疗用于早期霍奇金淋巴瘤，在美国、澳大利亚、比利时、加拿大等地开展。

?

适用疾病: Hodgkin Lymphoma；Classical Hodgkin Lymphoma；Stage IB Hodgkin Lymphoma
干预: Involved site radiotherapy，Doxorubicin，Bleomycin，Brentuximab vedotin
地点: United States，Australia，Belgium，Canada 等 8 个
申办方: University College, London

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT05045664

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

AI 简述这是一项III期试验，研究放疗联合抗CD20抗体用于早期滤泡性淋巴瘤。

?

适用疾病: Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
干预: Standard，Experimental，Standard，Experimental
地点: Germany
申办方: Heidelberg University

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT05595447

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

AI 简述这是一项II/III期试验，研究Brentuximab Vedotin用于复发/难治性霍奇金淋巴瘤，在墨西哥开展。

?

适用疾病: Hodgkin Lymphoma；Refractory Hodgkin Lymphoma；Relapsed Hodgkin's Disease, Adult
干预: Brentuximab Vedotin 50 MG [Adcetris]
地点: Mexico
申办方: Hospital Regional de Alta Especialidad del Bajio

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05645107

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

AI 简述这是一项III期试验，研究XEMBIFY联合标准医疗与安慰剂联合标准医疗，用于预防低丙种球蛋白血症和反复感染患者的感染，涉及B细胞慢性淋巴细胞白血病、多发性骨髓瘤和非霍奇金淋巴瘤等。

?

适用疾病: Hypogammaglobulinemia；Bacterial Infections；B-cell Chronic Lymphocytic Leukemia
干预: Xembify，Placebo
地点: United States，Bosnia and Herzegovina，Bulgaria，Croatia 等 4 个
申办方: Grifols Therapeutics LLC

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT05770037

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

AI 简述这是一项2/3期试验，研究Alectinib用于ALK阳性血液肿瘤或实体瘤，在英国开展。

?

适用疾病: Haematological Malignancy；Malignant Neoplasm；Lymphoproliferative Disorders
干预: Alectinib
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05820841

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

AI 简述这是一项III期试验，研究Acalabrutinib联合R-miniCHOP用于初治弥漫大B细胞淋巴瘤。在德国开展。

?

适用疾病: Large B-cell Lymphoma；Diffuse Large B Cell Lymphoma
干预: R-miniCHOP + Acalabrutinib，R-miniCHOP
地点: Germany
申办方: Universität des Saarlandes

正在招募 Phase 3 其他放疗

ClinicalTrials.gov NCT05929222

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

AI 简述这是一项III期试验，在意大利比较放疗单用或联合Obinutuzumab治疗早期滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphoma
干预: Radiotherapy，Radiotherapy plus Obinutuzumab
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT05947851 / NCI-2023-09679

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

AI 简述这是一项3期试验，比较Nemtabrutinib联合Venetoclax与VR用于复发难治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Leukemia, Lymphocytic, Chronic, B-Cell；Leukemia, Chronic Lymphocytic；Small-Cell Lymphoma
干预: Nemtabrutinib，Venetoclax，Rituximab
地点: United States，Argentina，Australia，Belgium 等 14 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov NCT05991388

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

AI 简述这是一项II/III期试验，研究Odronextamab等药物用于儿童和青少年复发难治性B细胞非霍奇金淋巴瘤，在澳大利亚、奥地利等地开展。

?

适用疾病: B-cell Non Hodgkin Lymphoma
干预: Odronextamab，Loncastuximab tesirine，Rituximab，Ifosfamide
地点: Australia，Austria，Belgium，Netherlands 等 3 个
申办方: University of Birmingham

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06006117

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

AI 简述这是一项III期试验，比较Mosunetuzumab联合来那度胺与标准治疗用于复发/难治性边缘区淋巴瘤。

?

适用疾病: Marginal Zone Lymphoma
干预: Mosunetuzumab (SC)，Rituximab (R)，Bendamustine，CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
地点: Belgium，France，Germany，Italy 等 1 个
申办方: The Lymphoma Academic Research Organisation

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06072131 / NCI-2024-00184

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

AI 简述这是一项III期试验，比较Belinostat或Pralatrexate联合CHOP与单独CHOP用于外周T细胞淋巴瘤。

?

适用疾病: Peripheral T Cell Lymphoma；Follicular Helper T-Cell Lymphoma；T-Cell Non-Hodgkin Lymphoma
干预: Belinostat Injection，Pralatrexate Injection，CHOP，COP
地点: United States，Canada，Germany，Hungary 等 6 个
申办方: Acrotech Biopharma Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06091254 / NCI-2024-00238

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

AI 简述这是一项III期试验，比较Odronextamab与利妥昔单抗联合化疗用于未经治疗的滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphoma (FL)；Grade 1 Follicular Lymphoma；Stage IV Follicular Lymphoma
干预: Odronextamab，Rituximab，Cyclophosphamide，Doxorubicin
地点: United States，Australia，Austria，Belgium 等 15 个
申办方: Regeneron Pharmaceuticals

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06091865 / NCI-2023-10035

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

AI 简述这是一项III期试验，比较Odronextamab联合化疗与Rituximab联合化疗用于未经治疗的弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-cell Lymphoma (DLBCL)；Diffuse Large B-Cell Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma
干预: Odronextamab，Rituximab，Cyclophosphamide，Doxorubicin
地点: United States，Australia，Austria，Belgium 等 16 个
申办方: Regeneron Pharmaceuticals

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06149286 / NCI-2024-03930

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

AI 简述这是一项III期试验，比较Odronextamab联合Lenalidomide与Rituximab联合Lenalidomide用于复发/难治性滤泡性淋巴瘤和边缘区淋巴瘤。

?

适用疾病: Relapsed/Refractory Follicular Lymphoma；Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)；Recurrent Grade 3a Follicular Lymphoma
干预: Odronextamab，Lenalidomide，Rituximab
地点: United States，Australia，Austria，Belgium 等 14 个
申办方: Regeneron Pharmaceuticals

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06220032 / NCI-2026-04106

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

AI 简述这是一项III期试验，研究Dexrazoxane预防蒽环类药物引起的心脏功能障碍用于弥漫大B细胞淋巴瘤，在荷兰开展。

?

适用疾病: DLBCL - Diffuse Large B Cell Lymphoma；High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements；Follicular Lymphoma
干预: Dexrazoxane，Rituximab，Cyclophosphamide，Doxorubicin
地点: Netherlands
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06284122

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

AI 简述这是一项III期试验，比较Mosunetuzumab联合Lenalidomide与抗CD20抗体+化疗用于滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphoma
干预: Mosunetuzumab，Lenalidomide，Rituximab，Obinutuzumab
地点: Austria，Belgium，France，Germany 等 3 个
申办方: The Lymphoma Academic Research Organisation

正在招募 Phase 3 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT06337318 / NCI-2024-02361

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

AI 简述这是一项III期试验，比较Rituximab和Mosunetuzumab用于低肿瘤负荷滤泡性淋巴瘤。

?

适用疾病: Classic Follicular Lymphoma；Follicular Lymphoma With Unusual Cytological Features；Follicular Lymphoma with Unusual Cytological Features
干预: Biospecimen Collection，Computed Tomography，Mosunetuzumab，Positron Emission Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06470451

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

AI 简述这是一项III期试验，在美国开展，比较外用HyBryte与安慰剂用于皮肤T细胞淋巴瘤。

?

适用疾病: CTCL/ Mycosis Fungoides；CTCL；Mycosis Fungoides
干预: Hypericin，Placebo
地点: United States
申办方: Soligenix

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06522737

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

AI 简述这是一项III期试验，比较Duvelisib与Gemcitabine或Bendamustine用于复发/难治性TFH表型淋巴结T细胞淋巴瘤，在比利时等地开展。

?

适用疾病: Lymphoma
干预: Duvelisib，Gemcitabine，Bendamustine
地点: Belgium，Czechia，Denmark，France 等 6 个
申办方: SecuraBio

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06561048 / NCI-2024-07003

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

AI 简述这是一项III期试验，比较Soquelitinib与标准治疗用于复发/难治性外周T细胞淋巴瘤。在美国等地开展。

?

适用疾病: Peripheral T-Cell Lymphoma, Not Otherwise Specified；Angioimmunoblastic T-cell Lymphoma；Follicular T-Cell Lymphoma
干预: Soquelitinib，Belinostat，Pralatrexate
地点: United States，Australia，Canada
申办方: Corvus Pharmaceuticals, Inc.

正在招募 Phase 3 药物其他手术/操作

ClinicalTrials.gov / NCI NCT06724237 / NCI-2024-06604

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

AI 简述这是一项III期试验，在美国和墨西哥开展，研究高剂量化疗联合自体干细胞移植用于外周T细胞淋巴瘤初始化疗后完全缓解患者。

?

适用疾病: Anaplastic Large Cell Lymphoma, ALK-Negative；Follicular Helper T-Cell Lymphoma；Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
干预: Autologous Hematopoietic Stem Cell Transplantation，Best Practice，Biospecimen Collection，Bone Marrow Aspiration
地点: United States，Mexico
申办方: Eastern Cooperative Oncology Group

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06756152

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

AI 简述这是一项II/III期试验，研究环磷酰胺、阿巴西普等预防儿童和青年血液肿瘤移植后GVHD。

?

适用疾病: Biphenotypic Acute Leukemia；Acute Lymphoblastic Leukemia；Myeloblastic Leukemia
干预: Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150
地点: Russia
申办方: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

正在招募 Phase 3 放疗

ClinicalTrials.gov / NCI NCT07029217 / NCI-2025-04559

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

AI 简述这是一项III期试验，比较两种剂量放疗用于B细胞淋巴瘤。

?

适用疾病: Follicular Lymphoma；Marginal Zone Lymphoma；Duodenal-Type Follicular Lymphoma
干预: Radiation (Standard)，Radiation (Very low dose)
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07104032 / NCI-2026-01488

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

AI 简述这是一项III期试验，比较Tirabrutinib与利妥昔单抗/替莫唑胺治疗复发难治原发中枢神经系统淋巴瘤，在美国开展。

?

适用疾病: Relapsed/Refractory Primary Central Nervous System Lymphoma；Recurrent Primary Central Nervous System Lymphoma；Refractory Primary Central Nervous System Lymphoma
干预: Tirabrutinib，Rituximab，Temozolomide
地点: United States
申办方: Ono Pharmaceutical Co., Ltd.

正在招募 Phase 3 生物制剂

ClinicalTrials.gov / NCI NCT07188558 / NCI-2026-00303

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

AI 简述这是一项III期试验，比较rondecabtagene autoleucel与研究者选择的CD19 CAR-T细胞治疗用于复发/难治性大B细胞淋巴瘤。

?

适用疾病: Large B-cell Lymphoma；Lymphoma, B-Cell；Relapsed Non-Hodgkin Lymphoma
干预: rondecabtagene autoleucel，axicabtagene ciloleucel，lisocabtagene maraleucel
地点: United States
申办方: Lyell Immunopharma, Inc.

正在招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov NCT07202052

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

AI 简述这是一项II/III期试验，研究抗生素或免疫球蛋白预防血液肿瘤感染。在澳大利亚等地开展。

?

适用疾病: Myeloma；Non-Hodgkin's Lymphoma；Leukemia
干预: Intravenous immunoglobulin，Trimethoprim / Sulfamethoxazole，Amoxicillin clavulanic acid，Intravenous immunoglobulin (IVIG)
地点: Australia
申办方: Monash University

正在招募 Phase 2, Phase 3 生物制剂

ClinicalTrials.gov NCT07202065

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

AI 简述这是一项II/III期试验，研究免疫球蛋白剂量用于血液肿瘤。在澳大利亚等地开展。

?

适用疾病: Myeloma；Non Hodgkin's Lymphoma；Leukemia
干预: Immune Globulin Intravenous
地点: Australia
申办方: Monash University

正在招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov NCT07202078

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

AI 简述这是一项II/III期试验，研究抗生素或免疫球蛋白起始用于血液肿瘤。在澳大利亚等地开展。

?

适用疾病: Myeloma；Non Hodgkin's Lymphoma；Leukemia
干预: Trimethoprim / Sulfamethoxazole，Immune Globulin Intravenous
地点: Australia
申办方: Monash University

正在招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov NCT07202091

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

AI 简述这是一项II/III期试验，研究免疫球蛋白停药或延长用于血液肿瘤。在澳大利亚等地开展。

?

适用疾病: Myeloma；Leukemia；Non Hodgkin's Lymphoma
干预: Trimethoprim Sulfamethoxazole，Amoxycillin/clavulanic acid，Immune Globulin Intravenous
地点: Australia
申办方: Monash University

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07342478

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

AI 简述这是一项3期试验，比较rocbrutinib与pirtobrutinib用于既往经共价BTK抑制剂治疗的复发/难治CLL/SLL。在美国开展。

?

适用疾病: CLL / SLL；CLL (Chronic Lymphocytic Leukemia)；CLL, Refractory
干预: Rocbrutinib，Pirtobrutinib
地点: United States
申办方: Newave Pharmaceutical Inc

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07479797

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

AI 简述这是一项III期试验，比较KITE-753与Axicabtagene Ciloleucel用于复发或难治性大B细胞淋巴瘤。

?

适用疾病: Relapsed or Refractory Large B-cell Lymphoma
干预: KITE-753，Axicabtagene Ciloleucel，Fludarabine，Cyclophosphamide
地点: United States，Australia
申办方: Kite, A Gilead Company

正在招募 Phase 2, Phase 3 生物制剂

ClinicalTrials.gov NCT07502118

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

AI 简述这是一项II/III期试验，研究Talikabtagene Autoleucel用于复发/难治性B细胞恶性肿瘤。

?

适用疾病: Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)；Relapsed/Refractory Non-Hodgkin Lymphoma；Diffuse Large B-Cell Lymphoma (DLBCL)
干预: Talikabtagene Autoleucel
地点: Turkey (Türkiye)
申办方: Health Institutes of Turkey

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07582432

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

AI 简述这是一项III期试验，研究Gamunex-C用于慢性淋巴细胞白血病、多发性骨髓瘤或非霍奇金淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
干预: Gamunex-C, 10% Injectable Solution
地点: United States
申办方: Grifols Biologicals, LLC

正在招募 Phase 2, Phase 3 生物制剂药物

ClinicalTrials.gov NCT07634471

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

AI 简述这是一项II/III期试验，研究MK-1045联合Rituximab用于滤泡性淋巴瘤，在美国等地开展。

?

适用疾病: Follicular Lymphoma
干预: MK-1045，Rituximab，Rituximab biosimilar，Bendamustine
地点: United States，Israel，Spain，Taiwan 等 1 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2

NCI NCT00441818 / NCI-2010-00951

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

AI 简述这是一项I/II期试验，研究TNX-650用于难治性霍奇金淋巴瘤。

?

适用疾病: Recurrent Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Tanox

正在招募 Phase 2

NCI NCT02495415 / NCI-2015-01195

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

AI 简述这是一项II期试验，研究静脉Fenretinide乳剂用于复发/难治性外周T细胞淋巴瘤。

?

适用疾病: Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma；Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: CerRx, Inc.

正在招募 Phase 2

NCI NCT03113500 / NCI-2017-00573

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with CD30-Positive Peripheral T-cell Lymphoma

AI 简述这是一项II期试验，研究Brentuximab Vedotin联合化疗用于CD30阳性外周T细胞淋巴瘤。

?

适用疾病: Intestinal T-Cell Lymphoma, NOS；Adult T-Cell Leukemia/Lymphoma；Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States，Canada
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT03418038 / NCI-2018-00057

Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia

AI 简述这是一项II期试验，研究抗坏血酸联合化疗用于复发难治性淋巴瘤、意义未明克隆性血细胞减少和慢性粒单核细胞白血病。

?

适用疾病: Double-Hit Lymphoma；Refractory Lymphoma；Recurrent Lymphoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 2

NCI NCT03516617 / NCI-2018-00591

Acalabrutinib with or without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Acalabrutinib联合或不联合Obinutuzumab用于早期慢性淋巴细胞白血病。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 2

NCI NCT03824483 / NCI-2019-01323

Zanubrutinib, Obinutuzumab, and Venetoclax in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Zanubrutinib、Obinutuzumab和Venetoclax用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Mantle Cell Lymphoma；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2

NCI NCT03922724 / NCI-2019-02842

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

AI 简述这是一项II期试验，研究异基因造血细胞移植用于外周T细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Refractory Anaplastic Large Cell Lymphoma；Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT04169737 / NCI-2019-06675

Acalabrutinib and Venetoclax with or without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，在美国研究Acalabrutinib和Venetoclax联合或不联合Obinutuzumab用于高危复发/难治性慢性淋巴细胞白血病。

?

适用疾病: Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma；Recurrent Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT04404088 / NCI-2020-01922

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

AI 简述这是一项II期试验，研究Acalabrutinib、来那度胺和利妥昔单抗用于CD20阳性III-IV级1-3a滤泡淋巴瘤，在美国开展。

?

适用疾病: Marginal Zone Lymphoma；Grade 3a Follicular Lymphoma；Stage III Grade 1 Follicular Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04329728 / NCI-2020-04547

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

AI 简述这是一项I/II期试验，在美国开展，研究AVM0703用于淋巴系统恶性肿瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: AVM Biotechnology Inc

正在招募 Phase 2

NCI NCT04249830 / NCI-2020-05892

Donor Stem Cell Transplant after TCR Alpha-Beta+ T Cells/CD19+ B Cell Depletion for the Treatment of Children and Young Adults with Malignant or Non-malignant Hematological Disorders

AI 简述这是一项II期试验，在美国研究TCRαβ+ T细胞/CD19+ B细胞去除后供体干细胞移植用于儿童恶性或非恶性血液疾病。

?

适用疾病: Childhood Myelodysplastic Syndrome with Excess Blasts；Childhood Myelodysplastic Syndrome with Low Blasts；Hematopoietic and Lymphoid Cell Neoplasm
干预: 未列出
地点: United States
申办方: Stanford Cancer Institute Palo Alto

正在招募 Phase 2

NCI NCT04644016 / NCI-2020-11789

Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders

AI 简述这是一项II期试验，研究克拉屈滨、氟达拉滨、白消安、环孢素-A用于儿童和年轻成人血液肿瘤的脐带血移植。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2

NCI NCT04745949 / NCI-2020-13888

PACIFIC: Primary Mediastinal large B-cell lymphoma treated with Antibody therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy

AI 简述这是一项2期试验，研究抗体疗法联合免疫化疗用于纵隔大B细胞淋巴瘤。

?

适用疾病: Stage I Mediastinal (Thymic) Large B-Cell Lymphoma；Stage II Mediastinal (Thymic) Large B-Cell Lymphoma；Stage III Mediastinal (Thymic) Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04588922 / NCI-2020-14192

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

AI 简述这是一项I/II期试验，研究SLS009用于血液恶性肿瘤，在美国和中国开展。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Lymphoma
干预: 未列出
地点: United States
申办方: Sellas Life Sciences Group

正在招募 Phase 1, Phase 2

NCI NCT04502394 / NCI-2021-00895

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

AI 简述这是一项I/II期试验，研究KRT-232联合Acalabrutinib用于复发/难治性DLBCL或CLL。在美国开展。

?

适用疾病: Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Chronic Lymphocytic Leukemia (CLL)；Recurrent Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Kartos Therapeutics, Inc.

正在招募 Phase 2

NCI NCT04803201 / NCI-2021-01380

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

AI 简述这是一项II期试验，研究Duvelisib或CC-486联合常规治疗用于外周T细胞淋巴瘤。

?

适用疾病: Follicular Helper T-Cell Lymphoma, Not Otherwise Specified；Peripheral T-Cell Lymphoma, Unclassifiable；Enteropathy-Associated T-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 2

NCI NCT05039073 / NCI-2021-01655

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors

AI 简述这是一项II期试验，研究Brentuximab Vedotin联合Nivolumab用于复发/难治性经典霍奇金淋巴瘤。

?

适用疾病: Recurrent Classical Hodgkin Lymphoma；Refractory Classical Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Emory University Hospital/Winship Cancer Institute

正在招募 Phase 2

NCI NCT04930653 / NCI-2021-03533

Extracorporeal Photopheresis and Mogamulizumab for the treatment of Erythrodermic Cutaneous T Cell Lymphoma

AI 简述这是一项II期试验，研究体外光分离置换联合Mogamulizumab用于红皮病性皮肤T细胞淋巴瘤。

?

适用疾病: Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8；Transformed Mycosis Fungoides
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT04941716 / NCI-2021-05947

Acalabrutinib in Combination with Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

AI 简述这是一项II期试验，研究Acalabrutinib联合Venetoclax用于复发难治性慢性淋巴细胞白血病。

?

适用疾病: Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma；Recurrent Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 1, Phase 2

NCI NCT04959175 / NCI-2021-07758

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

AI 简述这是一项I/II期试验，研究移植后环磷酰胺减量用于血液肿瘤老年或体弱患者，在美国开展。

?

适用疾病: Hematopoietic and Lymphoid Cell Neoplasm；Mature T-Cell and NK-Cell Neoplasm；Primary Myelofibrosis
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT04844528 / NCI-2021-08252

Niacinamide for the Treatment of Patients with Chronic Lymphocytic Leukemia with History of Non-melanoma Skin Cancer

AI 简述这是一项II期试验，研究烟酰胺用于有非黑色素瘤皮肤癌史的慢性淋巴细胞白血病患者。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Non-Melanoma Skin Cancer；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 2

NCI NCT04747236 / NCI-2021-08824

Azacitidine and Romidepsin for the Treatment of Relapse or Refractory Peripheral T-cell Lymphoma

AI 简述这是一项2期试验，研究Azacitidine和Romidepsin用于复发难治性外周T细胞淋巴瘤。

?

适用疾病: Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Primary Cutaneous Anaplastic Large Cell Lymphoma；Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
干预: 未列出
地点: United States
申办方: University of Virginia Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05110742 / NCI-2021-10898

iC9 CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Relapsed or Refractory T-cell Leukemia or Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

AI 简述这是一项I/II期试验，研究iC9 CD5 CAR NK细胞用于复发或难治T细胞白血病或淋巴瘤。

?

适用疾病: Recurrent Mycosis Fungoides and Sezary Syndrome；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT05183854 / NCI-2021-13373

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients with Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

AI 简述这是一项II期试验，研究肺炎球菌疫苗（PCV20和PPSV23）用于慢性淋巴细胞白血病相关免疫缺陷患者，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 2

NCI NCT05289687 / NCI-2021-13973

Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy

AI 简述这是一项II期试验，研究Daratumumab用于化疗难治性微小残留病灶阳性的T细胞急性淋巴细胞白血病。

?

适用疾病: Recurrent T Acute Lymphoblastic Leukemia；Refractory T Acute Lymphoblastic Leukemia；Recurrent T Lymphoblastic Lymphoma
干预: 未列出
地点: United States
申办方: ECOG-ACRIN Cancer Research Group

正在招募 Phase 2

NCI NCT05336812 / NCI-2022-01752

Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Acalabrutinib联合Venetoclax或Obinutuzumab用于初治慢性淋巴细胞白血病。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT05168930 / NCI-2022-02035

Zanubrutinib and Venetoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Zanubrutinib联合Venetoclax用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma；Recurrent Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 2

NCI NCT05388006 / NCI-2022-02068

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Acalabrutinib、Venetoclax和Durvalumab用于Richter转化。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Richter Syndrome；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT05327023 / NCI-2022-03436

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

AI 简述这是一项1/2期试验，研究供体淋巴细胞输注用于高危血液恶性肿瘤，在美国开展。

?

适用疾病: Aggressive B-Cell Non-Hodgkin Lymphoma；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05351593 / NCI-2022-03704

Lenalidomide with Tafasitamab for the Treatment of Relapsed Central Nervous System Diffuse Large B-cell Lymphoma

AI 简述这是一项I/II期试验，研究Lenalidomide联合Tafasitamab用于复发中枢神经系统弥漫大B细胞淋巴瘤。

?

适用疾病: Recurrent Central Nervous System Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
干预: 未列出
地点: United States
申办方: University of California San Francisco

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 2

NCI NCT04679012 / NCI-2022-05396

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

AI 简述这是一项II期试验，研究Polatuzumab Vedotin联合化疗用于Richter转化。

?

适用疾病: Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma；Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: NYP/Weill Cornell Medical Center

正在招募 Phase 1, Phase 2

NCI NCT05436418 / NCI-2022-05514

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

AI 简述这是一项1/2期试验，在United States开展，研究环磷酰胺联合西罗莫司和他克莫司用于预防移植物抗宿主病。

?

适用疾病: Refractory Chronic Myelomonocytic Leukemia (CMML)；Mature T-Cell and NK-Cell Neoplasm；Primary Myelofibrosis
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05470491 / NCI-2022-06140

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

AI 简述这是一项I/II期试验，研究减低强度单倍体相合造血干细胞移植后环磷酰胺、硼替佐米等预防移植物抗宿主病用于血液恶性肿瘤。

?

适用疾病: Recurrent T-Cell Prolymphocytic Leukemia；Recurrent B-Cell Prolymphocytic Leukemia；Recurrent Plasma Cell Neoplasm
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT05536349 / NCI-2022-07625

Combination Pirtobrutinib, Venetoclax, and Obinutuzumab for the Treatment of Untreated Chronic Lymphocytic Leukemia or Untreated, Recurrent, or Refractory Richter Transformation

AI 简述这是一项II期试验，研究Pirtobrutinib、Venetoclax和Obinutuzumab三药联合用于初治慢性淋巴细胞白血病或Richter转化。

?

适用疾病: Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia；Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT05600686 / NCI-2022-07762

Loncastuximab Tesirine and Rituximab followed by DA-EPOCH-R for Treating Patients with High-Risk Diffuse Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Loncastuximab Tesirine联合Rituximab用于高风险弥漫大B细胞淋巴瘤。

?

适用疾病: Double-Hit Lymphoma；Triple-Hit Lymphoma；High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT05672251 / NCI-2022-10312

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究Loncastuximab Tesirine和Mosunetuzumab用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma；Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma；Recurrent Transformed Chronic Lymphocytic Leukemia
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT04858256 / NCI-2023-02384

Pacritinib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

AI 简述这是一项II期试验，研究Pacritinib用于复发/难治性T细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent Sezary Syndrome；Refractory Sezary Syndrome；Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 2

NCI NCT05929612 / NCI-2023-05151

Response Adapted Ultra-Low Dose External Beam Radiation Therapy for Treatment of Marginal Zone Lymphoma

AI 简述这是一项II期试验，在美国研究超低剂量放疗用于边缘区淋巴瘤。

?

适用疾病: Marginal Zone Lymphoma；Stage I Marginal Zone Lymphoma；Stage II Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06013423 / NCI-2023-05598

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases

AI 简述这是一项II期试验，研究脐血移植联合环磷酰胺、氟达拉滨和全身照射用于高危血液疾病。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)；Chronic Myelogenous Leukemia (CML)
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 2

NCI NCT05872854 / NCI-2023-06140

Visible Light Activated Synthetic Hypericin Ointment for the Treatment of Patients with Mycosis Fungoides

AI 简述这是一项II期试验，研究可见光激活合成金丝桃素软膏用于蕈样肉芽肿患者。

?

适用疾病: Stage IA Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 2

NCI NCT06045247 / NCI-2023-07174

Epcoritamab in Combination with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-miniCVP) for Older, Unfit and Frail Patients or Anthracycline-Ineligible Patients with Diffuse Large B-Cell Lymphoma

AI 简述这是一项2期试验，研究Epcoritamab联合R-miniCVP用于不适合蒽环类药物的弥漫大B细胞淋巴瘤。在美国开展。

?

适用疾病: High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；High Grade B-Cell Lymphoma, Not Otherwise Specified
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05589896 / NCI-2023-08596

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

AI 简述这是一项I/II期试验，首次人体研究HLA部分或完全匹配的异体冻干死供者骨髓移植用于血液恶性肿瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Ossium Health, Inc.

正在招募 Phase 2

NCI NCT06028828 / NCI-2023-08957

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

AI 简述这是一项II期试验，调整预处理方案用于异基因造血干细胞移植治疗白血病和淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: UC Irvine Health/Chao Family Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06043674 / NCI-2023-09314

Glofitamab and Obinutuzumab with or without Polatuzumab Vedotin, Pirtobrutinib or Atezolizumab for the Treatment Richter's Transformation

AI 简述这是一项II期试验，研究Glofitamab单药或联合Polatuzumab Vedotin等用于Richter转化。在美国开展。

?

适用疾病: Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia；Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 2

NCI NCT06242834 / NCI-2024-00285

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following Autologous Stem Cell Transplantation (ASCT) or Chimeric Antigen Receptor (CAR) T-cell therapy in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma

AI 简述这是一项II期试验，研究Pembrolizumab和Tazemetostat用于B细胞非霍奇金淋巴瘤患者的治疗。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Northwestern University

正在招募 Phase 2

NCI NCT06285825 / NCI-2024-01736

Emapalumab for Improving Blood Cell Counts in Large B-cell Lymphoma Patients with Cytopenia after CAR T-Cell Therapy

AI 简述这是一项II期试验，研究Emapalumab用于改善CAR-T治疗后血细胞减少的大B细胞淋巴瘤患者的血细胞计数。

?

适用疾病: Recurrent Grade 3a Follicular Lymphoma；Recurrent High-Grade B-Cell Lymphoma；Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06442475 / NCI-2024-02289

Low Dose Mosunetuzumab for the Treatment of Patients with Indolent B-Cell Lymphoma

AI 简述这是一项II期试验，研究低剂量Mosunetuzumab用于惰性B细胞淋巴瘤。

?

适用疾病: Grade 1 Follicular Lymphoma；Stage IV Follicular Lymphoma；Stage II Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 2

NCI NCT06386315 / NCI-2024-03242

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

AI 简述这是一项II期试验，研究减量放疗用于惰性B细胞非霍奇金淋巴瘤，在美国等地开展。

?

适用疾病: Indolent B-Cell Non-Hodgkin Lymphoma；Recurrent Indolent B-Cell Non-Hodgkin Lymphoma；Refractory Indolent B-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 2

NCI NCT06333262 / NCI-2024-03573

Pirtobrutinib in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Pirtobrutinib联合Obinutuzumab用于慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 2

NCI NCT06453044 / NCI-2024-04429

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma

AI 简述这是一项II期试验，研究Mosunetuzumab和Polatuzumab Vedotin用于复发或难治滤泡性淋巴瘤。

?

适用疾病: Recurrent Grade 3a Follicular Lymphoma；Refractory Grade 1 Follicular Lymphoma；Refractory Grade 2 Follicular Lymphoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06466122 / NCI-2024-04627

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi

AI 简述这是一项II期试验，在美国开展，研究Pirtobrutinib联合维奈克拉用于对共价BTK抑制剂耐药的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06082947 / NCI-2024-05357

αβT Cell/CD19+ B Cell Depletion for Alternative Donor Stem Cell Transplant for Children and Young Adults with Hematologic Malignancies

AI 简述这是一项I/II期试验，研究αβT/CD19+B细胞清除异基因移植用于儿童和年轻成人血液恶性肿瘤，在美国开展。

?

适用疾病: Refractory Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Secondary Acute Myeloid Leukemia (AML)；Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: Nationwide Children's Hospital

正在招募 Phase 2

NCI NCT05800210 / NCI-2024-06014

Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers

AI 简述这是一项II期试验，研究造血祖细胞血细胞移植物用于儿童和年轻成人血液癌症，在美国开展。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Recurrent Juvenile Myelomonocytic Leukemia；Acute Lymphoblastic Leukemia (ALL)
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 2

NCI NCT06575686 / NCI-2024-06708

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

AI 简述这是一项II期试验，研究Epcoritamab和Tazemetostat用于治疗复发或难治性I-IIIa级滤泡性淋巴瘤。

?

适用疾病: Recurrent Grade 3a Follicular Lymphoma；Refractory Grade 1 Follicular Lymphoma；Refractory Grade 2 Follicular Lymphoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06542250 / NCI-2024-07237

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

AI 简述这是一项I/II期试验，研究AZD5492用于复发/难治性B细胞恶性肿瘤，在美国开展。

?

适用疾病: Recurrent Follicular Lymphoma；Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT06578624 / NCI-2024-07864

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究SA53-OS用于局部晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Metastatic Dedifferentiated Liposarcoma
干预: 未列出
地点: United States
申办方: Lamassu Bio Inc

正在招募 Phase 2

NCI NCT06300528 / NCI-2024-08420

Pemigatinib for the Treatment of Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

AI 简述这是一项II期试验，研究Pemigatinib用于复发难治B细胞非霍奇金淋巴瘤。

?

适用疾病: Refractory Marginal Zone Lymphoma；Refractory Nodal Marginal Zone Lymphoma；Recurrent Nodal Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 2

NCI NCT06569680 / NCI-2024-09737

Mosunetuzumab for the Treatment of Patients with Newly Diagnosed Extranodal Marginal Zone Lymphoma

AI 简述这是一项II期试验，研究Mosunetuzumab用于新诊断的结外边缘区淋巴瘤，在美国等地开展。

?

适用疾病: Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
干预: 未列出
地点: United States
申办方: University of Miami Miller School of Medicine-Sylvester Cancer Center

正在招募 Phase 2

NCI NCT06745076 / NCI-2024-09815

Personalized Reduction of Chemotherapy Intensity through ctDNA Evaluation for the Treatment of Patients with Advanced Hodgkin Lymphoma

AI 简述这是一项II期试验，通过ctDNA评估个体化降低化疗强度用于晚期霍奇金淋巴瘤。

?

适用疾病: Lugano Classification Stage III Hodgkin Lymphoma AJCC v8；Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8；Advanced Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 2

NCI NCT05025423 / NCI-2024-09879

Venetoclax and Rituximab for the Initial Treatment of Older Patients with Untreated Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Venetoclax联合Rituximab用于初治老年套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma
干预: 未列出
地点: United States
申办方: Johns Hopkins University/Sidney Kimmel Cancer Center

正在招募 Phase 2

NCI NCT06784726 / NCI-2024-10534

Odronextamab for the Treatment of Relapsed and Refractory Large B-cell Lymphomas before CAR-T

AI 简述这是一项II期试验，研究Odronextamab用于复发难治性大B细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent High-Grade B-Cell Lymphoma；Refractory High-Grade B-Cell Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 2

NCI NCT06760156 / NCI-2025-00073

Tafasitamab and Lenalidomide as First Salvage Therapy for Relapsed or Refractory Large B-Cell Lymphoma after Axicabtagene Ciloleucel

AI 简述这是一项II期试验，研究Tafasitamab联合来那度胺用于Axicabtagene Ciloleucel治疗后复发/难治大B细胞淋巴瘤。

?

适用疾病: Recurrent High-Grade B-Cell Lymphoma；Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Refractory High-Grade B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募 Phase 2

NCI NCT06863402 / NCI-2025-01256

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

AI 简述这是一项II期试验，研究Nemtabrutinib和Pembrolizumab用于Richter转化（弥漫大B细胞淋巴瘤亚型）。

?

适用疾病: Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma；Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma；Richter Syndrome
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2

NCI NCT06948786 / NCI-2025-02708

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

AI 简述这是一项II期试验，研究吡托布鲁替尼联合莫妥珠单抗用于复发/难治性1-3A级滤泡性淋巴瘤。在美国开展。

?

适用疾病: Grade 1 Follicular Lymphoma；Recurrent Follicular Lymphoma；Grade 3a Follicular Lymphoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 2

NCI NCT06849713 / NCI-2025-03732

Zanubrutinib, Obinutuzumab, and Sonrotoclax for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Zanubrutinib、Obinutuzumab、Sonrotoclax用于初治慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 2

NCI NCT06854653 / NCI-2025-05193

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

AI 简述这是一项II期试验，研究PTX 100用于复发/难治性皮肤T细胞淋巴瘤。

?

适用疾病: Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma；Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Prescient Therapeutics, Ltd.

正在招募 Phase 2

NCI NCT07218510 / NCI-2025-07205

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

AI 简述这是一项II期试验，研究Venetoclax、Obinutuzumab联合Epcoritamab用于未经治疗的慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07225985 / NCI-2025-07661

Pralatrexate with Bendamustine and Total-Body Irradiation followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究Pralatrexate联合Bendamustine及全身照射后供体干细胞移植用于复发/难治性T细胞非霍奇金淋巴瘤。

?

适用疾病: Recurrent T-Cell Non-Hodgkin Lymphoma；Refractory T-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 1, Phase 2

NCI NCT07052695 / NCI-2025-08486

Evaluating Mosunetuzumab for Clearance of Detectable Minimal Residual Disease for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTKi and/or BCL2i

AI 简述这是一项I/II期试验，研究Mosunetuzumab联合BTK抑制剂用于慢性淋巴细胞白血病微小残留病灶清除。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 2

NCI NCT07257055 / NCI-2025-08762

Acalabrutinib or Zanubrutinib and Rituximab Followed by Glofitamab and Maintenance Acalabrutinib or Zanubrutinib and Rituximab for the Treatment of High Risk Mantel Cell Lymphoma, WINDOW-4 Trial

AI 简述这是一项2期试验，研究阿卡替尼或泽布替尼联合利妥昔单抗后格罗菲他单抗维持用于套细胞淋巴瘤。在美国开展。

?

适用疾病: Mantle Cell Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT07293403 / NCI-2025-09029

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

AI 简述这是一项II期试验，在美国研究Duvelisib维持治疗用于外周T细胞淋巴瘤。

?

适用疾病: Follicular Helper T-Cell Lymphoma；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT07316010 / NCI-2025-09715

Lisocabtagene Maraleucel for the Treatment of Diffuse Large B-cell Lymphoma or High Grade B-cell Lymphoma

AI 简述这是一项II期试验，研究Lisocabtagene Maraleucel用于治疗弥漫大B细胞淋巴瘤或高级别B细胞淋巴瘤，在美国开展。

?

适用疾病: High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；High Grade B-Cell Lymphoma, Not Otherwise Specified
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07294677 / NCI-2026-01627

Capivasertib, Venetoclax, and Low-Intensity Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma, CAVALRY Trial

AI 简述这是一项I/II期试验，在美国开展，研究Capivasertib、Venetoclax和低强度化疗用于急性淋巴细胞白血病/淋巴母细胞淋巴瘤。

?

适用疾病: Early T Precursor Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募 Phase 4

NCI NCT07426484 / NCI-2026-03336

Cosibelimab for the Treatment of Special Populations with Advanced Cutaneous Squamous Cell Carcinoma, CosiMaster Trial

AI 简述这是一项IV期试验，研究Cosibelimab用于晚期皮肤鳞状细胞癌。

?

适用疾病: Recurrent Skin Squamous Cell Carcinoma；Locally Advanced Skin Squamous Cell Carcinoma；Unresectable Skin Squamous Cell Carcinoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT01371630 / NCI-2011-01123

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

AI 简述这是一项I/II期试验，研究Inotuzumab Ozogamicin联合化疗用于急性淋巴细胞白血病。

?

适用疾病: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1；B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Burkitt-Like Lymphoma With 11q Aberration
干预: Blinatumomab，Cyclophosphamide，Cytarabine，Dexamethasone
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT02332668 / NCI-2015-00528

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

AI 简述这是一项I/II期试验，研究Pembrolizumab用于儿童晚期实体瘤或淋巴瘤，在美国、巴西、法国、德国等地开展。

?

适用疾病: Melanoma；Lymphoma；Solid Tumor
干预: Pembrolizumab
地点: United States，Brazil，France，Germany 等 6 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT02393157 / NCI-2019-05721

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

AI 简述这是一项II期试验，研究Obinutuzumab联合ICE化疗用于复发/难治性CD20+成熟非霍奇金淋巴瘤。

?

适用疾病: Non-Hodgkin Lymphoma；Burkitt Lymphoma；Diffuse Large B-Cell Lymphoma
干预: Obinutuzumab，Liposomal ARA-C，Ifosfamide，Carboplatin
地点: United States
申办方: New York Medical College

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT02693535 / NCI-2017-00510

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

AI 简述这是一项II期试验，研究FDA已批准药物靶向肿瘤基因异常用于晚期实体瘤、非霍奇金淋巴瘤、多发性骨髓瘤。

?

适用疾病: Lymphoma, Non-Hodgkin；Multiple Myeloma；Advanced Solid Tumors
干预: Palbociclib，Sunitinib，Temsirolimus，Trastuzumab and Pertuzumab
地点: United States，Puerto Rico
申办方: American Society of Clinical Oncology

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT02727803 / NCI-2016-00584

Personalized NK Cell Therapy in CBT

AI 简述这是一项II期试验，研究NK-92细胞联合化疗用于急性白血病、慢性粒细胞白血病等。

?

适用疾病: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Acute Biphenotypic Leukemia；Acute Lymphoblastic Leukemia
干预: Allogeneic Natural Killer Cell Line NK-92，Anti-Thymocyte Globulin，Busulfan，Clofarabine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT02859402

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

AI 简述这是一项II期试验，在韩国开展，研究白消安、氟达拉滨预处理后异基因干细胞移植用于复发/难治T细胞、NK/T细胞淋巴瘤。

?

适用疾病: T-cell Non-Hodgkin Lymphoma；Lymphoma, Extranodal NK-T-Cell
干预: Busulfan，Fludarabine
地点: South Korea
申办方: Keimyung University Dongsan Medical Center

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT02877303 / NCI-2017-00596

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，在美国开展，研究Blinatumomab、Inotuzumab Ozogamicin联合化疗用于B急性淋巴细胞白血病、B淋巴母细胞淋巴瘤等。

?

适用疾病: B Acute Lymphoblastic Leukemia；B Lymphoblastic Lymphoma；Double-Hit Lymphoma
干预: Blinatumomab，Cyclophosphamide，Cytarabine，Dexamethasone
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT02974647 / NCI-2016-01850

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

AI 简述这是一项II期试验，研究Ruxolitinib用于复发或难治性T细胞或NK细胞淋巴瘤。

?

适用疾病: Lymphoma；T-Cell Non-Hodgkin Lymphoma；Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
干预: Ruxolitinib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT02981628 / NCI-2016-01494

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究Inotuzumab Ozogamicin用于复发难治CD22阳性B急性淋巴细胞白血病或B淋巴母细胞淋巴瘤年轻患者。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Recurrent B Lymphoblastic Lymphoma；Refractory B Acute Lymphoblastic Leukemia
干预: Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Calaspargase Pegol
地点: United States，Puerto Rico
申办方: Children's Oncology Group

正在招募 Phase 1, Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT03011814 / NCI-2016-02061

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

AI 简述这是一项I/II期试验，研究Durvalumab联合或不联合Lenalidomide用于复发难治皮肤或外周T细胞淋巴瘤。

?

适用疾病: Folliculotropic Mycosis Fungoides；Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma；Recurrent Mycosis Fungoides
干预: Durvalumab，Laboratory Biomarker Analysis，Lenalidomide
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03125642 / NCI-2017-01037

Auto Stem Cell Transplant for Lymphoma Patients

AI 简述这是一项II期试验，研究自体干细胞移植用于淋巴瘤，使用Etoposide等预处理方案。

?

适用疾病: Non-Hodgkin Lymphoma；Hodgkin Lymphoma；Refractory Central Nervous System Lymphoma
干预: Etoposide，BCNU，AraC，Melphalan
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03136146 / NCI-2018-01198

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

AI 简述这是一项II期试验，研究联合化疗用于复发难治性急性淋巴细胞白血病、淋巴母细胞淋巴瘤、伯基特淋巴瘤/白血病，在美国开展。

?

适用疾病: Recurrent Acute Lymphoblastic Leukemia；Recurrent Adult Lymphoblastic Lymphoma；Recurrent Burkitt Leukemia
干预: Bortezomib，Clofarabine，Cyclophosphamide，Dexamethasone
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT03161223

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

AI 简述这是一项I/II期试验，研究Durvalumab联合Pralatrexate、Romidepsin和口服5-阿扎胞苷用于T细胞淋巴瘤，在美国开展。

?

适用疾病: Lymphoma, T-Cell
干预: Durvalumab，Pralatrexate，Romidepsin，5-Azacitidine
地点: United States
申办方: University of Virginia

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03223610 / NCI-2018-03526

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

AI 简述这是一项I/II期试验，研究Venetoclax、Ibrutinib、Prednisone、Obinutuzumab用于复发/难治B细胞淋巴瘤。

?

适用疾病: Lymphoma；Non-Hodgkin Lymphoma；Diffuse Large B-Cell Lymphoma
干预: Venetoclax，Ibrutinib，Prednisone，Obinutuzumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT03258567 / NCI-2018-03584

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

AI 简述这是一项II期试验，研究Nivolumab用于EB病毒阳性淋巴增殖性疾病和淋巴瘤。

?

适用疾病: Epstein-Barr Virus Infections；Lymphoma；Lymphoproliferative Disorder
干预: Nivolumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03297606

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

AI 简述这是一项II期试验，研究Olaparib、Dasatinib、Nivolumab联合Ipilimumab、Axitinib用于多种实体瘤和血液肿瘤。

?

适用疾病: Lymphoma, Non-Hodgkin；Multiple Myeloma；Advanced Solid Tumors
干预: Olaparib，Dasatinib，Nivolumab plus Ipilimumab，Axitinib
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT03314974 / NCI-2017-02310

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

AI 简述一项II期试验，研究清髓性异基因造血干细胞移植用于急性白血病、淋巴瘤等血液疾病。

?

适用疾病: Acute Leukemia；Acute Myeloid Leukemia；Acute Lymphoblastic Leukemia
干预: HSCT with TBI Regimen，HSCT with Non-TBI Regimen
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03328078 / NCI-2018-00732

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

AI 简述一项I/II期试验，研究Emavusertib用于复发/难治性原发中枢神经系统淋巴瘤。

?

适用疾病: Relapsed Hematologic Malignancy；Refractory Hematologic Malignancy；Relapsed Primary Central Nervous System Lymphoma
干预: Emavusertib，Ibrutinib
地点: United States，Czechia，France，Israel 等 3 个
申办方: Curis, Inc.

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov NCT03356054

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

AI 简述一项I/II期试验，研究R-DHAP联合Brentuximab Vedotin用于CD30阳性弥漫大B细胞淋巴瘤。

?

适用疾病: DLBCL
干预: R-DHAP，Brentuximab Vedotin
地点: Netherlands
申办方: Stichting Hemato-Oncologie voor Volwassenen Nederland

正在招募 Phase 4 药物放疗

ClinicalTrials.gov NCT03500133

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

AI 简述这是一项IV期试验，研究低累积剂量化疗和减少放疗用于儿童霍奇金淋巴瘤。在阿根廷开展。

?

适用疾病: Pediatric Hodgkin's Disease
干预: No radiotherapy if CR at the end of chemotherapy.，Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.，Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.，IN 30Gy RT in case of PR at the end of chemotherapy
地点: Argentina
申办方: Hospital JP Garrahan

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03523975 / NCI-2019-01588

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

AI 简述这是一项I/II期试验，研究Venetoclax联合来那度胺和利妥昔单抗用于未经治疗的套细胞淋巴瘤。在美国开展。

?

适用疾病: Mantle Cell Lymphoma
干预: Venetoclax，Lenalidomide，Rituximab
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT03571568 / NCI-2018-02697

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

AI 简述这是一项I/II期试验，研究BI-1206联合Rituximab加或不加Acalabrutinib用于惰性B细胞非霍奇金淋巴瘤。

?

适用疾病: Indolent B-Cell Non-Hodgkin Lymphoma；Refractory Marginal Zone Lymphoma；Recurrent Follicular Lymphoma
干预: BI-1206，Rituximab，Acalabrutinib
地点: United States，Brazil，Germany，Poland 等 2 个
申办方: BioInvent International AB

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03587844 / NCI-2018-01543

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

AI 简述这是一项II期试验，研究Brentuximab vedotin不同剂量用于蕈样肉芽肿或Sezary综合征。

?

适用疾病: Mycosis Fungoides；Lymphomatoid Papulosis；Sezary Syndrome
干预: brentuximab vedotin
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT03618550 / NCI-2018-01802

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

AI 简述这是一项II期试验，研究pembrolizumab联合GVD用于复发或难治性霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma；Relapsed or Refractory Hodgkin Lymphoma；Recurrent Classical Hodgkin Lymphoma
干预: pembrolizumab，gemcitabine，vinorelbine，liposomal doxorubicin
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT03676504

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

AI 简述这是一项I/II期试验，研究CD19.CAR T细胞用于复发或难治性CD19+淋巴系统疾病。

?

适用疾病: Acute Lymphoblastic Leukemia, Adult；Acute Lymphoblastic Leukemia, Pediatric；Chronic Lymphocytic Leukemia
干预: CD19.CAR T Cells，Fludarabine，Cyclophosphamide
地点: Germany
申办方: University Hospital Heidelberg

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03681561 / NCI-2018-03321

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究纳武利尤单抗和芦可替尼用于复发或难治性经典型霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma；Recurrent Classical Hodgkin Lymphoma；Refractory Classical Hodgkin Lymphoma
干预: Ruxolitinib，Nivolumab
地点: United States
申办方: Veronika Bachanova

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03739502

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

AI 简述一项II期随机试验，研究高压氧改善脐血干细胞移植植入用于白血病等，在美国开展。

?

适用疾病: AML；NHL；Hodgkin Disease
干预: Hyperbaric oxygen
地点: United States
申办方: University of Rochester

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03758989 / NCI-2025-05685

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

AI 简述这是一项II期试验，研究PET指导治疗用于初治局限期弥漫大B细胞淋巴瘤。

?

适用疾病: DLBCL；Diffuse Large B-Cell Lymphoma
干预: Rituximab Prednisone，Cyclophosphamide，Doxorubicin，Vincristine
地点: United States
申办方: University of Rochester

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT03765177

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

AI 简述这是一项I/II期试验，研究CLIC-1901用于复发/难治CD19阳性血液肿瘤，在加拿大开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Non-Hodgkin's Lymphoma；Chronic Lymphocytic Leukemia
干预: CLIC-1901
地点: Canada
申办方: Ottawa Hospital Research Institute

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT03779854

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

AI 简述这是一项II期试验，研究去除初始T细胞预防儿童和年轻成人血液肿瘤移植后慢性移植物抗宿主病。

?

适用疾病: Acute Biphenotypic Leukemia；Acute Leukemia；Acute Leukemia of Ambiguous Lineage
干预: Total-Body Irradiation，Thiotepa，Fludarabine，Cyclophosphamide
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03852407

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

AI 简述这是一项II期试验，在比利时开展，比较Flu-Mel-PTCy与Flu-Mel-ATG预处理方案用于异基因造血干细胞移植。

?

适用疾病: Acute Myeloid Leukemia in Remission；Myelodysplastic Syndromes；Chronic Myeloid Leukemia in Remission
干预: Thymoglobulin，Melphalan，Fludarabine，Cyclophosphamid
地点: Belgium
申办方: University of Liege

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT03938987

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

AI 简述这是一项I/II期试验，研究自体CD19 CAR-T细胞用于复发难治侵袭性淋巴瘤或急性淋巴细胞白血病，在加拿大开展。

?

适用疾病: Relapsed Non Hodgkin Lymphoma；Relapsed Adult ALL；Relapsed Pediatric ALL
干预: autologous CD19-directed chimeric antigen receptor (CAR) T-cells
地点: Canada
申办方: University of Alberta

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04002947 / NCI-2019-04596

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Acalabrutinib联合DA-EPOCH-R或R-CHOP用于初治弥漫大B细胞淋巴瘤。

?

适用疾病: Non-Hodgkin's Lymphoma；Diffuse Large B-Cell Lymphoma；DLBCL
干预: DA-EPOCH，Rituximab，CHOP，Acalabrutinib
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04068597 / NCI-2022-05781

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

AI 简述这是一项I/II期试验，研究CCS1477用于血液恶性肿瘤，如急性髓系白血病。

?

适用疾病: Haematological Malignancy；Acute Myeloid Leukemia；Non Hodgkin Lymphoma
干预: CCS1477，Pomalidomide，Dexamethasone，Azacitidine
地点: United States，France，Spain，Sweden 等 1 个
申办方: CellCentric Ltd.

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04083495 / NCI-2019-06539

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

AI 简述这是一项II期试验，研究CD30 CAR-T细胞用于复发/难治性CD30+ T细胞淋巴瘤。

?

适用疾病: Peripheral T Cell Lymphoma；Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
干预: ATLCAR.CD30 T cells，Bendamustine，Fludarabine，Cyclophosphamide
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04094610 / NCI-2019-08056

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

AI 简述这是一项I/II期试验，研究Repotrectinib用于儿童和年轻成人ALK/ROS1/NTRK突变肿瘤。

?

适用疾病: Locally Advanced Solid Tumors；Metastatic Solid Tumors；Lymphoma
干预: Oral repotrectinib (TPX-0005)
地点: United States，Australia，Canada，Denmark 等 7 个
申办方: Turning Point Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04099966

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

AI 简述这是一项II期试验，研究αβT细胞和CD19+B细胞去除的异基因移植用于血液病。

?

适用疾病: Acute Leukemia；Severe Aplastic Anemia；Non-hodgkin Lymphoma
干预: alpha beta depletion
地点: United States
申办方: Mitchell Cairo

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04104776 / NCI-2020-01007

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

AI 简述这是一项I/II期试验，研究Tulmimetostat用于晚期实体瘤和淋巴瘤。

?

适用疾病: Advanced Solid Tumor；Diffuse Large B Cell Lymphoma；Lymphoma, T-Cell
干预: Tulmimetostat，Enzalutamide
地点: United States，France，Italy，Poland 等 3 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT04128072

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

AI 简述这是一项II期试验，研究Mogamulizumab联合全皮肤电子束治疗用于IB-IIB期皮肤T细胞淋巴瘤。在丹麦、法国等地开展。

?

适用疾病: Stage IB-IIB Cutaneous T-Cell Lymphoma
干预: Mogamulizumab，Total Skin Electron Beam Therapy (TSEB)，Mogamulizumab (subsequent cycles post TSEB)
地点: Denmark，France，Germany，Greece 等 3 个
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT04186520

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

AI 简述这是一项I/II期试验，研究CAR-20/19-T细胞用于复发难治B细胞恶性肿瘤。

?

适用疾病: Non Hodgkin Lymphoma (NHL)；Mantle Cell Lymphoma (MCL)；Chronic Lymphocytic Leukemia (CLL)
干预: 8/12-Day Production of Car-T Cells，8/12-Day Production of Cryopreserved Car-T Cells，12-Day Production of Car-T Cells
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04195633 / NCI-2019-07697

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

AI 简述这是一项II期试验，研究供体干细胞移植联合Treosulfan、氟达拉滨和全身照射用于血液恶性肿瘤。

?

适用疾病: Acute Leukemia；Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia
干预: Allogeneic Hematopoietic Stem Cell Transplantation，Cyclophosphamide，Cyclosporine，Filgrastim
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT04315324

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

AI 简述这是一项I/II期试验，研究OBI-3424用于复发性或难治性T细胞急性淋巴细胞白血病或淋巴瘤。

?

适用疾病: Recurrent T Acute Lymphoblastic Leukemia；Refractory T Acute Lymphoblastic Leukemia；Refractory T Lymphoblastic Lymphoma
干预: AKR1C3-activated Prodrug AST-3424，Biopsy Procedure，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04378647

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

AI 简述这是一项II期试验，研究维布妥昔单抗用于成人霍奇金淋巴瘤的二线治疗，在西班牙开展。

?

适用疾病: Hodgkin Lymphoma, Adult
干预: Induction with Brentuximab vedotin (BV)，Induction without Brentuximab Vedotin，Consolidation with Brentuximab Vedotin
地点: Spain
申办方: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04421560 / NCI-2020-06772

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

AI 简述这是一项I/II期试验，研究Pembrolizumab、Ibrutinib和Rituximab联合用于原发中枢神经系统淋巴瘤。

?

适用疾病: Primary Central Nervous System Lymphoma；Recurrent Cancer；Refractory Cancer
干预: Ibrutinib，Pembrolizumab，Rituximab
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 4 生物制剂

ClinicalTrials.gov NCT04460235

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

AI 简述这是一项IV期试验，评估PCV13+PPV23对比PREVENAR20的肺炎球菌疫苗接种方案，在法国开展。

?

适用疾病: Vaccine；Streptococcus Pneumoniae；Lymphoma, Non-Hodgkin
干预: Prevenar 13 + Pneumovax 23，PREVENAR20
地点: France
申办方: Poitiers University Hospital

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04484012 / NCI-2020-04550

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究CD19 CAR-T细胞联合Acalabrutinib用于复发难治套细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Acalabrutinib，CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04491370

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究自体干细胞移植后使用Polatuzumab vedotin用于B细胞和霍奇金淋巴瘤。

?

适用疾病: B-cell Lymphoma；Burkitt Lymphoma；Diffuse Large B Cell Lymphoma
干预: Polatuzumab vedotin
地点: United States
申办方: New York Medical College

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04496349 / NCI-2021-07729

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

AI 简述这是一项II期试验，研究APG-115单药或联合APG-2575用于复发/难治性T-PLL和NHL。在美国开展。

?

适用疾病: T-Prolymphocytic Leukemia；Non-Hodgkins Lymphoma；Recurrent T-Cell Prolymphocytic Leukemia
干预: APG-115，APG-2575
地点: United States
申办方: Ascentage Pharma Group Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04510636

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Pembrolizumab联合Bendamustine用于霍奇金淋巴瘤。在加拿大开展。

?

适用疾病: Classical Hodgkin Lymphoma；Relapsed Cancer；Refractory Cancer
干预: Pembrolizumab，Bendamustine Hydrochloride
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04544592 / NCI-2020-08490

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

AI 简述这是一项1/2期试验，在美国研究CD19CAR-T细胞用于儿童B-ALL和B-NHL。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；B-cell Non Hodgkin Lymphoma；Refractory Transformed Non-Hodgkin Lymphoma
干预: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04560322

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

AI 简述这是一项II期试验，研究Venetoclax联合Obinutuzumab加或不加Acalabrutinib用于复发/难治性慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Venetoclax，Obinutuzumab，Acalabrutinib
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04561206 / NCI-2020-05332

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Brentuximab Vedotin联合Nivolumab用于复发/难治性经典型霍奇金淋巴瘤。

?

适用疾病: Relapsed Classic Hodgkin Lymphoma；Recurrent Classical Hodgkin Lymphoma；Refractory Classical Hodgkin Lymphoma
干预: Brentuximab Vedotin，Nivolumab
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04587687 / NCI-2020-06645

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

AI 简述这是一项II期试验，研究Brentuximab Vedotin联合Bendamustine用于复发/难治滤泡性淋巴瘤。

?

适用疾病: Recurrent Follicular Lymphoma；Refractory Follicular Lymphoma；Grade 1 Follicular Lymphoma
干预: Bendamustine Hydrochloride，Brentuximab Vedotin
地点: United States
申办方: University of California, Davis

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT04626791

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究改良VR-CAP方案联合Acalabrutinib用于适合移植的套细胞淋巴瘤一线治疗，在美国开展。

?

适用疾病: Mantle Cell Lymphoma
干预: Acalabrutinib，Bortezomib，Cyclophosphamide，Cytarabine
地点: United States
申办方: Academic and Community Cancer Research United

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04669171 / NCI-2022-00695

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究EO2463联合Lenalidomide和Rituximab用于惰性非霍奇金淋巴瘤。

?

适用疾病: Follicular Lymphoma；Marginal Zone Lymphoma；Refractory Marginal Zone Lymphoma
干预: EO2463，lenalidomide，rituximab
地点: United States，France，Italy，Spain
申办方: Enterome

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04752826 / NCI-2023-10441

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

AI 简述这是一项1/2期试验，研究BI-1808单药或联合帕博利珠单抗用于晚期恶性肿瘤，包括卵巢癌、T细胞淋巴瘤等。

?

适用疾病: Advanced Malignancies；Ovarian Cancer；T-cell Lymphoma
干预: BI-1808，Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
地点: United States，Denmark，Hungary，Russia 等 3 个
申办方: BioInvent International AB

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04792489 / NCI-2021-08357

DALY II USA/ MB-CART2019.1 for DLBCL

AI 简述这是一项II期试验，在美国和加拿大研究zamtocabtagene autoleucel用于复发难治DLBCL。

?

适用疾病: Refractory Diffuse Large B Cell Lymphoma (DLBCL)；Relapsed Diffuse Large B Cell Lymphoma；High Grade B-cell Lymphoma (HGBCL)
干预: zamtocabtagene autoleucel (MB-CART2019.1)，Cyclophosphamide，Fludarabine，Bendamustine
地点: United States，Canada
申办方: Miltenyi Biomedicine GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04792502 / NCI-2023-10767

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

AI 简述这是一项II期试验，在美国研究Mosunetuzumab联合Lenalidomide一线治疗滤泡性和边缘区淋巴瘤。

?

适用疾病: Follicular Lymphoma；Marginal Zone Lymphoma；B-cell Lymphoma
干预: Mosunetuzumab，Lenalidomide
地点: United States
申办方: Brown University

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT04836507

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

AI 简述这是一项I/II期试验，研究CRC01用于复发难治性大B细胞淋巴瘤和B细胞急性淋巴细胞白血病。

?

适用疾病: Relapsed Large B-cell Lymphoma；Refractory Large B-cell Lymphoma；Diffuse Large B-cell Lymphoma (DLBCL)
干预: CRC01，Fludarabine，Cyclophosphamide
地点: South Korea
申办方: Curocell Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04837859

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Tislelizumab用于早期预后不良经典霍奇金淋巴瘤。

?

适用疾病: Classical Hodgkin Lymphoma
干预: Tislelizumab
地点: Germany
申办方: University of Cologne

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04838652

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Pembrolizumab联合挽救化疗用于首次复发难治经典霍奇金淋巴瘤。

?

适用疾病: Classical Hodgkin Lymphoma
干预: Pembrolizumab plus Chemotherapy (ICE or DHAP)
地点: Germany
申办方: University of Cologne

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT04840602

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

AI 简述这是一项II期试验，研究Venetoclax联合Rituximab用于Waldenstrom巨球蛋白血症/淋巴浆细胞淋巴瘤。

?

适用疾病: Lymphoplasmacytic Lymphoma；Waldenstrom Macroglobulinemia
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物基因治疗

ClinicalTrials.gov NCT04844866

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

AI 简述这是一项II期试验，比较MB-CART2019.1与标准治疗用于弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-cell Lymphoma
干预: MB-CART2019.1，Standard of Care
地点: Austria，Belgium，Croatia，Czechia 等 10 个
申办方: Miltenyi Biomedicine GmbH

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04851119 / NCI-2021-02852

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

AI 简述这是一项I/II期试验，研究Tegavivint用于复发或难治性实体瘤，包括淋巴瘤和硬纤维瘤。

?

适用疾病: Colorectal Carcinoma；Endometrial Carcinoma；Melanoma
干预: Biospecimen Collection，Dual X-ray Absorptiometry，Tegavivint，X-Ray Imaging
地点: United States
申办方: Children's Oncology Group

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04855695 / NCI-2021-08421

Avo In R/R And Previously Untreated MCL

AI 简述这是一项I/II期试验，研究Acalabrutinib联合Venetoclax和Obinutuzumab用于套细胞淋巴瘤，在美国开展。

?

适用疾病: Mantle Cell Lymphoma；Refractory Lymphoma；Recurrent Mantle Cell Lymphoma
干预: Acalabrutinib，Venetoclax，Obinutuzumab
地点: United States
申办方: Austin I Kim

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04870944 / NCI-2021-03150

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CBL0137用于复发/难治性实体瘤、CNS肿瘤和淋巴瘤。

?

适用疾病: Diffuse Midline Glioma, H3 K27-Altered；Metastatic Malignant Neoplasm in the Central Nervous System；Recurrent Diffuse Intrinsic Pontine Glioma
干预: Biospecimen Collection，Bone Marrow Aspirate，Bone Marrow Biopsy，Echocardiography Test
地点: United States，Australia
申办方: Children's Oncology Group

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04871607 / NCI-2021-03073

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

AI 简述这是一项II期试验，研究钇-90标记抗CD25单抗联合BEAM化疗用于复发/难治性霍奇金淋巴瘤。

?

适用疾病: Recurrent Hodgkin Lymphoma；Refractory Hodgkin Lymphoma
干预: Basiliximab，Carmustine，Cytarabine，Etoposide
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04889716

CAR-T Followed by Bispecific Antibodies

AI 简述这是一项II期试验，研究CAR-T后接双特异性抗体用于大B细胞淋巴瘤。

?

适用疾病: Large B-cell Lymphoma；DLBCL - Diffuse Large B Cell Lymphoma
干预: mosunetuzumab，glofitamab，obinutuzumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04906096 / NCI-2021-06092

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

AI 简述这是一项II期试验，研究Paxalisib用于复发或难治性原发中枢神经系统淋巴瘤。

?

适用疾病: Primary Central Nervous System Lymphoma；Non-Hodgkin Lymphoma of Extranodal Site；Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
干预: PAXALISIB
地点: United States
申办方: Lakshmi Nayak, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04915248

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

AI 简述这是一项II期试验，研究Daratumumab、硼替佐米和地塞米松联合治疗浆母细胞淋巴瘤，在意大利开展。

?

适用疾病: Plasmablastic Lymphoma
干预: Daratumumab，Bortezomib，Dexamethasone
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04920617

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究DPX-Survivac联合Pembrolizumab加或不加环磷酰胺用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Relapsed Diffuse Large B-cell Lymphoma；Refractory Diffuse Large B-cell Lymphoma
干预: DPX-Survivac，Pembrolizumab，CPA
地点: United States，Australia，Canada，France 等 6 个
申办方: ImmunoVaccine Technologies, Inc. (IMV Inc.)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04925609

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

AI 简述这是一项I/II期试验，研究Brigatinib用于ALK阳性ALCL、炎性肌纤维母细胞瘤等，在法国、荷兰开展。

?

适用疾病: Anaplastic Large Cell Lymphoma, ALK-Positive；Inflammatory Myofibroblastic Tumor；Other Solid Tumor
干预: Brigatinib
地点: France，Netherlands
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04935684

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

AI 简述这是一项II期试验，研究粪便微生物群移植用于异基因干细胞移植后的血液肿瘤。

?

适用疾病: Acute Leukemia in Remission；Myelodysplastic Syndromes；Myeloproliferative Syndrome
干预: Fecal Microbiota Transplantation
地点: France
申办方: University Hospital, Clermont-Ferrand

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04989803 / NCI-2021-10014

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

AI 简述这是一项I/II期试验，研究KITE-363或KITE-753用于复发难治B细胞淋巴瘤，在美国、澳大利亚等地开展。

?

适用疾病: Relapsed and/or Refractory B-cell Lymphoma；Recurrent B-Cell Non-Hodgkin Lymphoma；Refractory B-Cell Non-Hodgkin Lymphoma
干预: Cyclophosphamide，Fludarabine，KITE-363，KITE-753
地点: United States，Australia，Canada，Germany 等 2 个
申办方: Kite, A Gilead Company

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04998669 / NCI-2021-12482

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

AI 简述这是一项II期试验，研究Loncastuximab tesirine联合利妥昔单抗用于复发或难治性滤泡性淋巴瘤，在美国开展。

?

适用疾病: Follicular Lymphoma；Recurrent Grade 3a Follicular Lymphoma；Refractory Grade 1 Follicular Lymphoma
干预: Loncastuximab tesirine，Rituximab
地点: United States
申办方: Juan P. Alderuccio, MD

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT05031897 / NCI-2021-08882

Two Step Haplo With Radiation Conditioning

AI 简述这是一项II期试验，研究两步半相合移植联合全身照射用于多种血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Adult T-Cell Leukemia/Lymphoma
干预: Fludarabine，Total-Body Irradiation，Donor Lymphocyte Infusion，Cyclophosphamide
地点: United States
申办方: Thomas Jefferson University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05092451 / NCI-2021-12093

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

AI 简述这是一项I/II期试验，研究CAR.70工程化脐血NK细胞联合化疗用于复发/难治性血液肿瘤。

?

适用疾病: B-Cell Lymphoma；Myelodysplastic Syndromes (MDS)；Acute Myeloid Leukemia (AML)
干预: Cyclophosphamide，CAR.70/IL15-transduced CB-NK cells，Fludarabine phosphate
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05180097

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

AI 简述这是一项II期试验，比较Pembrolizumab联合Brentuximab Vedotin与GDP方案用于复发/难治性经典型霍奇金淋巴瘤，在澳大利亚和加拿大开展。

?

适用疾病: Hodgkin Lymphoma
干预: Gemcitabine，Dexamethasone，Cisplatin，Brentuximab vedotin
地点: Australia，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05230680

Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)

AI 简述这是一项I/II期试验，研究ACHOP用于T细胞淋巴瘤。

?

适用疾病: T Cell Lymphoma
干预: ACHOP
地点: South Korea
申办方: Won Seog Kim

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05245656

A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

AI 简述这是一项II期试验，比较RB/RBAC交替方案与RB方案用于老年套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma
干预: RB/RBAC alternating，RB
地点: South Korea
申办方: Kim, Seok Jin

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05249959

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

AI 简述这是一项II期试验，研究loncastuximab tesirine巩固治疗用于BTKi治疗后复发/难治套细胞淋巴瘤。

?

适用疾病: Relapsed Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))，Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT05253495 / NCI-2024-02183

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

AI 简述这是一项II期试验，研究放化疗联合靶向免疫治疗用于儿童淋巴瘤，包括霍奇金和非霍奇金淋巴瘤。

?

适用疾病: Non-hodgkin Lymphoma；Hodgkin Lymphoma；Burkitt-Like Lymphoma with 11q Aberration
干预: DOC Group B，Pv-COMRAD 1 and 2 Group B，Pv-R-CYM 1 and 2 Group B，DOC Group C
地点: United States
申办方: New York Medical College

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05256641 / NCI-2021-12421

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

AI 简述这是一项I/II期试验，研究Acalabrutinib维持治疗用于大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma；High-grade B-cell Lymphoma；Transformed Lymphoma
干预: Acalabrutinib
地点: United States
申办方: Jonsson Comprehensive Cancer Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05260957 / NCI-2022-06935

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

AI 简述这是一项II期试验，研究CAR-T细胞疗法、Mosunetuzumab和Polatuzumab用于复发/难治性侵袭性非霍奇金淋巴瘤。

?

适用疾病: Refractory Non-Hodgkin Lymphoma；Relapsed Non Hodgkin Lymphoma；Aggressive Non-Hodgkin Lymphoma
干预: Mosunetuzumab，Polatuzumab，CAR-T Cell Therapy
地点: United States
申办方: Lazaros Lekakis

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05281809

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

AI 简述这是一项II期试验，研究本地生产的CAR-T细胞用于B细胞淋巴瘤和B急性淋巴细胞白血病，在美国开展。

?

适用疾病: B-Cell Lymphoma；B Acute Lymphoblastic Leukemia；Diffuse Large B Cell Lymphoma
干预: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
地点: United States
申办方: John Lister

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05296070 / NCI-2022-05151

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

AI 简述这是一项II期试验，研究Loncastuximab tesirine用于复发/难治性边缘区淋巴瘤，在美国开展。

?

适用疾病: Marginal Zone Lymphoma；Refractory Marginal Zone Lymphoma；Refractory Nodal Marginal Zone Lymphoma
干预: Loncastuximab tesirine 150 µg/Kg，Loncastuximab tesirine 75µg/Kg
地点: United States
申办方: University of Miami

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov NCT05300282

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

AI 简述这是一项I/II期试验，研究Atezolizumab联合BEGEV方案用于复发或难治性霍奇金淋巴瘤，在意大利开展。

?

适用疾病: Relapsed or Refractory Hodgkin's Lymphoma
干预: Atezolizumab，BEGEV
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05313243 / NCI-2023-05152

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

AI 简述这是一项2期试验，在美国研究Pembrolizumab和Brentuximab vedotin用于复发难治T细胞淋巴瘤。

?

适用疾病: T-Cell Lymphoma；Recurrent Hepatosplenic T-Cell Lymphoma；Refractory Hepatosplenic T-Cell Lymphoma
干预: Brentuximab vedotin，Pembrolizumab
地点: United States
申办方: Yale University

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05326243

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

AI 简述这是一项1/2期试验，研究CD19 CAR-T细胞用于复发或难治性B细胞淋巴瘤，在台湾开展。

?

适用疾病: Diffuse Large B Cell Lymphoma；Primary Mediastinal Large B Cell Lymphoma；Large B-cell Lymphoma
干预: CD19-targeted chimeric antigen receptor T-cell
地点: Taiwan
申办方: Pell Bio-Med Technology Co., Ltd.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05338931

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

AI 简述这是一项I/II期试验，研究AT101（抗CD19 CAR-T细胞）用于复发/难治性B细胞非霍奇金淋巴瘤。在韩国开展。

?

适用疾病: B-cell Non Hodgkin Lymphoma
干预: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
地点: South Korea
申办方: AbClon

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT05346809

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

AI 简述这是一项II期试验，研究Isatuximab在干细胞采集和移植用于多发性骨髓瘤和淋巴瘤。

?

适用疾病: Lymphoma；Multiple Myeloma；Non-Hodgkin Lymphoma
干预: Isatuximab，Standard Procedures
地点: United States
申办方: Divaya Bhutani

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05355051 / NCI-2022-03778

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

AI 简述这是一项II期试验，研究Azacytidine联合Pembrolizumab用于复发/难治霍奇金淋巴瘤。

?

适用疾病: Hodgkin's Lymphoma；Refractory Acute Myeloid Leukemia (AML)；Recurrent Acute Myeloid Leukemia (AML)
干预: Azacytidine，Pembrolizumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05389293 / NCI-2022-04729

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

AI 简述这是一项II期试验，研究Mosunetuzumab单用或联合Zanubrutinib用于滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphoma；Lymphoma；Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8
干预: Mosunetuzumab，Zanubrutinib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05442515 / NCI-2022-05683

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

AI 简述这是一项I/II期试验，研究CD19/CD22双顺反子CAR-T细胞用于儿童和年轻成人复发/难治性B细胞恶性肿瘤。

?

适用疾病: B-NHL；B-Non Hodgkin Lymphoma；Acute Lymphocytic Leukemia
干预: CD19/CD22-CAR-transduced T cells，cyclophosphamide，fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05463263 / NCI-2023-10514

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

AI 简述这是一项I/II期试验，研究STP938用于复发难治性B细胞和T细胞淋巴瘤。

?

适用疾病: Lymphoma, B-Cell；Lymphoma, T-Cell；Recurrent T-Cell Non-Hodgkin Lymphoma
干预: STP938
地点: United States，France，United Kingdom
申办方: Step Pharma, SAS

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05464719 / NCI-2022-05750

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

AI 简述这是一项II期试验，研究Loncastuximab Tesirine作为CAR-T后部分缓解的大B细胞淋巴瘤的巩固治疗。

?

适用疾病: Large B-cell Lymphoma；Lymphoma；Recurrent High-Grade B-Cell Lymphoma
干预: Loncastuximab Tesirine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05475925 / NCI-2022-07922

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

AI 简述这是一项1/2期试验，研究DR-01用于大颗粒淋巴细胞白血病或细胞毒性淋巴瘤，在美国、澳大利亚、法国、德国等地开展。

?

适用疾病: LGLL - Large Granular Lymphocytic Leukemia；Primary Cutaneous Gamma-Delta T-Cell Lymphoma；Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma
干预: DR-01
地点: United States，Australia，France，Germany 等 5 个
申办方: Dren Bio

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05480449

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

AI 简述这是一项1/2期试验，研究自体huCART19 T细胞用于儿童B细胞急性淋巴细胞白血病，在美国开展。

?

适用疾病: B Cell Acute Lymphoblastic Leukemia (B-ALL)；B Lineage Lymphoblastic Lymphoma
干预: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
地点: United States
申办方: Stephan Grupp MD PhD

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05518383

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

AI 简述这是一项IV期试验，采用多药联合方案用于儿童和青少年B细胞成熟非霍奇金淋巴瘤，在俄罗斯开展。

?

适用疾病: Non-hodgkin Lymphoma,B Cell；Burkitt Lymphoma；Primary Mediastinal Lymphoma
干预: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate，Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine，Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine，Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
地点: Russia
申办方: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05529069 / NCI-2022-07498

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

AI 简述这是一项II期试验，研究吡托布替尼联合维奈托克用于复发/难治性套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma；Non Hodgkin Lymphoma；Hematologic Malignancy
干预: Pirtobrutinib，Venetoclax
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05583071

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

AI 简述这是一项II期试验，研究Tafasitamab、来那度胺、利妥昔单抗联合甲氨蝶呤用于原发性中枢神经系统淋巴瘤。

?

适用疾病: Non-Hodgkin Lymphoma
干预: Tafasitamab，Lenalidomide，Rituximab，Methotrexate
地点: Germany
申办方: University of Cologne

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05607420 / NCI-2023-02114

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究UCART20x22用于B细胞非霍奇金淋巴瘤。

?

适用疾病: B-cell Non-Hodgkin Lymphoma (B-NHL)；Refractory Double-Hit Lymphoma；Recurrent Double-Hit Lymphoma
干预: UCART20x22，CLLS52
地点: United States，France，Spain
申办方: Cellectis S.A.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05615636 / NCI-2022-09576

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

AI 简述这是一项II期试验，研究Mosunetuzumab、Polatuzumab、Tafasitamab、Lenalidomide用于复发B细胞非霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma；B-Cell Lymphoma；Relapsed B-cell NHL
干预: Mosunetuzumab，Polatuzumab vedotin，Tafasitamab，Lenalidomide
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT05633615 / NCI-2022-07930

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Axicabtagene Ciloleucel用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma；Grade 3b Follicular Lymphoma；Primary Mediastinal (Thymic) Large B-Cell Lymphoma
干预: Axicabtagene Ciloleucel，Biospecimen Collection，Computed Tomography，Cyclophosphamide
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05635162

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Zanubrutinib联合Rituximab用于惰性套细胞淋巴瘤，在英国开展。

?

适用疾病: Mantle Cell Lymphoma
干预: Zanubrutinib，Rituximab
地点: United Kingdom
申办方: University College, London

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05641428

Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL

AI 简述这是一项II期试验，比较现场生产的CAR T细胞ARI-0001与商业CAR T细胞Axi-cel用于复发/难治性大B细胞淋巴瘤，在荷兰开展。

?

适用疾病: NHL；DLBCL - Diffuse Large B Cell Lymphoma
干预: ARI-0001，Axi-cel
地点: Netherlands
申办方: University Medical Center Groningen

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05643742

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

AI 简述这是一项I/II期试验，研究CTX112用于复发或难治性B细胞恶性肿瘤，在美国和澳大利亚开展。

?

适用疾病: B-cell Lymphoma；Non-Hodgkin Lymphoma；B-cell Malignancy
干预: CTX112
地点: United States，Australia
申办方: CRISPR Therapeutics AG

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT05648019

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

AI 简述这是一项II期试验，研究CD19导向的嵌合抗原受体T细胞疗法用于复发/难治性B细胞白血病/淋巴瘤，在新加坡开展。

?

适用疾病: Lymphoblastic Leukemia；Lymphoblastic Leukemia in Children；Lymphoblastic Leukemia, Acute Adult
干预: Anti-CD19 CAR T-cells
地点: Singapore
申办方: KK Women's and Children's Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05658640

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究Trametinib联合地塞米松和化疗用于儿童复发/难治性血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预: Trametinib，Dexamethasone，Cyclophosphamide，Cytarabine
地点: Austria，Belgium，Denmark，Finland 等 11 个
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05674175

Co-administration of CART22-65s and huCART19 for B-ALL

AI 简述这是一项I/II期试验，联合使用CART22-65s和huCART19用于B细胞急性淋巴细胞白血病。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；B Lineage Lymphoblastic Lymphoma
干预: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)，Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
地点: United States
申办方: Stephan Grupp MD PhD

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT05680558

Photopheresis in Early-stage Mycosis Fungoides

AI 简述这是一项II期试验，研究体外光化学疗法用于早期蕈样肉芽肿。

?

适用疾病: Cutaneous T Cell Lymphoma；Mycosis Fungoides
干预: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis，THERAKOS® CELLEX photopheresis system
地点: United States
申办方: Columbia University

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT05681195

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

AI 简述这是一项II期试验，研究Zanubrutinib联合Pemetrexed用于复发难治性原发及继发中枢神经系统淋巴瘤。

?

适用疾病: Primary Central Nervous System Lymphoma；Secondary Central Nervous System Lymphoma；Relapsed Cancer
干预: Pemetrexed，Zanubrutinib，Autologous Stem Cell Transplant (ASCT)，Whole Brain Radiation Therapy (WBRT)
地点: United States
申办方: Baptist Health South Florida

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05702853 / NCI-2023-10201

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

AI 简述这是一项I/II期试验，在美国研究代谢优化的CD19 CAR-T细胞治疗用于复发/难治B细胞淋巴瘤。

?

适用疾病: B-cell Non Hodgkin Lymphoma；Chronic Lymphocytic Leukemia；Recurrent Waldenstrom Macroglobulinemia
干预: Cyclophosphamide injection，Fludarabine Injection，CD19-CD34t metabolically programmed CAR transduced T-cells
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05735717 / NCI-2023-05517

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

AI 简述这是一项2期试验，研究TCRα/β去除的PBSC移植用于血液恶性肿瘤。

?

适用疾病: Hematologic Malignancy；Acute Leukemia；Remission
干预: Fludarabine，Busulfan，Melphalan，Rituximab
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05745714

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究芦可替尼联合维奈托克、地塞米松、环磷酰胺和阿糖胞苷用于复发难治性儿童血液恶性肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预: Ruxolitinib，Venetoclax，Dexamethasone，Cyclophosphamide
地点: Austria，Belgium，Denmark，Finland 等 10 个
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05751044

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究Dasatinib等药物用于儿童复发难治血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预: Dasatinib，Venetoclax，Dexamethasone，Cyclophosphamide
地点: Austria，Belgium，Denmark，Finland 等 10 个
申办方: Princess Maxima Center for Pediatric Oncology

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05757219 / NCI-2023-01299

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

AI 简述这是一项2期试验，研究Itacitinib预调节联合CAR-T治疗用于弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma；Diffuse Large B-Cell Lymphoma
干预: Itacitinib，Chimeric antigen receptor (CAR) T-cell therapy
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05783609 / NCI-2023-05084

Epcoritamab and Rituximab for First-line Follicular Lymphoma

AI 简述这是一项II期试验，研究Epcoritamab联合Rituximab一线治疗滤泡性淋巴瘤。在美国开展。

?

适用疾病: Follicular Lymphoma；Low Grade Non-Hodgkin's Lymphoma, Adult；Grade 1 Follicular Lymphoma
干预: Epcoritamab，Rituximab
地点: United States
申办方: Reid Merryman, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05800366 / NCI-2023-03106

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Glofitamab联合Polatuzumab-R-CHP用于高风险弥漫大B细胞淋巴瘤，在美国开展。

?

适用疾病: Lymphoma；Lymphoma, Large B-Cell, Diffuse；Double-Hit Lymphoma
干预: Glofitamab，Polatuzumab，Rituximab，Doxorubicin Hydrochloride
地点: United States
申办方: Jennifer Crombie, MD

正在招募 Phase 2 生物制剂药物放疗

ClinicalTrials.gov NCT05805605

Allo HSCT Using RIC and PTCy for Hematological Diseases

AI 简述这是一项II期试验，研究减低强度预处理和移植后环磷酰胺用于异基因造血干细胞移植治疗血液病。

?

适用疾病: Acute Myelogenous Leukemia；Acute Lymphocytic Leukemia；Biphenotypic Acute Leukemia
干预: Peripheral Blood Stem Cell Transplant，Allopurinol 300 MG，Fludarabine，Cyclophosphamide
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05826535 / NCI-2023-03746

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

AI 简述这是一项I/II期试验，研究Rondecabtagene autoleucel用于复发/难治性大B细胞淋巴瘤。

?

适用疾病: Relapsed Non-Hodgkin Lymphoma；Refractory Non-Hodgkin Lymphoma；Non-Hodgkin Lymphoma
干预: Rondecabtagene autoleucel (ronde-cel)，Fludarabine，Cyclophosphamide
地点: United States，Australia
申办方: Lyell Immunopharma, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05833724

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

AI 简述这是一项II期试验，研究Chidamide用于复发或难治性外周T细胞淋巴瘤。

?

适用疾病: Relapsed or Refractory Peripheral T-cell Lymphoma
干预: Chidamide
地点: Taiwan
申办方: Great Novel Therapeutics Biotech & Medicals Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05833763

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

AI 简述这是一项II期试验，研究Glofitamab和Pirtobrutinib用于既往BTK抑制剂暴露的套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma；Mantle Cell Lymphoma Refractory
干预: Glofitamab，Pirtobrutinib，Obinutuzumab，Tocilizumab
地点: Australia
申办方: Australasian Leukaemia and Lymphoma Group

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05848765

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

AI 简述这是一项2期试验，比较Epcoritamab与标准化疗用于复发滤泡性淋巴瘤。

?

适用疾病: Relapsed Follicular Lymphoma；Refractory Follicular Lymphoma
干预: Epcoritamab，Lenalidomide，Rituximab，Obinutuzumab
地点: United Kingdom
申办方: University of Birmingham

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05849857

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

AI 简述这是一项2期试验，研究Mosunetuzumab用于早期复发滤泡性淋巴瘤。在芬兰、挪威等地开展。

?

适用疾病: Lymphoma, Follicular
干预: Mosunetuzumab
地点: Finland，Norway
申办方: Oslo University Hospital

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05852717 / NCI-2023-04820

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

AI 简述这是一项2期试验，研究Epcoritamab联合GDP化疗用于复发难治大B细胞淋巴瘤。

?

适用疾病: Large Cell Lymphoma, Diffuse；Relapsed Cancer；Refractory Cancer
干预: AutoSCT OR CAR T-cell Therapy，GDP，Epcoritamab
地点: United States
申办方: Dipenkumar Modi

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05861050 / NCI-2023-03181

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

AI 简述这是一项I/II期试验，研究Glofitamab联合其他药物用于新诊断高危套细胞淋巴瘤，在美国开展。

?

适用疾病: Blastoid Variant Mantle Cell Lymphoma；Mantle Cell Lymphoma；Pleomorphic Variant Mantle Cell Lymphoma
干预: Biopsy，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05868395

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Polatuzumab、苯达莫司汀和利妥昔单抗用于复发/难治性套细胞淋巴瘤。

?

适用疾病: Mantle-cell Lymphoma
干预: Polatuzumab, bendamustin und rituximab
地点: Austria
申办方: Medical University of Vienna

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05873712 / NCI-2023-03669

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

AI 简述这是一项II期试验，研究Zanubrutinib联合Lisocabtagene Maraleucel用于Richter综合征，在美国开展。

?

适用疾病: Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia；Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
干预: Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Cyclophosphamide
地点: United States
申办方: Aseel Alsouqi

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05884333 / NCI-2023-04726

Cord Blood Transplant in Adults With Blood Cancers

AI 简述这是一项II期试验，研究脐血移植用于成人血液肿瘤，在美国开展。

?

适用疾病: Acute Myelogenous Leukemia (AML)；Acute Lymphoblastic Leukemia (ALL)；Chronic Myelogenous Leukemia (CML)
干预: Conditioning Chemotherapy，Cord blood graft
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 生物制剂其他手术/操作

ClinicalTrials.gov / NCI NCT05886036 / NCI-2023-04108

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

AI 简述这是一项II期试验，比较Rituximab与Mosunetuzumab用于结节性淋巴细胞为主型霍奇金淋巴瘤。

?

适用疾病: Nodular Lymphocyte Predominant B-Cell Lymphoma；Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma；Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
干预: Biopsy Procedure，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States，Canada
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05891821

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

AI 简述这是一项II期试验，研究Balstilimab用于复发/难治性淋巴瘤，在亚美尼亚开展。

?

适用疾病: Lymphoma
干预: Balstilimab
地点: Armenia
申办方: Immune Oncology Research Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05905328 / NCI-2023-09252

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

AI 简述这是一项I/II期试验，在美国研究CTO1681用于DLBCL患者CAR-T治疗后的CRS。

?

适用疾病: Cytokine Release Syndrome；Recurrent Diffuse Large B-Cell Lymphoma；Refractory Diffuse Large B-Cell Lymphoma
干预: CTO1681 10 μg，CTO1681 20 μg，CTO1681 30 μg
地点: United States
申办方: CytoAgents, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05907759 / NCI-2023-05088

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

AI 简述这是一项II期试验，在美国研究Daratumumab用于复发/难治原发渗出性淋巴瘤等。

?

适用疾病: Lymphoma, Primary Effusion；HHV8-Positive Multicentric Castleman Disease；Recurrent Primary Effusion Lymphoma
干预: Daratumumab SC
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05908409

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

AI 简述这是一项I/II期试验，在西班牙研究IDP-121用于复发/难治血液恶性肿瘤。

?

适用疾病: Multiple Myeloma (MM)；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Double Hit Lymphoma
干预: IDP-121
地点: Spain
申办方: IDP Discovery Pharma S.L.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05909059

CAR T-cell Therapy in Patients With Renal Dysfunction

AI 简述这是一项II期试验，在美国研究CAR-T细胞治疗用于肾功能不全的血液肿瘤。

?

适用疾病: Non-hodgkin Lymphoma,B Cell；Multiple Myeloma；Acute Lymphoblastic Leukemia, Adult
干预: Fludarabine，Cyclophosphamide
地点: United States
申办方: Northside Hospital, Inc.

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05910801 / NCI-2023-03968

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

AI 简述这是一项II期试验，在美国研究Tafasitamab、Lenalidomide和Venetoclax用于复发/难治套细胞淋巴瘤。

?

适用疾病: Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Biopsy，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: Academic and Community Cancer Research United

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05934448 / NCI-2023-08781

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

AI 简述这是一项II期试验，研究帕博利珠单抗联合CAR-T细胞疗法用于复发/难治性原发纵隔大B细胞淋巴瘤，在美国开展。

?

适用疾病: Primary Mediastinal Large B-cell Lymphoma (PMBCL)；Primary Mediastinal Large B Cell Lymphoma；Primary Mediastinal Large B-Cell Lymphoma Refractory
干预: Pembrolizumab，Lymphodepletion Chemotherapy，Chimeric Antigen Receptor (CAR) Therapy Infusion，Leukapheresis
地点: United States
申办方: Jennifer Crombie, MD

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05950165

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

AI 简述这是一项1/2期试验，研究CHO-H01单药或联合来那度胺用于复发或难治性非霍奇金淋巴瘤，在台湾开展。

?

适用疾病: Non-Hodgkin Lymphoma
干预: CHO-H01，CHO-H01 at RP2D，Lenalidomide
地点: Taiwan
申办方: Cho Pharma Inc.

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05952024 / NCI-2024-08888

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

AI 简述这是一项2期试验，研究阿卡替尼联合利妥昔单抗用于未经治疗的老年或体弱弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma；Stage II Diffuse Large B-Cell Lymphoma；Stage III Diffuse Large B-Cell Lymphoma
干预: Acalabrutinib，Rituximab
地点: United States，Brazil，Puerto Rico，South Korea 等 1 个
申办方: AstraZeneca

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05956041 / NCI-2023-10364

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

AI 简述这是一项II期试验，研究Pembrolizumab和Mogamulizumab用于晚期复发难治性皮肤T细胞淋巴瘤，在美国开展。

?

适用疾病: Cutaneous T Cell Lymphoma；Fungoides Mycosis Sezary Syndrome；Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
干预: Pembrolizumab，Mogamulizumab
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05977673

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

AI 简述这是一项II期试验，研究替雷利珠单抗一线用于不适合标准化疗的经典型霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma
干预: Tislelizumab
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05996185 / NCI-2025-01817

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

AI 简述这是一项II期试验，研究Mogamulizumab联合DA-EPOCH或CHOEP用于侵袭性T细胞淋巴瘤，在美国开展。

?

适用疾病: T Cell Lymphoma；T-cell Lymphoma；Aggressive T-Cell Non-Hodgkin Lymphoma
干预: Mogamulizumab，DA-EPOCH Protocol，CHOEP protocol
地点: United States
申办方: Yale University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05998642

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

AI 简述这是一项II期试验，研究Ibrutinib联合甲氨蝶呤和利妥昔单抗用于新诊断原发中枢神经系统淋巴瘤，在加拿大开展。

?

适用疾病: Non-hodgkin Lymphoma
干预: Methotrexate，Rituximab (where available)，Ibrutinib
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT06002659

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

AI 简述这是一项I/II期试验，研究CAR20(NAP)-T疗法用于B细胞淋巴瘤。

?

适用疾病: B-cell Lymphoma
干预: CAR20(NAP)-T，Cyclophosphamide，Fludarabine
地点: Sweden
申办方: Uppsala University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06029309 / NCI-2024-03607

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

AI 简述这是一项I/II期试验，研究Zanubrutinib联合Tafasitamab用于复发套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma；Recurrent Mantle Cell Lymphoma
干预: Zanubrutinib，Tafasitamab
地点: United States
申办方: Alvaro Alencar, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06043323 / NCI-2023-07173

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

AI 简述这是一项II期试验，研究Axicabtagene Ciloleucel联合放疗用于复发/难治性滤泡性淋巴瘤。在美国开展。

?

适用疾病: Follicular Lymphoma；Grade 1 Follicular Lymphoma；Recurrent Follicular Lymphoma
干预: Axicabtagene Ciloleucel，Cyclophosphamide，Fludarabine phosphate，Prednisone
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06045910

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

AI 简述这是一项1/2期试验，研究ALETA-001用于B细胞恶性肿瘤。在英国开展。

?

适用疾病: Lymphoma, Non-Hodgkin；Lymphoma, Large B-Cell, Diffuse；Lymphoma, Mantle-Cell
干预: ALETA-001
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06054776 / NCI-2023-06838

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

AI 简述这是一项II期试验，在美国开展，研究阿卡替尼、奥妥珠单抗和Glofitamab用于复发/难治性套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma；Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Acalabrutinib，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT06059391

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

AI 简述这是一项2期试验，研究CMV-MVA Triplex疫苗接种于HLA匹配的干细胞供者以预防移植后CMV感染。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Chronic Lymphocytic Leukemia
干预: Allogeneic Hematopoietic Stem Cell Transplantation，Biospecimen Collection，Granulocyte Colony-Stimulating Factor，Hematopoietic Cell Transplantation Conditioning Regimen
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06064903

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL

AI 简述这是一项I/II期试验，研究CD7-CART01用于儿童复发难治CD7+ T细胞急性淋巴细胞白血病/淋巴瘤。在意大利开展。

?

适用疾病: T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
干预: CD7-CART01
地点: Italy
申办方: Bambino Gesù Hospital and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06071871

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Polatuzumab vedotin、Obinutuzumab和Glofitamab用于大B细胞淋巴瘤的CAR-T治疗策略。在英国开展。

?

适用疾病: Large B-cell Lymphoma
干预: Glofitamab，Polatuzumab vedotin，Obinutuzumab
地点: United Kingdom
申办方: University College, London

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06090864 / NCI-2024-02015

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

AI 简述这是一项I/II期试验，研究ATLCAR.CD30.CCR4细胞用于CD30阳性霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma；Relapse；Refractory
干预: Chemotherapy，Cell infusion
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06101381

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

AI 简述这是一项I/II期试验，在巴西研究CD19靶向CAR-T细胞疗法用于复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤。

?

适用疾病: Leukemia, Acute Lymphoblastic；Lymphoma, Non-Hodgkin
干预: CART-19
地点: Brazil
申办方: University of Sao Paulo

正在招募 Phase 2 生物制剂放疗

ClinicalTrials.gov / NCI NCT06104592 / NCI-2023-09289

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

AI 简述这是一项II期试验，研究消融桥接放疗联合CD19 CAR-T用于高危复发难治大B细胞淋巴瘤，在美国开展。

?

适用疾病: Large B-cell Lymphoma；Relapsed Non-Hodgkin Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma
干预: Comprehensive Ablative Bridging Irradiation (CABI)，Chimeric Antigen Receptor T-Cell Therapy
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06119685 / NCI-2023-09842

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

AI 简述这是一项I/II期试验，研究IDP-023单药或联合抗体治疗用于晚期血液癌症。

?

适用疾病: NHL；Multiple Myeloma；Blood Cancer
干预: IDP-023，Rituximab，Daratumumab，Interleukin-2
地点: United States
申办方: Indapta Therapeutics, INC.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06160843

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

AI 简述这是一项II期试验，研究帕博利珠单抗联合奥拉帕利用于复发或难治性外周T细胞淋巴瘤，在新加坡开展。

?

适用疾病: Relapsed Peripheral T-Cell Lymphoma；Refractory Peripheral T-Cell Lymphoma
干预: Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
地点: Singapore
申办方: National Cancer Centre, Singapore

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06167785

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

AI 简述这是一项II期试验，研究Zanubrutinib联合Tislelizumab用于CAR-T治疗后进展的大B细胞淋巴瘤。

?

适用疾病: Large B-cell Lymphoma
干预: Tislelizumab，Zanubrutinib，Tislelizumab + Zanubrutinib
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06207123 / NCI-2024-08920

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

AI 简述这是一项1/2期试验，研究LP-118联合Ponatinib、Vincristine和Dexamethasone用于复发/难治性急性淋巴细胞白血病或淋巴母细胞淋巴瘤。

?

适用疾病: Acute Leukemia；Lymphoblastic Leukemia；Lymphoblastic Lymphoma
干预: LP-118，Ponatinib，Vincristine，Dexamethasone
地点: United States
申办方: University of Chicago

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06213311 / NCI-2024-00209

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

AI 简述这是一项2期试验，研究Axicabtagene Ciloleucel联合Glofitamab用于复发或难治性大B细胞淋巴瘤的二线治疗。

?

适用疾病: B Cell Lymphoma；Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma；Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
干预: Glofitamab，Obinutuzumab，Axi-cel
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂其他手术/操作

ClinicalTrials.gov / NCI NCT06238648 / NCI-2023-10170

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

AI 简述这是一项2期试验，研究Epcoritamab用于CD19 CAR-T治疗后未完全缓解的B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Primary Mediastinal Large B-Cell Lymphoma；Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
干预: Biopsy，Biospecimen Collection，Computed Tomography，Epcoritamab
地点: United States
申办方: Academic and Community Cancer Research United

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06249191 / NCI-2024-00070

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

AI 简述这是一项I/II期试验，研究Mosunetuzumab联合化疗用于未经治疗的C-Myc重排阳性高级别B细胞淋巴瘤或弥漫大B细胞淋巴瘤，在美国开展。

?

适用疾病: Diffuse Large B-Cell Lymphoma；High Grade B-Cell Lymphoma
干预: Biopsy，Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Computed Tomography
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 2 生物制剂器械药物

ClinicalTrials.gov / NCI NCT06252675 / NCI-2024-00054

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Glofitamab联合Pirtobrutinib用于复发或难治性套细胞淋巴瘤。在美国开展。

?

适用疾病: Mantle Cell Lymphoma；Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Obinutuzumab，Glofitamab，Pirtobrutinib，Tumor Imaging
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06263491 / NCI-2024-01325

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

AI 简述这是一项II期试验，研究Pirtobrutinib联合Rituximab用于未经治疗的套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma
干预: Rituximab，Pirtobrutinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06271057

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

AI 简述这是一项II期试验，研究Golcadomide用于CAR-T细胞治疗后复发/难治性大B细胞淋巴瘤高风险患者。

?

适用疾病: Diffuse Large B-cell Lymphoma Refractory；Refractory Primary Mediastinal Large B-Cell Lymphoma；Refractory Transformed B-cell Non-Hodgkin Lymphoma
干预: golcadomide
地点: France
申办方: The Lymphoma Academic Research Organisation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06287398

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

AI 简述这是一项II期试验，研究Epcoritamab联合方案用于复发大B细胞淋巴瘤。在澳大利亚开展。

?

适用疾病: DLBCL - Diffuse Large B Cell Lymphoma；High-grade B-cell Lymphoma；High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
干预: Epcoritamab
地点: Australia
申办方: Australasian Leukaemia and Lymphoma Group

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06343311 / NCI-2024-06803

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

AI 简述这是一项I/II期试验，研究EB103 T细胞疗法用于复发难治B细胞非霍奇金淋巴瘤，在美国开展。

?

适用疾病: B-Cell Non-Hodgkin's Lymphoma (NHL)；Lymphoma, Non-Hodgkins；Lymphomas Non-Hodgkin's B-Cell
干预: EB103
地点: United States
申办方: Estrella Biopharma, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06350318 / NCI-2024-03114

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

AI 简述这是一项II期试验，研究Zanubrutinib联合Rituximab用于惰性B细胞淋巴瘤。

?

适用疾病: Follicular Lymphoma；Marginal Zone Lymphoma；B-Cell Lymphoma
干预: Zanubrutinib，Rituximab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06357676 / NCI-2024-01208

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

AI 简述这是一项I/II期试验，研究Glofitamab联合Ibrutinib和Obinutuzumab用于套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma
干预: Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Echocardiography
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06364423 / NCI-2024-03377

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

AI 简述这是一项I/II期试验，研究抗CD19 CAR T细胞用于B细胞慢性淋巴细胞白血病、急性淋巴细胞白血病等，在美国开展。

?

适用疾病: Leukemia, Lymphocytic, Chronic, B-Cell；B-Lymphocytic Leukemia, Chronic；B-Cell Chronic Lymphocytic Leukemia
干预: Autologous HuCD19 ( Anti-CD19)CAR T cells，Cyclophosphamide，Fludarabine，Rituximab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06377540 / NCI-2024-03899

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Pembrolizumab联合BEAM方案及自体干细胞移植用于复发难治经典型霍奇金淋巴瘤。

?

适用疾病: Autologous Stem Cell Transplant；Classic Hodgkin Lymphoma；Recurrent Classical Hodgkin Lymphoma
干预: Pembrolizumab，Autologous stem cell transplant，Carmustine，Etoposide
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT06377566 / NCI-2024-03567

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

AI 简述这是一项II期试验，研究BV-AVD方案用于大肿块霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma；Stage IB Hodgkin Lymphoma；Stage IIB Hodgkin Lymphoma
干预: Brentuximab vedotin，Doxorubicin，Vinblastine，Dacarbazine
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06378190

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

AI 简述这是一项I/II期试验，研究CAR-T细胞疗法用于复发难治B细胞淋巴瘤。

?

适用疾病: Refractory B-Cell Lymphoma；B-cell Lymphoma Recurrent
干预: CAR-T cells therapy
地点: Spain
申办方: Instituto de Investigación Biomédica de Salamanca

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06390319

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

AI 简述这是一项II期试验，研究达沙替尼或维奈托克联合化疗用于新诊断的T细胞急性淋巴细胞白血病或淋巴瘤，在美国开展。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；T-cell Lymphoma；Mixed Phenotype Acute Leukemia
干预: Dexamethasone，Vincristine，Daunorubicin，Calaspargase pegol
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06390956 / NCI-2024-10109

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

AI 简述这是一项II期试验，研究Pirtobrutinib联合利妥昔单抗用于未经治疗的边缘区淋巴瘤，在美国开展。

?

适用疾病: Marginal Zone Lymphoma
干预: Pirtobrutinib，Rituximab
地点: United States
申办方: University of Utah

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06395103 / NCI-2024-04094

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

AI 简述这是一项I/II期试验，研究Zilovertamab vedotin用于儿童和年轻成人的血液恶性肿瘤或实体瘤。在美国、澳大利亚等地开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Diffuse Large B-cell Lymphoma；Burkitt Lymphoma
干预: Zilovertamab vedotin
地点: United States，Australia，Belgium，Brazil 等 19 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06414148

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究Epcoritamab或Epcoritamab联合来那度胺、利妥昔单抗用于CAR-T细胞治疗后大B细胞淋巴瘤，在澳大利亚开展。

?

适用疾病: Relapsed/Refractory Large B-cell Lymphoma
干预: Epcoritamab，Epcoritamab, lenalidomide and rituximab
地点: Australia
申办方: Peter MacCallum Cancer Centre, Australia

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06430736

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

AI 简述这是一项II期试验，比较预防性与按需使用托珠单抗用于CAR-T输注后骨髓瘤、淋巴瘤、白血病患者，在瑞士开展。

?

适用疾病: Myeloma；Lymphoma；Leukemia
干预: Tocilizumab before CAR-T cell infusion，Tocilizumab at emerging CRS
地点: Switzerland
申办方: Insel Gruppe AG, University Hospital Bern

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06458439 / NCI-2024-08153

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

AI 简述这是一项II期试验，在美国研究Epcoritamab用于大B细胞淋巴瘤。

?

适用疾病: Lymphoma, Non-Hodgkin；Relapsed Diffuse Large B Cell Lymphoma；Refractory Diffuse Large B-cell Lymphoma
干预: Epcoritamab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06482684

CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

AI 简述这是一项II期试验，研究KTE-X19联合Ibrutinib用于初治高危套细胞淋巴瘤，在德国开展。

?

适用疾病: Mantle Cell Lymphoma
干预: KTE-X19，Ibrutinib
地点: Germany
申办方: Christian Schmidt, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06484920

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

AI 简述这是一项II期试验，研究Pembrolizumab联合ATRA用于复发难治霍奇金淋巴瘤和B细胞非霍奇金淋巴瘤。

?

适用疾病: Relapsed Hodgkin Lymphoma；Refractory Hodgkin Lymphoma；Relapsed Non-Hodgkin Lymphoma
干预: ATRA，Pembrolizumab
地点: United States
申办方: Rita Assi

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT06486051

A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

AI 简述这是一项II期试验，研究WZTL-002 CAR T细胞用于复发难治大B细胞淋巴瘤。

?

适用疾病: Large B-cell Lymphoma；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Primary Mediastinal Large B-cell Lymphoma (PMBCL)
干预: Fludarabine，Cyclophosphamide，WZTL-002 CAR T-cells
地点: New Zealand
申办方: Malaghan Institute of Medical Research

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06492837

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

AI 简述这是一项II期试验，研究Mosunetuzumab联合Zanubrutinib用于复发/难治性滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphoma
干预: Mosunetuzumab in combination with Zanubrutinib
地点: Australia，Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06495723

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

AI 简述这是一项1/2期试验，研究LIS1用于外周T细胞淋巴瘤。

?

适用疾病: Peripheral T Cells Lymphoma (PTCL)
干预: LIS1
地点: France，Italy
申办方: Xenothera SAS

正在招募 Phase 2 器械药物基因治疗

ClinicalTrials.gov / NCI NCT06500273 / NCI-2024-06245

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

AI 简述这是一项II期试验，研究Cema-cel作为一线MRD阳性大B细胞淋巴瘤的巩固治疗，在美国、澳大利亚等地开展。

?

适用疾病: Large B-cell Lymphoma；High Grade B-Cell Lymphoma；Diffuse Large B-Cell Lymphoma
干预: cemacabtagene ansegedleucel，Fludarabine，Cyclophosphamide，Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
地点: United States，Australia，Canada，South Korea
申办方: Allogene Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

AI 简述这是一项II期试验，研究维生素A和D补充用于移植后白血病和淋巴瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Biphenotypic Acute Leukemia
干预: Vitamin A，Vitamin D3
地点: Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06510309 / NCI-2026-01688

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

AI 简述这是一项II期试验，研究利妥昔单抗联合维奈克拉用于一线边缘区淋巴瘤。

?

适用疾病: Lymphoma；Marginal Zone Lymphoma；MZL
干预: Venetoclax，Rituximab
地点: United States
申办方: Gottfried von Keudell, MD PhD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06510361 / NCI-2024-09808

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

AI 简述这是一项II期试验，研究Epcoritamab用于初始化疗未达完全缓解的滤泡性淋巴瘤。

?

适用疾病: Lymphoma；Follicular Lymphoma；Lymphoma,Non-Hodgkin
干预: Epcoritamab
地点: United States
申办方: Beth Israel Deaconess Medical Center

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06514794 / NCI-2025-00960

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

AI 简述这是一项II期试验，研究WU-CART-007用于T细胞急性淋巴细胞白血病和淋巴母细胞淋巴瘤，在美国和澳大利亚开展。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: WU-CART-007
地点: United States，Australia
申办方: Wugen, Inc.

正在招募 Phase 1, Phase 2 基因治疗

ClinicalTrials.gov NCT06533579

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

AI 简述这是一项I/II期试验，研究VNX-101用于CD19阳性血液恶性肿瘤，包括B细胞急性淋巴细胞白血病、大B细胞淋巴瘤等，在美国开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Large B-cell Lymphoma；Chronic Lymphocytic Leukemia
干预: Dose Level 1, VNX-101，Dose Level 2, VNX-101，Dose Level 3, VNX-101，Dose Level 4, VNX-101
地点: United States
申办方: Vironexis Biotherapeutics Inc.

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06534060 / NCI-2024-09507

MB-105 in Patients With CD5 Positive T-cell Lymphoma

AI 简述一项II期试验，研究MB-105用于CD5阳性T细胞淋巴瘤，在美国开展。

?

适用疾病: Lymphoma, T-Cell；Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma；Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
干预: Genetic: MB-105
地点: United States
申办方: March Biosciences Inc

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06534437

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

AI 简述一项II期试验，研究MEN1703联合Glofitamab用于复发/难治性侵袭性B细胞非霍奇金淋巴瘤。

?

适用疾病: Non-Hodgkin Lymphoma, B-cell
干预: MEN1703，Glofitamab
地点: France，Poland，Spain，United Kingdom
申办方: Ryvu Therapeutics SA

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06536049 / NCI-2024-05519

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究Epcoritamab联合Ibrutinib用于复发或难治性侵袭性B细胞非霍奇金淋巴瘤。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Recurrent Grade 3b Follicular Lymphoma；Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: Yazeed Sawalha

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06550141 / NCI-2024-07989

Emapalumab Prevention of CAR-T Cell Associated Toxicities

AI 简述这是一项II期试验，研究Emapalumab预防CAR-T细胞相关毒性用于大B细胞淋巴瘤，在美国开展。

?

适用疾病: Large B-cell Lymphoma；Relapsed Non-Hodgkin Lymphoma；Refractory Non-Hodgkin Lymphoma
干预: Emapalumab，Cyclophosphamide，Fludarabine Phosphate，Axicabtagene Ciloleucel
地点: United States
申办方: Marcela V. Maus, M.D.,Ph.D.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06552559

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究塞利尼索联合ICE化疗用于继发中枢神经系统受累的B细胞非霍奇金淋巴瘤，在韩国开展。

?

适用疾病: B-cell Lymphoma Recurrent；B-cell Lymphoma Refractory；CNS Metastases
干预: Selinexor
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06553872 / NCI-2024-06881

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

AI 简述这是一项II期试验，在美国开展，研究Pirtobrutinib和Brexucabtagene Autoleucel用于复发/难治套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma；Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Pirtobrutinib，Brexucabtagene Autoleucel
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06558604

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

AI 简述这是一项II期试验，研究Glofitamab联合Venetoclax加或不加泽布替尼用于高危套细胞淋巴瘤。在比利时、法国开展。

?

适用疾病: Lymphoma, Mantle-Cell
干预: Obinutuzumab，Glofitamab，Venetoclax Oral Product，Zanubrutinib Oral Capsule
地点: Belgium，France
申办方: The Lymphoma Academic Research Organisation

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06561074 / NCI-2024-06907

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

AI 简述这是一项II期试验，研究卡拉斯帕加酶、地西他滨联合维奈克拉用于复发/难治性T细胞急性淋巴细胞白血病和淋巴母细胞淋巴瘤。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；T-Cell Lymphoblastic Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: Decitabine，Venetoclax，Calaspargase pegol-mknl
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06563505 / NCI-2024-06965

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

AI 简述这是一项II期试验，研究Mosunetuzumab和Zanubrutinib用于复发/难治性边缘区淋巴瘤。

?

适用疾病: Lymphoma；Refractory Marginal Zone Lymphoma；Stage II Marginal Zone Lymphoma
干预: Mosunetuzumab，Zanubrutinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06563596 / NCI-2025-00568

Epco, Zanu, Ritux for R/R FL or MZL

AI 简述这是一项II期试验，研究Epcoritamab、Zanubrutinib和Rituximab用于复发/难治性滤泡性淋巴瘤或边缘区淋巴瘤。

?

适用疾病: Follicular Lymphoma；Lymphoma；Non-Hodgkin Lymphoma
干预: Zanubrutinib，Rituximab，Epcoritamab
地点: United States
申办方: Reid Merryman, MD

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06572618 / NCI-2024-06740

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Nemtabrutinib联合Rituximab用于套细胞淋巴瘤，在美国等地开展。

?

适用疾病: Mantle Cell Lymphoma
干预: Biospecimen Collection，Bone Marrow Biopsy，Nemtabrutinib，Positron Emission Tomography and Computed Tomography Scan
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06588478 / NCI-2025-02626

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Pirtobrutinib用于复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，在美国、澳大利亚、比利时、加拿大等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: Pirtobrutinib
地点: United States，Australia，Belgium，Canada 等 14 个
申办方: Loxo Oncology, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06630091 / NCI-2024-08417

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

AI 简述这是一项II期试验，研究Golidocitinib联合化疗用于新诊断外周T细胞淋巴瘤，在美国开展。

?

适用疾病: Peripheral T Cell Lymphoma；Follicular Helper T-Cell Lymphoma；Peripheral T-Cell Lymphoma, Unclassifiable
干预: Golidocitinib，Cyclophosphamide，Doxorubicin，Vincristine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06649812 / NCI-2024-08642

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

AI 简述这是一项II期试验，在美国研究ViPOR方案用于复发/难治性侵袭性B细胞淋巴瘤。

?

适用疾病: High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements；Recurrent Diffuse Large B-Cell Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
干预: Biopsy Procedure，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06678659

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

AI 简述这是一项I/II期试验，研究REC-1245用于不可切除、局部晚期或转移性癌症，在美国、加拿大开展。

?

适用疾病: Unresectable；Locally Advanced；Metastatic Cancers
干预: REC-1245
地点: United States，Canada
申办方: Recursion Pharmaceuticals Inc.

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06687772 / NCI-2024-10486

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

AI 简述这是一项II期试验，研究基于塞替派的自体干细胞移植预防高危弥漫大B细胞淋巴瘤中枢神经系统复发。

?

适用疾病: Diffuse Large B Cell Lymphoma；High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements；High Grade B-Cell Lymphoma
干预: Thiotepa，Carmustine，Autologous Stem Cell Transplant，Anthracycline-based induction chemotherapy
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06697184

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

AI 简述这是一项1/2期试验，研究Sonrotoclax联合Zanubrutinib用于血癌患者的新剂量递增方案。

?

适用疾病: Chronic Lymphocytic Leukemia；CLL；Mantle Cell Lymphoma
干预: Sonrotoclax，Zanubrutinib
地点: United States，Australia，France，United Kingdom
申办方: BeOne Medicines

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06698484

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

AI 简述这是一项2期试验，研究自体CD19 CAR-T细胞用于复发/难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
干预: CAR-T cells
地点: Malaysia
申办方: National University of Malaysia

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06698822 / NCI-2024-09674

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

AI 简述这是一项2期试验，研究Tofacitinib 2%乳膏用于早期蕈样肉芽肿。

?

适用疾病: Cutaneous T-Cell Lymphoma；Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
干预: tofacitinib 2% cream
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06712121

Venetoclax and Decitabine in R/R T-ALL

AI 简述这是一项II期试验，研究地西他滨联合Venetoclax用于复发/难治性T淋巴细胞白血病/淋巴瘤。在韩国开展。

?

适用疾病: T Lymphoblastic Leukemia/Lymphoma
干预: decitabine plus venetoclax
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06723457 / NCI-2024-09812

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

AI 简述这是一项II期试验，在美国开展，研究Epcoritamab联合来那度胺用于复发性或难治性免疫缺陷相关大B细胞淋巴瘤。

?

适用疾病: Recurrent B-Cell Non-Hodgkin Lymphoma；Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder；Refractory B-Cell Non-Hodgkin Lymphoma
干预: Biospecimen Collection，Computed Tomography，Epcoritamab，Lenalidomide
地点: United States
申办方: Reem Karmali

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06737250

NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

AI 简述这是一项II期试验，研究NB02（Poseltinib）联合利妥昔单抗和来那度胺治疗复发/难治原发中枢神经系统淋巴瘤。在韩国开展。

?

适用疾病: Primary CNS Lymphoma (PCNSL)
干预: R2P -> RP
地点: South Korea
申办方: NOBO Medicine

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06756308 / NCI-2025-00035

A Study of Enasidenib in People With T-Cell Lymphoma

AI 简述这是一项II期试验，研究Enasidenib联合利妥昔单抗用于T细胞淋巴瘤。

?

适用疾病: T-cell Lymphoma；Refractory Angioimmunoblastic T-Cell Lymphoma；Recurrent Angioimmunoblastic T-Cell Lymphoma
干预: Enasidenib，Rituximab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06765317 / NCI-2025-00464

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Glofitamab联合其他药物治疗弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma (DLBCL)；High Grade B Cell Lymphoma；High Grade B-Cell Lymphoma
干预: Glofitamab，Polatuzumab，Rituximab，Cyclophosphamide
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06768905 / NCI-2025-03900

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

AI 简述这是一项I/II期试验，研究Iomab-B序贯CAR-T细胞治疗复发/难治性弥漫大B细胞淋巴瘤。在美国开展。

?

适用疾病: Non Hodgkin Lymphoma；Diffuse Large B Cell Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: Iomab-B，CAR-T cell
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06788964 / NCI-2025-01989

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

AI 简述这是一项II期试验，研究Loncastuximab Tesirine和利妥昔单抗作为CAR-T治疗前的桥接治疗用于大B细胞淋巴瘤。

?

适用疾病: Relapsed or Refractory Large B-cell Lymphoma；Refractory Double-Hit Lymphoma；Recurrent Double-Hit Lymphoma
干预: Loncastuximab Tesirine，Rituximab
地点: United States
申办方: University of Utah

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06792825 / NCI-2025-01591

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

AI 简述这是一项II期试验，研究Tafasitamab联合Lenalidomide和Rituximab用于初治的滤泡性淋巴瘤和边缘区淋巴瘤。

?

适用疾病: Follicular Lymphoma；Marginal Zone Lymphoma；Grade 1 Follicular Lymphoma
干预: Tafasitamab，Rituximab，Lenalidomide
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06796998 / NCI-2025-06276

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

AI 简述这是一项II期试验，研究Epcoritamab用于新诊断的边缘区淋巴瘤。

?

适用疾病: Marginal Zone Lymphoma；Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue；Splenic Marginal Zone Lymphoma
干预: Epcoritamab
地点: United States
申办方: Izidore Lossos, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06806033 / NCI-2025-02584

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

AI 简述这是一项II期试验，研究Glofitamab联合吉西他滨和奥沙利铂用于复发/难治性侵袭性B细胞非霍奇金淋巴瘤。

?

适用疾病: B-Cell Non-Hodgkins Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
干预: Obinutuzumab，Glofitamab，Gemcitabine，Oxaliplatin
地点: United States，Australia，Canada，France 等 3 个
申办方: Hoffmann-La Roche

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06810778 / NCI-2025-00574

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

AI 简述这是一项I/II期试验，研究Duvelisib联合Venetoclax用于复发或难治性外周T细胞淋巴瘤。

?

适用疾病: T-cell-prolymphocytic Leukemia；Cutaneous T-Cell Lymphoma Refractory；Recurrent Hepatosplenic T-Cell Lymphoma
干预: Duvelisib，Venetoclax
地点: United States
申办方: Jonsson Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06811272 / NCI-2025-04270

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

AI 简述这是一项II期试验，在美国开展，研究Epcoritamab用于复发/难治性大B细胞淋巴瘤。

?

适用疾病: Relapsed Large B-cell Lymphoma；Refractory Large B-cell Lymphoma；Refractory Double-Hit Lymphoma
干预: Epcoritamab
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06812858

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

AI 简述这是一项II期试验，在哈萨克斯坦和俄罗斯开展，研究PD-1抑制剂（Nivolumab、Pembrolizumab）用于移植后霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma
干预: Nivolumab, Pembrolizumab
地点: Kazakhstan，Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT06828991 / NCI-2025-07539

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

AI 简述这是一项II期试验，研究Mosunetuzumab巩固治疗用于老年弥漫大B细胞淋巴瘤患者，这些患者在Pola-R-mini-CHP治疗结束时ctDNA可检出。

?

适用疾病: Diffuse Large B-Cell Lymphoma (DLBCL)；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes；Transformed Non-Hodgkin Lymphoma
干预: Mosunetuzumab，ClonoSEQ
地点: United States
申办方: Danielle Wallace

正在招募 Phase 4 药物

ClinicalTrials.gov NCT06831370

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

AI 简述这是一项IV期试验，研究Brentuximab Vedotin联合化疗用于印度成人霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma
干预: Brentuximab Vedotin，Doxorubicin，Vinblastine，Dacarbazine
地点: India
申办方: Takeda

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06834373 / NCI-2025-01094

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

AI 简述这是一项II期试验，研究Golcadomide和Rituximab作为CAR-T前的桥接治疗用于复发/难治性侵袭性B细胞非霍奇金淋巴瘤，在美国开展。

?

适用疾病: Large B-Cell Lymphoma With IRF4 Rearrangement；Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma；Recurrent ALK-Positive Large B-Cell Lymphoma
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Chimeric Antigen Receptor T-Cell Therapy
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06835530

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

AI 简述这是一项II期试验，研究Rituximab联合CC-99282作为老年体弱弥漫大B细胞淋巴瘤患者的一线治疗，在意大利开展。

?

适用疾病: Diffuse Large B Cell Non-Hodgkin Lymphoma
干预: Rituximab + Golcadomide (CC-99282)
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06839053 / NCI-2025-00319

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

AI 简述这是一项II期试验，在美国研究Sonrotoclax、利妥昔单抗和泽布替尼用于慢性淋巴细胞白血病、小淋巴细胞淋巴瘤和套细胞淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Mantle Cell Lymphoma；Recurrent Chronic Lymphocytic Leukemia
干预: Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Gastrointestinal Endoscopy
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06846463 / NCI-2025-03897

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

AI 简述这是一项II期试验，研究泽布替尼用于伴有MYD88或NOTCH1突变或CD5+的弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-cell Lymphoma；DLBCL - Diffuse Large B Cell Lymphoma；Diffuse Large B-Cell Lymphoma
干预: Zanubrutinib
地点: United States
申办方: Virginia Commonwealth University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06854003 / NCI-2025-02382

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Bendamustine、Rituximab、Cytarabine、Zanubrutinib用于初治套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma；Lymphoma
干预: Bendamustine，Rituximab，Cytarabine，Zanubrutinib
地点: United States
申办方: Christine Ryan

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06854159 / NCI-2025-00900

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

AI 简述这是一项II期试验，研究Odronextamab用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Refractory Diffuse Large B-Cell Lymphoma
干预: Chimeric Antigen Receptor T-Cell Therapy，Odronextamab
地点: United States
申办方: University of California, Davis

正在招募 Phase 4 药物

ClinicalTrials.gov / NCI NCT06876649 / NCI-2025-03405

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

AI 简述这是一项4期试验，评估Pirtobrutinib用于慢性淋巴细胞白血病或非霍奇金淋巴瘤的长期安全性。

?

适用疾病: Chronic Lymphocytic Leukemia；Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Pirtobrutinib
地点: United States，Australia，France，Italy 等 4 个
申办方: Eli Lilly and Company

正在招募 Phase 4 药物

ClinicalTrials.gov / NCI NCT06876662 / NCI-2025-06033

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

AI 简述这是一项4期试验，研究Pirtobrutinib用于既往治疗过的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤或非霍奇金淋巴瘤。

?

适用疾病: Chronic Lymphocytic Leukemia；Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia (CLL)
干预: Pirtobrutinib
地点: United States，Australia，France，Italy 等 4 个
申办方: Eli Lilly and Company

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06890884 / NCI-2025-04358

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

AI 简述这是一项II期试验，比较Zilovertamab vedotin联合R-CHP与Polatuzumab vedotin联合R-CHP用于弥漫大B细胞淋巴瘤，在美国等地开展。

?

适用疾病: Lymphoma, Large B-Cell, Diffuse；Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
干预: Zilovertamab vedotin，Rituximab，Cyclophosphamide，Doxorubicin
地点: United States，Belgium，Germany，Ireland 等 5 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06905509 / NCI-2025-01557

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Epcoritamab联合化疗及自体造血干细胞移植用于复发/难治大B细胞淋巴瘤。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
干预: Autologous Hematopoietic Stem Cell Transplantation，Carboplatin，Cytarabine，Dexamethasone
地点: United States
申办方: University of California, Davis

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06915246 / NCI-2025-02742

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

AI 简述这是一项II期试验，研究卡莫司汀联合VI-0609用于淋巴瘤（含非霍奇金和霍奇金）。

?

适用疾病: Lymphoma；Non-Hodgkin Lymphoma；Hodgkin Lymphoma
干预: VI-0609，BiCNU
地点: United States
申办方: VIVUS LLC

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT06918431

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

AI 简述这是一项II期试验，研究Erwinia Chrysanthemi天冬酰胺酶联合化疗用于新诊断的高危急性淋巴细胞白血病。

?

适用疾病: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Lymphoblastic Lymphoma
干预: Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06918912

Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

AI 简述这是一项II期试验，研究Loncastuximab Tesirine用于CAR-T治疗失败的复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma；High-grade B-cell Lymphoma (HGBCL)；B-Cell Lymphoma Treatment
干预: Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
地点: Italy
申办方: Istituto Clinico Humanitas

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06919939 / NCI-2025-09316

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

AI 简述这是一项II期试验，研究Epcoritamab联合Loncastuximab Tesirine用于复发/难治性大B细胞淋巴瘤。

?

适用疾病: Large B-cell Lymphoma；Relapse；Refractory Double-Hit Lymphoma
干预: Epcoritamab，Loncastuximab Tesirine
地点: United States
申办方: University of Miami

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06931652

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

AI 简述这是一项II期试验，研究Epcoritamab用于来那度胺和利妥昔单抗治疗后复发的原发中枢神经系统淋巴瘤，在法国开展。

?

适用疾病: Primary CNS Lymphoma (PCNSL)
干预: Epcoritamab
地点: France
申办方: The Lymphoma Academic Research Organisation

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT06954805

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

AI 简述这是一项II期试验，研究利妥昔单抗、依托泊苷等用于移植后淋巴增殖性疾病。

?

适用疾病: Lymphoma；Lymphoma, B-Cell
干预: Rituximab，Etoposide，Prednisone，Vincristine
地点: United States
申办方: Jennifer Amengual

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06984146

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Nivolumab联合化疗用于晚期经典型霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma, Adult
干预: Nivolumab，Doxorubicin，Vinblastine，Dacarbazine
地点: Russia
申办方: National Medical Research Radiological Centre of the Ministry of Health of Russia

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06986174

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

AI 简述这是一项II期试验，研究Pacritinib用于复发难治性Waldenström巨球蛋白血症。

?

适用疾病: Waldenström Macroglobulinemia；Lymphoplasmacytic Lymphoma；B-Cell Lymphoproliferative Disorder
干预: Pacritinib
地点: United States
申办方: Shayna Sarosiek, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07002216 / NCI-2025-04493

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

AI 简述这是一项II期试验，研究BrECADD方案用于IIB-IV期霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma；Advanced Hodgkin Lymphoma；Early Unfavorable Hodgkin Lymphoma
干预: Brentuximab Vedotin，Etoposide，Cyclophosphamide，Doxorubicin
地点: United States
申办方: University of Miami

正在招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT07003295 / NCI-2025-03915

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

AI 简述这是一项II期试验，研究Glofitamab用于CAR-T治疗后复发的套细胞淋巴瘤。

?

适用疾病: Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Biospecimen Collection，Computed Tomography，Glofitamab，Obinutuzumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07013565

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

AI 简述这是一项II期试验，在美国开展，研究化疗免疫疗法用于ALK阳性复发难治性间变性大细胞淋巴瘤。

?

适用疾病: Anaplastic Large Cell Lymphoma, ALK-Positive
干预: Vinblastine (Velban)，Brentuximab vedotin (Adcetris)，Nivolumab (Opdivo)
地点: United States
申办方: New York Medical College

正在招募 Phase 4 药物

ClinicalTrials.gov NCT07016165

Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies

AI 简述这是一项IV期试验，比较环丙沙星与头孢他啶经验性治疗儿童血液肿瘤高热伴中性粒细胞减少。

?

适用疾病: Neutropenic Fever；Acute Lymphoblastic Leukemia；Acute Myeloblastic Leukemia
干预: Ceftazidime，Ciprofloxacin
地点: Indonesia
申办方: Gadjah Mada University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07018752

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

AI 简述这是一项I/II期平台试验，评估新药或联合方案用于复发/难治性外周T细胞淋巴瘤。

?

适用疾病: Peripheral T Cells Lymphoma (PTCL)
干预: roginolisib，golcadomide，azacitidine
地点: France
申办方: The Lymphoma Academic Research Organisation

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07024706 / NCI-2026-00233

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

AI 简述这是一项II期试验，研究Acalabrutinib联合Venetoclax用于复发CLL/SLL，在美国等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Small Lymphocytic Lymphoma
干预: Acalabrutinib，Venetoclax
地点: United States，Austria，Brazil，Czechia 等 4 个
申办方: AstraZeneca

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07029737

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

AI 简述这是一项II期试验，研究Acalabrutinib联合R-CHOP用于未经治疗的套细胞淋巴瘤。

?

适用疾病: Mantle-cell Lymphoma
干预: Acalabrutinib + R-CHOP standard of care，Acalabrutinib combination with Rituximab，Acalabrutinib monotherapy
地点: Spain
申办方: AstraZeneca

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07042438 / NCI-2025-03771

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

AI 简述这是一项II期试验，研究粪便微生物移植用于接受CAR-T细胞治疗的复发/难治淋巴瘤患者，在美国开展。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements；Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: Axicabtagene Ciloleucel，Biospecimen Collection，Chemotherapy，Fecal Microbiota Transplantation
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT07061951 / NCI-2025-04637

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Mirdametinib用于复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia
干预: Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Echocardiography Test
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 基因治疗

ClinicalTrials.gov NCT07062627

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

AI 简述这是一项II期试验，研究Anbal-cabtagene Autoleucel用于复发/难治性原发中枢神经系统淋巴瘤，在韩国开展。

?

适用疾病: Primary CNS Lymphoma (PCNSL)；Diffuse Large B Cell Lymphoma (DLBCL)
干预: Anbal-cel
地点: South Korea
申办方: Hyungwoo Cho

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT07069699 / NCI-2025-04787

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

AI 简述这是一项I/II期试验，研究CX-5461用于MYC基因改变的淋巴瘤。

?

适用疾病: Burkitt Lymphoma；Double-Expressor Lymphoma；High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Lumbar Puncture
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07070219 / NCI-2025-06834

A Study of CTD402 in T-ALL/LBL Patients

AI 简述这是一项I/II期试验，研究CTD402 CAR-T用于复发难治T细胞急性淋巴细胞白血病/淋巴瘤。

?

适用疾病: Acute Lymphocytic Leukemia Refractory；Lymphoma, Lymphoblastic；Recurrent T Acute Lymphoblastic Leukemia
干预: CTD402 CAR T Cell Injection
地点: United States
申办方: BIOHENG THERAPEUTICS US LLC

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT07097363 / NCI-2025-04889

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

AI 简述这是一项2期试验，研究Epcoritamab联合EPOCH-R用于侵袭性B细胞非霍奇金淋巴瘤，在美国开展。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；Burkitt Lymphoma；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: University of Washington

正在招募 Phase 1, Phase 2 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT07098364 / NCI-2025-04890

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

AI 简述这是一项1/2期试验，研究Vevoctadekin联合Liso-cel用于复发/难治性大B细胞淋巴瘤。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Recurrent Grade 3b Follicular Lymphoma
干预: Vevoctadekin，Bone Marrow Aspiration，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07125872

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

AI 简述这是一项II期试验，研究CD19 t-haNK静脉用于复发难治B细胞非霍奇金淋巴瘤。

?

适用疾病: Relapsed B-Cell Non Hodgkin Lymphoma
干预: CD19 t-haNK- IV Administration
地点: South Africa
申办方: ImmunityBio, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07126236

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

AI 简述这是一项II期试验，研究Epcoritamab用于复发/难治性大B细胞淋巴瘤，在西班牙开展。

?

适用疾病: Large B Cell Lymphoma
干预: Epcoritamab，Epcoritamab, tafasitamab and lenalidomide
地点: Spain
申办方: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT07128641 / NCI-2025-06679

Odronextamab in Low Tumor Volume Advanced FL

AI 简述这是一项II期试验，研究Odronextamab用于低肿瘤负荷晚期滤泡性淋巴瘤，在美国开展。

?

适用疾病: Follicular Lymphoma；Lymphoma；Advanced Follicular Lymphoma
干预: Odronextamab
地点: United States
申办方: Gottfried von Keudell, MD PhD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07188090

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

AI 简述这是一项II期试验，研究普乐沙福联合G-CSF用于自体造血干细胞移植（多发性骨髓瘤、淋巴瘤）。在美国开展。

?

适用疾病: Multiple Myeloma；Hodgkin Lymphoma；Non-hodgkin Lymphoma
干预: Plerixafor，Gcsf
地点: United States
申办方: Thomas Jefferson University

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT07194980 / NCI-2025-06406

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AI 简述这是一项II期试验，研究Nemtabrutinib和Lisocabtagene Maraleucel用于复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: Nemtabrutinib，Lisocabtagene Maraleucel
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT07209059

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Nivolumab一线治疗晚期霍奇金淋巴瘤。在俄罗斯开展。

?

适用疾病: Hodgkin Lymphoma；Hodgkin Disease；Advanced Hodgkin Lymphoma
干预: Nivolumab，N-EACOPD-14，N-AVD
地点: Russia
申办方: National Research Center for Hematology, Russia

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07220616 / NCI-2026-01652

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

AI 简述这是一项I/II期试验，研究DS3790a用于血液恶性肿瘤。

?

适用疾病: Hematological Malignancies；B-cell Non-Hodgkin Lymphoma；Non-Hodgkin Lymphoma
干预: DS3790a，Combination drug
地点: United States，France，Japan
申办方: Daiichi Sankyo

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07221500 / NCI-2025-09040

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

AI 简述这是一项II期试验，研究NX-5948用于既往治疗后的CLL/SLL。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Refractory Chronic Lymphocytic Leukemia (CLL)
干预: NX-5948
地点: United States，France，Italy，Poland 等 1 个
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07222631 / NCI-2026-03909

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

AI 简述这是一项I/II期试验，研究SB-4826单用或联合利妥昔单抗用于晚期实体瘤或非霍奇金淋巴瘤。

?

适用疾病: Non Hodgkin Lymphoma；Solid Tumor；Recurrent Malignant Solid Tumor
干预: SB-4826，Rituximab
地点: United States
申办方: University of California, San Diego

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07231952

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

AI 简述这是一项II期试验，研究Pirtobrutinib、Venetoclax和Rituximab用于Waldenström巨球蛋白血症/淋巴浆细胞淋巴瘤。在美国开展。

?

适用疾病: Waldenstrom Macroglobulinemia；Lymphoplasmacytic Lymphoma
干预: Pirtobrutinib，Venetoclax，Rituximab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07234487

Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL

AI 简述这是一项II期试验，比较Nivo-AVD与BEACOPP-like方案用于晚期经典霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma
干预: Nivo-AVD，BEACOPP-like
地点: Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07249905

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

AI 简述这是一项I/II期试验，研究MDX2003用于多种淋巴瘤。

?

适用疾病: Lymphoma；Waldenström Macroglobulinemia (WM)；DLBCL - Diffuse Large B Cell Lymphoma
干预: MDX2003
地点: Australia
申办方: ModeX Therapeutics, An OPKO Health Company

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07254754

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，在西班牙研究Axicabtagene Ciloleucel用于晚期复发弥漫大B细胞淋巴瘤。

?

适用疾病: DIFFUSE LARGE B-CELL LYMPHOMA
干预: Axicabtagene Ciloleucel
地点: Spain
申办方: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT07275216 / NCI-2025-08524

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

AI 简述这是一项II期试验，研究Pembrolizumab联合化疗用于不适合标准治疗的虚弱经典霍奇金淋巴瘤患者，在美国开展。

?

适用疾病: Classic Hodgkin Lymphoma；Classical Hodgkin Lymphoma
干预: Biospecimen Collection，Brentuximab Vedotin，Computed Tomography，Dacarbazine
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07283679 / NCI-2025-09213

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究ONC-PluReceptor NK细胞联合Epcoritamab和Tafasitamab用于复发或难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Recurrent B-Cell Non-Hodgkin Lymphoma；Refractory B-cell Non-Hodgkin Lymphoma；Recurrent Follicular Lymphoma
干预: ONC-PluReceptor NK cells
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07283822 / NCI-2026-00243

Amping up With PemJAK

AI 简述这是一项II期试验，研究Ruxolitinib联合Pembrolizumab用于复发难治性非霍奇金淋巴瘤、霍奇金淋巴瘤等。

?

适用疾病: Non-Hodgkin Lymphoma；Hodgkin Disease Lymphoma；Non-Hodgkin Lymphoma Refractory/ Relapsed
干预: Ruxolitinib，Pembrolizumab
地点: United States
申办方: Seda S. Tolu

正在招募 Phase 1, Phase 2 药物其他

ClinicalTrials.gov NCT07284433

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

AI 简述这是一项I/II期试验，研究异体CAR-T（靶向CD19/CD20）用于复发或难治性B细胞恶性肿瘤。在美国和德国开展。

?

适用疾病: Lymphoma Diffuse Large B-cell；Leukemia and Lymphoma；Leukemia Relapse
干预: Cyclophosphamide (Non-IMP, Lymphodepletion)，Fludarabine (Non-IMP, Lymphodepletion)，Allo-QuadCAR01-T
地点: United States，Germany
申办方: AvenCell Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07285590

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Pirtobrutinib联合利妥昔单抗用于套细胞淋巴瘤。在葡萄牙、西班牙等地开展。

?

适用疾病: Mantle Cell Lymphoma (MCL)
干预: Pirtobrutinib and rituximab
地点: Portugal，Spain
申办方: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07288879

DALY II Japan/MB-CART2019.1 for DLBCL

AI 简述这是一项II期试验，研究MB-CART2019.1用于弥漫大B细胞淋巴瘤。

?

适用疾病: DLBCL - Diffuse Large B Cell Lymphoma；CAR T Cell Therapy
干预: MB-CART2019.1
地点: Japan
申办方: Miltenyi Biomedicine GmbH

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT07341191

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

AI 简述这是一项2期试验，研究sonrotoclax联合zanubrutinib用于复发/难治套细胞淋巴瘤后计划接受CAR-T治疗。在加拿大开展。

?

适用疾病: Mantle Cell Lymphoma
干预: Zanubrutinib，Sonrotoclax，CAR-T Cell Therapy
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT07356245 / NCI-2026-00140

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

AI 简述这是一项II期试验，在美国研究芦可替尼维持治疗用于T细胞淋巴瘤造血干细胞移植后。

?

适用疾病: T-cell Lymphoma；Graft Versus Host Disease；Lymphoma, T-Cell
干预: Ruxolitinib，Positron emission tomography-computed tomography，Bone Marrow Biopsy，Biopsy Procedure
地点: United States
申办方: Jonathan Brammer

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07365306 / NCI-2025-09718

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究Epcoritamab联合R-GemOx方案作为自体干细胞移植前挽救治疗用于复发/难治性弥漫大B细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified；Recurrent Primary Mediastinal Large B-Cell Lymphoma
干预: Autologous Hematopoietic Stem Cell Transplantation，Biopsy Procedure，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07387471

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

AI 简述这是一项II期试验，研究Venetoclax用于复发/难治性华氏巨球蛋白血症/淋巴浆细胞淋巴瘤。

?

适用疾病: Waldenstrom Macroglobulinemia；Lymphoplasmacytic Lymphoma
干预: Venetoclax
地点: Japan
申办方: AbbVie

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07439653 / NCI-2026-01995

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

AI 简述这是一项I/II期试验，研究TORL-5-700用于复发/难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma；Mucosa-Associated Lymphoid Tissue；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: TORL-5-700，TORL-5-700 at MTD/RP2D，TORL-5-700 at MTD/RP2D in combination with another agent
地点: United States
申办方: TORL Biotherapeutics, LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07451652

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

AI 简述这是一项II期试验，研究低剂量Epcoritamab联合GemOx用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Relapsed/Refractory Diffuse Large B Cell Lymphoma
干预: Epcoritamab，Gemcitabine (1000 mg/m2)，Oxaliplatin
地点: Mexico
申办方: Hospital Universitario Dr. Jose E. Gonzalez

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07453095

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

AI 简述这是一项II期试验，研究Glofitamab用于CAR-T治疗后缓解不佳或复发的套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma
干预: Glofitamab
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07473167

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

AI 简述这是一项I/II期试验，研究TC011用于复发难治大B细胞非霍奇金淋巴瘤。

?

适用疾病: Relapsed Large B-cell Lymphoma；Refractory Large B-cell Lymphoma；Diffuse Large B-cell Lymphoma (DLBCL)
干预: TC011
地点: South Korea
申办方: TICAROS Co., Ltd.

正在招募 Phase 2 生物制剂药物放疗

ClinicalTrials.gov / NCI NCT07566377 / NCI-2026-03537

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

AI 简述这是一项II期试验，研究脐带血移植用于儿童和年轻成人血癌。

?

适用疾病: Acute Myelogenous Leukemia；Acute Lymphoblastic Leukemia；Myelodysplastic Syndromes
干预: Cord Blood Units，Total Body Irradiation，Cyclophosphamide，Fludarabine
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 3 放疗

ClinicalTrials.gov NCT07256158

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma

AI 简述这是一项III期试验，在意大利研究PET引导下放疗剂量递减用于早期不利型霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma
干预: 20 Gy Involved site radiotherapy，30 Gy Involved site radiotherapy
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

即将招募 Phase 2

NCI NCT07557056 / NCI-2026-02422

Nemtabrutinib and Venetoclax for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

AI 简述一项II期试验，研究Nemtabrutinib和Venetoclax用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT04913103

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

AI 简述这是一项II期试验，研究PV联合苯达莫司汀和利妥昔单抗用于复发/难治性套细胞淋巴瘤，在捷克开展。

?

适用疾病: Lymphoma, Mantle-Cell
干预: Polatuzumab vedotin，Bendamustine Hydrochloride，Rituximab
地点: Czechia
申办方: Czech Lymphoma Study Group

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06045195

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

AI 简述这是一项2期试验，研究Pembrolizumab一线治疗晚期经典型霍奇金淋巴瘤。在德国开展。

?

适用疾病: Hodgkin Lymphoma
干预: Pembrolizumab
地点: Germany
申办方: University of Cologne

即将招募 Phase 2 药物其他

ClinicalTrials.gov NCT06594939

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究Mosunetuzumab和Polatuzumab Vedotin联合CHP化疗用于老年弥漫大B细胞淋巴瘤，在美国开展。

?

适用疾病: Diffuse Large B Cell Lymphoma (DLBCL)
干预: Polatuzumab Vedotin，Mosunetuzumab，Cyclophosphamide，Doxorubicin
地点: United States
申办方: Medical College of Wisconsin

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06617286

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

AI 简述这是一项I/II期试验，研究CD30 CAR T细胞用于复发难治性经典霍奇金淋巴瘤，在美国开展。

?

适用疾病: Classical Hodgkin Lymphoma
干预: CD30 CAR T-cell
地点: United States
申办方: New York Medical College

即将招募 Phase 2 器械药物手术/操作

ClinicalTrials.gov / NCI NCT07021989 / NCI-2025-04294

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

AI 简述这是一项II期试验，研究ctDNA引导治疗用于复发/难治性霍奇金淋巴瘤，在美国开展。

?

适用疾病: Hodgkin Lymphoma, Adult；Refractory Hodgkin Lymphoma；Classic Hodgkin Lymphoma
干预: Pembrolizumab，Non-investigational, involved site radiotherapy (ISRT)，Gemcitabine，Vinorelbine
地点: United States
申办方: Michael Spinner, MD

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07144657

Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma

AI 简述这是一项II期试验，在台湾研究抗生素治疗用于早期HP阴性胃MALT淋巴瘤。

?

适用疾病: MALT Lymphoma of Stomach
干预: Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole
地点: Taiwan
申办方: National Taiwan University Hospital

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07162571

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

AI 简述这是一项1/2期试验，研究CD19/22 CAR-T细胞用于复发/难治性急性淋巴细胞白血病/淋巴瘤，在白俄罗斯开展。

?

适用疾病: Acute Lymphobkastic Leukemia；B Cell Lymphoma
干预: CD19/22 CAR-T cells
地点: Belarus
申办方: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology

即将招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07164469 / NCI-2025-06569

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

AI 简述这是一项II期试验，研究CD70.CAR NK细胞用于大B细胞淋巴瘤和霍奇金淋巴瘤，在美国开展。

?

适用疾病: Large B-cell Lymphoma；Hodgkin Lymphoma；Recurrent Classical Hodgkin Lymphoma
干预: Fludarabine，Cyclophosphamide，CD70.CAR NK Cells，Rimiducid (AP1903)
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07197307

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

AI 简述这是一项II期试验，研究Loncastuximab Tesirine联合Epcoritamab用于复发/难治性弥漫大B细胞淋巴瘤。在德国开展。

?

适用疾病: Aggressive Diffuse Large B-cell Lymphoma；High-grade B-cell Lymphoma (HGBL)；Follicular Lymphoma (FL) Grade 3B
干预: Loncastuximab Tesirine and Epcoritamab
地点: Germany
申办方: Universität Münster

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07207785

PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

AI 简述这是一项II期试验，研究Pirtobrutinib用于老年不适合/虚弱套细胞淋巴瘤患者的一线治疗。在意大利开展。

?

适用疾病: Mantle Cell Lymphoma
干预: Pirtobrutinib
地点: Italy
申办方: Fondazione Italiana Linfomi - ETS

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07269639

Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma

AI 简述这是一项I/II期试验，研究Golcadomide+Poseltinib+Rituximab用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Large B-Cell Lymphoma (LBCL)
干预: Golcadomide + Poseltinib + Rituximab
地点: South Korea
申办方: Seoul National University Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07502872

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

AI 简述这是一项II期试验，研究Tafasitamab、Polatuzumab vedotin和Glofitamab用于弥漫大B细胞淋巴瘤和高级别B细胞淋巴瘤一线治疗。

?

适用疾病: Diffuse Large B Cell Lymphoma；High-grade B-cell Lymphoma；Lymphoma
干预: Tafasitamab，Polatuzumab vedotin，Glofitamab，Obinutuzumab
地点: United States
申办方: Brown University

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07503353

A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

AI 简述这是一项I/II期试验，研究表达新型CD19嵌合抗原受体的T细胞（SHB-02-CD19）用于CD19阳性B细胞恶性肿瘤。

?

适用疾病: B Cell Malignancies；Acute Lymphobkastic Leukemia；Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
干预: SHB-02-CD19 (anti CD19 CAR-T cells)
地点: Israel
申办方: Sheba Medical Center

即将招募 Phase 2 其他放疗

ClinicalTrials.gov NCT07517705

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究低剂量放疗联合标准一线化学免疫治疗用于弥漫大B细胞淋巴瘤，在美国开展。

?

适用疾病: Diffuse Large B-Cell Lymphoma
干预: Low-Dose Radiation Therapy (LDRT)，Standard Frontline Chemoimmunotherapy
地点: United States
申办方: University of Nebraska

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07542678

Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept

AI 简述这是一项II期试验，研究Glofitamab联合化疗用于复发/难治性大B细胞淋巴瘤，在德国开展。

?

适用疾病: Relapsed /Refractory DLBCL
干预: Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy，Glofitamab as Consolidation therapy
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07551583

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

AI 简述这是一项II期试验，在美国研究Nivolumab联合AVD方案用于儿童、青少年和青年经典霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma
干预: Nivolumab，Doxorubicin Hydrochloride，Vinblastine，Dacarbazine
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov NCT07576725

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

AI 简述这是一项II期试验，在乌干达研究低剂量减少频率的Nivolumab用于不可切除或转移性癌症。

?

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Nivolumab
地点: Uganda
申办方: Fred Hutchinson Cancer Center

即将招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07578077

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

AI 简述这是一项I/II期试验，在美国研究Golcadomide联合Rituximab用于复发或难治性套细胞淋巴瘤。

?

适用疾病: Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Biopsy Procedure，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07583810 / NCI-2026-03180

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

AI 简述这是一项II期试验，研究Nemtabrutinib联合Rituximab用于边缘区淋巴瘤。在美国开展。

?

适用疾病: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma；Gastric Mucosa-Associated Lymphoid Tissue Lymphoma；Marginal Zone Lymphoma
干预: Biopsy Procedure，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07593482

Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.

AI 简述这是一项II期试验，在瑞士开展，比较苯达莫司汀与氟达拉滨/环磷酰胺用于B细胞淋巴瘤CAR-T细胞治疗的淋巴细胞耗竭。

?

适用疾病: B-cell Lymphoma
干预: bendamustine hydrochloride，Cyclophosphamide，Fludarabine
地点: Switzerland
申办方: Swiss Cancer Institute

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07607925

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

AI 简述这是一项I/II期试验，研究GSK5926371用于复发或难治性B细胞非霍奇金淋巴瘤。在美国、加拿大、日本等地开展。

?

适用疾病: Lymphoma, Non-Hodgkin
干预: GSK5926371
地点: United States，Canada，Japan
申办方: GlaxoSmithKline

即将招募 Phase 2 药物其他放疗

ClinicalTrials.gov NCT07634289

Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

AI 简述这是一项II期试验，研究Glofitamab联合放疗用于复发/难治性弥漫大B细胞淋巴瘤，在澳大利亚等地开展。

?

适用疾病: Relapsed /Refractory DLBCL
干预: Glofitamab，Radiotherapy，Obinutuzumab，89Zr-Df-crefmirlimab
地点: Australia
申办方: Olivia Newton-John Cancer Research Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07654426

The CARDIOPROTECT Trial

AI 简述这是一项II期试验，研究右雷佐生用于预防弥漫大B细胞淋巴瘤化疗相关心脏毒性。

?

适用疾病: Diffuse Large B-cell Lymphoma (DLBCL)；Cardiotoxicity；Lymphoma
干预: Dexrazoxane，Dexrazoxane placebo，Doxorubicin，Liposomal Doxorubicin
地点: United States
申办方: Beth Israel Deaconess Medical Center

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07662928

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

AI 简述这是一项II期试验，研究Epcoritamab联合剂量调整EPOCH-R用于高危伯基特淋巴瘤。

?

适用疾病: Adult Burkitt Lymphoma
干预: Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: AIDS Malignancy Consortium

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07673367

Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Nemtabrutinib联合CAR-T治疗用于复发难治套细胞淋巴瘤。在美国开展。

?

适用疾病: Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Nemtabrutinib，Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
地点: United States
申办方: Vanderbilt-Ingram Cancer Center

正在招募 Phase 1

NCI NCT03328104 / NCI-2017-01717

Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma

AI 简述一项I期试验，研究Everolimus、Nelarabine等药物用于复发/难治性T细胞淋巴母细胞白血病或淋巴瘤。

?

适用疾病: Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Recurrent T Lymphoblastic Leukemia/Lymphoma；Refractory T Lymphoblastic Leukemia/Lymphoma
干预: 未列出
地点: United States
申办方: Children's Healthcare of Atlanta - Arthur M Blank Hospital

正在招募 O

NCI NCT03537482 / NCI-2018-02408

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

AI 简述这是一项其他阶段的试验，研究APG-2575用于血液系统恶性肿瘤。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Refractory Acute Myeloid Leukemia (AML)；Refractory Waldenstrom Macroglobulinemia
干预: 未列出
地点: United States
申办方: Ascentage Pharma

正在招募 Phase 1

NCI NCT03921879 / NCI-2019-05350

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

AI 简述这是一项I期试验，研究OT-82用于复发难治性淋巴瘤，在美国开展。

?

适用疾病: Refractory Lymphoma；Recurrent Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Oncotartis, Inc.

正在招募 Phase 1

NCI NCT04215809 / NCI-2020-05583

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

AI 简述这是一项I期试验，研究APG-2575单药或联合其他药物用于CLL/SLL，在美国、澳大利亚等地开展。

?

适用疾病: Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma；Recurrent Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: Ascentage Pharma

正在招募 Phase 1

NCI NCT04609046 / NCI-2020-08331

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

AI 简述这是一项1期试验，研究来那度胺和纳武利尤单抗加入常规治疗用于原发性中枢神经系统淋巴瘤，在美国开展。

?

适用疾病: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 1

NCI NCT04902443 / NCI-2021-01289

Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV

AI 简述这是一项I期试验，研究Pomalidomide联合Nivolumab用于病毒相关恶性肿瘤，包括头颈癌、鼻咽癌。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: NCI - Center for Cancer Research

正在招募 Phase 1

NCI NCT04848064 / NCI-2021-01375

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

AI 简述这是一项I期试验，研究第三方自然杀伤细胞和Mogamulizumab用于复发性或难治性皮肤T细胞淋巴瘤。

?

适用疾病: Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma；Recurrent Adult T-Cell Leukemia/Lymphoma；Refractory Adult T-Cell Leukemia/Lymphoma
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT04637763 / NCI-2021-04061

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

AI 简述这是一项I期试验，研究CRISPR编辑的同种异体抗CD19 CAR-T细胞用于复发/难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Refractory Non-Hodgkin Lymphoma；Recurrent B-Cell Non-Hodgkin Lymphoma；Refractory B-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Caribou Biosciences, Inc.

正在招募 Phase 1

NCI NCT04684563 / NCI-2021-05843

huCART19-IL18 Cells for the Treatment of Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Acute Lymphoblastic Leukemia

AI 简述这是一项I期试验，研究huCART19-IL18细胞用于复发/难治CD19+非霍奇金淋巴瘤、慢性淋巴细胞白血病或急性淋巴细胞白血病，在美国开展。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia；Refractory Double-Hit Lymphoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1

NCI NCT04640987 / NCI-2021-06751

T-allo10 Infusion Therapy to Prevent Graft Versus Host Disease and Improve Potential Immune Reconstitution in Patients who received Hematopoietic Stem Cell Transplantation

AI 简述这是一项I期试验，研究T-allo10输注预防移植物抗宿主病并改善造血干细胞移植患者的免疫重建。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Recurrent Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Lucile Packard Children's Hospital Stanford University

正在招募 Phase 1

NCI NCT04704323 / NCI-2021-08719

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

AI 简述这是一项I期试验，研究CAP-100用于复发/难治性慢性淋巴细胞白血病，在美国和西班牙开展。

?

适用疾病: Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma；Recurrent Chronic Lymphocytic Leukemia (CLL)
干预: 未列出
地点: United States
申办方: Catapult Therapeutics

正在招募 Phase 1

NCI NCT04118868 / NCI-2022-03703

Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

AI 简述这是一项I期试验，研究Pembrolizumab通过Sofusa DoseConnect给药用于复发难治皮肤T细胞淋巴瘤。

?

适用疾病: Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8
干预: 未列出
地点: United States
申办方: Sorrento Therapeutics, Inc.

正在招募 Phase 1

NCI NCT05003141 / NCI-2022-04194

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

AI 简述这是一项I期试验，研究PSB202用于复发难治惰性B细胞恶性肿瘤。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Refractory Waldenstrom Macroglobulinemia；Refractory Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

正在招募 Phase 1

NCI NCT05487651 / NCI-2022-07299

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

AI 简述这是一项I期试验，研究同种异体CAR-T细胞（靶向CD19）用于B细胞恶性肿瘤。

?

适用疾病: Refractory Acute Lymphoblastic Leukemia (ALL)；Recurrent Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia
干预: 未列出
地点: United States
申办方: Athenex, Inc.

正在招募阶段未标明

NCI NCT05893940 / NCI-2023-03605

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

AI 简述这是一项研究低强度机械刺激用于血液系统恶性肿瘤患者。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Follicular Lymphoma；Hematopoietic and Lymphoid System Neoplasm
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1

NCI NCT05943496 / NCI-2023-04657

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

AI 简述这是一项I期试验，研究Tafasitamab、Acalabrutinib和Obinutuzumab用于未经治疗的慢性淋巴细胞白血病。在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1

NCI NCT05780034 / NCI-2023-10648

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

AI 简述这是一项I期试验，研究AC676用于复发/难治性B细胞恶性肿瘤。在美国开展。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Refractory Waldenstrom Macroglobulinemia；Refractory Marginal Zone Lymphoma
干预: 未列出
地点: United States
申办方: Accutar Biotechnology Inc

正在招募 Phase 1

NCI NCT06008808 / NCI-2024-02152

Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies

AI 简述这是一项I期试验，研究Ruxolitinib联合或不联合Abatacept用于预防单倍体干细胞移植后的移植物抗宿主病和细胞因子释放综合征，适用于血液恶性肿瘤。

?

适用疾病: Graft Versus Host Disease；Acute Lymphoblastic Leukemia (ALL)；Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 1

NCI NCT04972942 / NCI-2024-02686

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

AI 简述这是一项I期试验，研究Daratumumab用于异基因移植后的高危T细胞急性淋巴细胞白血病，在美国开展。

?

适用疾病: High Risk Acute Lymphoblastic Leukemia；Recurrent T Lymphoblastic Lymphoma；T cell acute lymphoblastic leukemia
干预: 未列出
地点: United States
申办方: New York Medical College

正在招募 Phase 1

NCI NCT06475235 / NCI-2024-05884

Pembrolizumab in Combination with Chemotherapy for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma

AI 简述这是一项I期试验，研究帕博利珠单抗联合化疗用于新诊断的原发性中枢神经系统淋巴瘤。

?

适用疾病: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 1

NCI NCT06607549 / NCI-2024-09549

Loncastuximab Tesirine and Rituximab after Stereotactic Radiosurgery for the Treatment of Primary and Secondary Central Nervous System Lymphomas, SOLAR Trial

AI 简述这是一项I期试验，在美国研究立体定向放射外科后Loncastuximab Tesirine和利妥昔单抗用于复发难治中枢神经系统淋巴瘤。

?

适用疾病: Recurrent Central Nervous System Lymphoma；Refractory Central Nervous System Lymphoma；Secondary Diffuse Large B-Cell Lymphoma of the Central Nervous System
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 1

NCI NCT06712810 / NCI-2024-09563

Q702 for the Treatment of Patients with Hematologic Malignancies

AI 简述这是一项I期试验，研究Q702用于复发性/难治性血液系统恶性肿瘤。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Recurrent Langerhans Cell Histiocytosis；Refractory Langerhans Cell Histiocytosis
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1

NCI NCT06590961 / NCI-2025-00075

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

AI 简述这是一项I期试验，研究UBX-303061用于复发/难治性B细胞恶性肿瘤，在美国开展。

?

适用疾病: Recurrent Waldenstrom Macroglobulinemia；Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Waldenstrom Macroglobulinemia
干预: 未列出
地点: United States
申办方: Ubix Therapeutics, Inc.

正在招募 O

NCI NCT06610344 / NCI-2025-00170

A Dietary Supplement (HVMN Ketone-IQ) for Treating Patients with B-cell Non-Hodgkin Lymphoma Receiving Anti-CD19 CAR T-Cells

AI 简述这是一项试验，研究膳食补充剂HVMN Ketone-IQ用于接受CAR T细胞的B细胞非霍奇金淋巴瘤患者。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1

NCI NCT07168486 / NCI-2025-00309

Autologous CAR19.20.22 Chimeric Antigen Receptor T Cells (CAR19.20.22 CART) for the Treatment of Recurrent or Refractory B-Cell Lymphomas

AI 简述这是一项I期试验，在United States开展，研究自体CAR19.20.22 CAR-T细胞用于复发或难治性B细胞淋巴瘤。

?

适用疾病: Refractory Marginal Zone Lymphoma；Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia
干预: 未列出
地点: United States
申办方: University of Maryland/Greenebaum Cancer Center

正在招募 Phase 1

NCI NCT06730542 / NCI-2025-00995

Zanubrutinib in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and High-Dose Methotrexate for the Treatment of Patients with Large B-cell Lymphoma with Central Nervous System Involvement

AI 简述这是一项I期试验，研究Zanubrutinib联合Polatuzumab Vedotin、利妥昔单抗等用于大B细胞淋巴瘤伴中枢神经系统受累。

?

适用疾病: Secondary Central Nervous System Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: University of Miami Miller School of Medicine-Sylvester Cancer Center

正在招募 Phase 1

NCI NCT06801002 / NCI-2025-01261

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

AI 简述这是一项I期试验，研究JBZ-001用于晚期实体瘤和血液肿瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jabez Bioscience, Inc

正在招募 Phase 1

NCI NCT06859008 / NCI-2025-01388

Zanubrutinib in Combination with Sonrotoclax for the Treatment of Underrepresented Minorities with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究泽布替尼联合Sonrotoclax用于复发或难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Recurrent Grade 3a Follicular Lymphoma；Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06904066 / NCI-2025-03016

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

AI 简述这是一项I期试验，研究自体T细胞转导识别新抗原的TCR用于血液恶性肿瘤，在美国开展。

?

适用疾病: Recurrent Myelodysplastic Syndrome；Recurrent Acute Myeloid Leukemia (AML)；Recurrent Chronic Myelomonocytic Leukemia
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1

NCI NCT06823167 / NCI-2025-03470

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

AI 简述这是一项I期试验，在美国开展，研究IM-1021用于多种晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Immunome, Inc.

正在招募阶段未标明

NCI NCT06898905 / NCI-2025-04658

Hyperfractionated Dual Equivalent Fractionated Bridging Radiation Therapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Undergoing T-cell Redirection Therapy

AI 简述这是一项试验，研究超分割双等效分割桥接放疗用于复发/难治弥漫大B细胞淋巴瘤的T细胞再导向治疗前。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Refractory Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Yale University

正在招募 Phase 1

NCI NCT07278856 / NCI-2025-08060

Ruxolitinib in Combination with CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

AI 简述这是一项1期试验，研究芦可替尼联合CHOP化疗用于未经治疗的结节性T滤泡辅助细胞淋巴瘤。在美国开展。

?

适用疾病: Follicular Helper T-Cell Lymphoma；Follicular Helper T-Cell Lymphoma, Not Otherwise Specified；Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT07382817 / NCI-2026-00809

Evaluation of JV-394 Autologous Anti-CD94 Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory CD94+ T/NK-cell neoplasms

AI 简述这是一项I期试验，在美国开展，研究JV-394自体抗CD94 CAR-T细胞疗法用于复发或难治性CD94+ T/NK细胞肿瘤。

?

适用疾病: Primary Nodal EBV-Positive T-Cell/NK-Cell Lymphoma；Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma；Recurrent Hepatosplenic T-Cell Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT07465835 / NCI-2026-02248

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

AI 简述这是一项I期试验，研究ELA026用于复发/难治T/NK细胞恶性肿瘤，在美国开展。

?

适用疾病: Recurrent T-Cell and NK-Cell Neoplasm；Refractory T-Cell and NK-Cell Neoplasm；Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Electra Therapeutics Inc.

正在招募 Phase 1

NCI NCT07195916 / NCI-2026-02281

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

AI 简述这是一项I期试验，研究INCA036873用于晚期实体瘤和血液恶性肿瘤。

?

适用疾病: Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
干预: 未列出
地点: United States
申办方: Incyte Corporation

正在招募 Phase 1

NCI NCT07572006 / NCI-2026-03867

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I期试验，研究JNJ-95804306用于复发/难治血液恶性肿瘤。

?

适用疾病: Refractory Acute Myeloid Leukemia (AML)；Refractory Myelodysplastic Syndrome；Recurrent Myelodysplastic Syndrome
干预: 未列出
地点: United States
申办方: Janssen Research & Development, LLC

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT01555892 / NCI-2013-01016

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

AI 简述这是一项I期试验，研究EBV特异性T细胞用于EBV阳性淋巴瘤，在美国开展。

?

适用疾病: Hodgkin's Disease；Non-Hodgkin's Lymphoma；Lymphoproliferative Disease
干预: EBV-specific T cells: A，EBV-specific T cells: B
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 基因治疗

ClinicalTrials.gov / NCI NCT01853631 / NCI-2013-01017

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

AI 简述这是一项I期试验，研究CD19特异性CAR-T细胞用于晚期B细胞淋巴瘤和白血病，在美国开展。

?

适用疾病: Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia；Acute Lymphocytic Leukemia
干预: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells，Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT02508038 / NCI-2015-01163

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

AI 简述这是一项I期试验，研究TCRαβ+/CD19+去除的半相合移植联合唑来膦酸用于儿童血液恶性肿瘤和实体瘤。

?

适用疾病: Acute Myeloid Leukemia；Acute Lymphoblastic Leukemia；Hodgkin Lymphoma
干预: TCRαβ+/CD19+ depleted Haploidentical HSCT，Zoledronate
地点: United States
申办方: University of Wisconsin, Madison

正在招募阶段未标明药物放疗

ClinicalTrials.gov NCT02797717

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

AI 简述这是一项试验，研究放化疗用于儿童和青少年经典霍奇金淋巴瘤。在以色列开展。

?

适用疾病: Classical Hodgkins Lymphoma in Children and Adolescents.
干预: Radiotherapy:，Vincristine，Etoposide，Prednisone
地点: Israel
申办方: GALIA AVRAHAMI

正在招募 Phase 1 基因治疗

ClinicalTrials.gov / NCI NCT02917083 / NCI-2018-00724

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

AI 简述这是一项I期试验，研究CAR T Cells用于复发CD30阳性淋巴瘤。

?

适用疾病: Hodgkin's Lymphoma；Non-Hodgkin Lymphoma；Peripheral T-Cell Lymphoma, Unclassifiable
干预: CAR T Cells
地点: United States
申办方: Baylor College of Medicine

正在招募阶段未标明放疗

ClinicalTrials.gov NCT02964858

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

AI 简述这是一项在印度开展的试验，优化放疗剂量用于弥漫大B细胞淋巴瘤。

?

适用疾病: NonHodgkin Lymphoma
干预: Standard Arm，Experimental Arm
地点: India
申办方: Tata Memorial Hospital

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03017820 / NCI-2017-00049

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

AI 简述这是一项I期试验，研究疫苗VSV-hIFNβ-NIS联合或不联合免疫治疗用于复发难治多发性骨髓瘤、急性髓系白血病或淋巴瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；Histiocytic and Dendritic Cell Neoplasm；Myelodysplastic Syndrome
干预: Biopsy Procedure，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 基因治疗

ClinicalTrials.gov / NCI NCT03081910 / NCI-2018-00726

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

AI 简述这是一项I期试验，研究CD5.CAR T细胞治疗T细胞恶性肿瘤，在美国开展。

?

适用疾病: T-cell Acute Lymphoblastic Lymphoma；T-non-Hodgkin Lymphoma；T-cell Acute Lymphoblastic Leukemia
干预: Autologous CD5.CAR/28zeta CAR T cells，Allogeneic CD5.CAR/28zeta CAR T cells
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT03666000 / NCI-2019-01892

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

AI 简述这是一项I期试验，研究Azer-cel用于复发/难治性非霍奇金淋巴瘤和B细胞急性淋巴细胞白血病。

?

适用疾病: Non-Hodgkin Lymphoma；B-cell Acute Lymphoblastic Leukemia；Chronic Lymphocytic Leukemia
干预: Azer-cel，Fludarabine，Cyclophosphamide，IL-2
地点: United States，Australia
申办方: Imugene Limited

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT03719105 / NCI-2021-00444

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

AI 简述一项早期I期试验，研究化疗免疫联合异基因干细胞移植用于NK/T细胞白血病/淋巴瘤，在美国开展。

?

适用疾病: NK-Cell Lymphoma；NK-Cell Leukemia；Peripheral T Cell Lymphoma
干预: Methotrexate，pralatraxate,，Ifosfamide，Dexamethasone
地点: United States
申办方: New York Medical College

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT03829540

CD4CAR for CD4+ Leukemia and Lymphoma

AI 简述这是一项I期试验，研究CD4CAR用于CD4阳性白血病和淋巴瘤。

?

适用疾病: T-cell Lymphoma；T-cell Leukemia
干预: CD4CAR
地点: United States
申办方: Huda Salman

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT04097067 / NCI-2022-05852

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

AI 简述这是一项非随机试验，研究20 Gy放疗用于惰性胃肠淋巴瘤。

?

适用疾病: Follicular Lymphoma (Gastric or Duodenal)；Marginal Zone Lymphoma (Gastric or Duodenal)；Duodenal-Type Follicular Lymphoma
干预: Radiation Therapy
地点: Germany，United States
申办方: University Hospital Muenster

正在招募 EARLY / Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT04139304 / NCI-2019-04794

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

AI 简述这是一项早期I期试验，研究Daratumumab联合剂量调整EPOCH用于浆母细胞淋巴瘤，在美国开展。

?

适用疾病: Plasmablastic Lymphoma；Ann Arbor Stage I Diffuse Large B-Cell Lymphoma；Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
干预: Cyclophosphamide，Daratumumab，Doxorubicin，Doxorubicin Hydrochloride
地点: United States
申办方: AIDS Malignancy Consortium

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04223765 / NCI-2019-08780

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

AI 简述这是一项I期试验，研究CAR.k.28细胞治疗用于复发/难治性非霍奇金淋巴瘤和慢性淋巴细胞白血病。

?

适用疾病: Mantle Cell Lymphoma；Follicular Lymphoma；Splenic Marginal Zone Lymphoma
干预: CAR.k.28，Fludarabine，Cyclophosphamide，Bendamustine
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04231877 / NCI-2019-08983

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

AI 简述这是一项I期试验，研究Polatuzumab Vedotin联合化疗用于未经治疗的侵袭性大B细胞淋巴瘤。

?

适用疾病: Aggressive Non-Hodgkin Lymphoma；ALK-Positive Large B-Cell Lymphoma；Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
干预: Polatuzumab Vedotin，Rituximab，Prednisone，Etoposide
地点: United States
申办方: University of Washington

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04234048 / NCI-2023-08592

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究Fenretinide用于复发/难治T细胞非霍奇金淋巴瘤。

?

适用疾病: T-cell Lymphoma；Cutaneous/Peripheral T-Cell Lymphoma；Peripheral T-cell Lymphoma
干预: Fenretinide
地点: United States
申办方: SciTech Development, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT04288726 / NCI-2021-01129

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

AI 简述这是一项I期试验，研究同种异体CD30.CAR-EBVST细胞用于复发/难治CD30阳性淋巴瘤。

?

适用疾病: Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type；Classical Hodgkin Lymphoma；Recurrent Aggressive Non-Hodgkin Lymphoma
干预: CD30.CAR-EBVST cells
地点: United States
申办方: Baylor College of Medicine

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04368702

CONFIRM: Magnetic Resonance Guided Radiation Therapy

AI 简述这是一项磁共振引导放射治疗的研究，用于多种癌症。

?

适用疾病: Gastric Cancer；Invasive Breast Cancer；in Situ Breast Cancer
干预: Viewray MRIdian® Linac
地点: United States
申办方: Brigham and Women's Hospital

正在招募 EARLY / Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT04512716 / NCI-2021-01361

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

AI 简述这是一项早期I期试验，研究131-I Apamistamab后接CD19靶向CAR T细胞治疗用于复发难治B细胞急性淋巴细胞白血病或弥漫大B细胞淋巴瘤。

?

适用疾病: B-ALL；DLBCL；B ALL
干预: 131-I Apamistamab，CAR T-cell
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT04545762 / NCI-2020-06711

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

AI 简述这是一项1期试验，在美国研究抗CD19 CAR-T细胞用于复发/难治非霍奇金淋巴瘤。

?

适用疾病: Refractory Non-Hodgkin Lymphoma；Burkitt Lymphoma；Mantle Cell Lymphoma
干预: Fludarabine，Cyclophosphamide，anti-CD19 CAR-T cells
地点: United States
申办方: C. Babis Andreadis

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT04664179 / NCI-2022-08324

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

AI 简述这是一项I期试验，研究EBV特异性T淋巴细胞用于EBV阳性淋巴瘤。

?

适用疾病: EBV-Related Hodgkin Lymphoma；EBV-Related Lymphoproliferative Disorder；EBV Related Non-Hodgkin's Lymphoma
干预: Dose Level 1A: 2 x 10^7 cells/m2，Dose Level 2A: 6 x 10^7 cells/m2，Dose Level 2B: 6 x 10^7 cells/m2，Dose Level 3B: 2 x 10^8 cells/m2
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04771572 / NCI-2021-03470

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

AI 简述这是一项I期试验，研究LP-118用于复发性或难治性血液恶性肿瘤。

?

适用疾病: Non Hodgkin Lymphoma；Richter Transformation；Multiple Myeloma
干预: LP-118
地点: United States
申办方: Newave Pharmaceutical Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04775745 / NCI-2021-06802

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

AI 简述这是一项I期试验，研究口服LP-168用于复发或难治性B细胞恶性肿瘤（包括慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、华氏巨球蛋白血症、滤泡淋巴瘤、弥漫大B细胞淋巴瘤、套细胞淋巴瘤），在美国开展。

?

适用疾病: CLL/SLL；Waldenstrom Macroglobulinemia；Follicular Lymphoma
干预: LP-168
地点: United States
申办方: Newave Pharmaceutical Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04830137 / NCI-2021-06410

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究NX-2127用于复发/难治性B细胞恶性肿瘤。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Waldenstrom Macroglobulinemia (WM)
干预: NX-2127
地点: United States
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04884035 / NCI-2021-07064

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

AI 简述这是一项I期试验，研究Iberdomide和CC-99282联合R-CHOP用于B细胞淋巴瘤，在美国、澳大利亚等地开展。

?

适用疾病: Lymphoma, B-Cell；B-Cell Non-Hodgkin Lymphoma
干预: CC-220，Rituximab，Cyclophosphamide，Doxorubicin
地点: United States，Australia，Greece，Poland 等 3 个
申办方: Celgene

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04892277 / NCI-2021-03969

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

AI 简述这是一项I期试验，研究CD19靶向CAR-T细胞治疗复发/难治性B细胞恶性肿瘤。

?

适用疾病: Recurrent B-Cell Non-Hodgkin Lymphoma；Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma
干预: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563，Bendamustine，Biospecimen Collection，Bone Marrow Aspiration
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04970901 / NCI-2022-04828

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

AI 简述这是一项I期试验，研究Loncastuximab Tesirine联合其他药物用于复发或难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；Relapsed B-Cell Non-Hodgkin Lymphoma；Refractory B-Cell Non-Hodgkin Lymphoma
干预: Loncastuximab Tesirine，Polatuzumab Vedotin，Glofitamab，Mosunetuzumab
地点: United States，Belgium，Czechia，Italy 等 2 个
申办方: ADC Therapeutics S.A.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05010005 / NCI-2021-09242

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

AI 简述这是一项I期试验，研究Ruxolitinib和Duvelisib用于淋巴瘤。

?

适用疾病: T-cell Lymphomas；NK-Cell Lymphomas；T-cell Prolymphocytic Leukemia
干预: Ruxolitinib，Duvelisib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05054257

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

AI 简述这是一项I期试验，研究CART19细胞用于复发难治B细胞急性淋巴细胞白血病和非霍奇金淋巴瘤。

?

适用疾病: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia；Non-Hodgkin's Lymphoma Refractory；Non-Hodgkin's Lymphoma, Relapsed
干预: Autologous CAR19 T lymphocytes
地点: Czechia
申办方: Institute of Hematology and Blood Transfusion, Czech Republic

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05077527 / NCI-2021-02771

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究CAR-T细胞疗法用于HIV合并B细胞非霍奇金淋巴瘤。

?

适用疾病: AIDS-Related Diffuse Large B-cell Lymphoma；AIDS-Related Non-Hodgkin Lymphoma；HIV Infection
干预: Axicabtagene Ciloleucel，Cyclophosphamide，Fludarabine
地点: United States
申办方: AIDS Malignancy Consortium

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05079282 / NCI-2022-03223

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

AI 简述这是一项I期试验，研究ONO-4685用于复发或难治性T细胞淋巴瘤。

?

适用疾病: Relapsed or Refractory T Cell Lymphoma；Follicular Helper T-Cell Lymphoma；Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
干预: ONO-4685
地点: United States
申办方: Ono Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05098613 / NCI-2021-11091

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

AI 简述这是一项I期试验，研究CD19x22 CAR T细胞用于复发/难治B细胞非霍奇金淋巴瘤。

?

适用疾病: Non-Hodgkin Lymphoma；B-cell Non-Hodgkin Lymphoma (B-NHL)；Mantle Cell Lymphoma (MCL)
干预: CD19x22 CAR T Cells
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05131022 / NCI-2023-01623

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究NX-5948用于复发/难治性B细胞恶性肿瘤，在美国、法国等地开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Diffuse Large B Cell Lymphoma (DLBCL)
干预: NX-5948
地点: United States，France，Italy，Netherlands 等 4 个
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05169515 / NCI-2022-06340

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究Mosunetuzumab或Glofitamab联合CC-220和/或CC-99282用于B细胞非霍奇金淋巴瘤，在多国开展。

?

适用疾病: Non-Hodgkin Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；B-Cell Non-Hodgkin Lymphoma
干预: SC Mosunetuzumab，IV Glofitamab，Iberdomide，Golcadomide
地点: United States，Israel，Italy，Spain 等 1 个
申办方: Hoffmann-La Roche

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05272384 / NCI-2022-01799

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

AI 简述这是一项I期试验，研究Nivolumab联合Decitabine和Cedazuridine用于复发或难治性B细胞淋巴瘤。

?

适用疾病: Recurrent B-Cell Non-Hodgkin Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma；Recurrent Hodgkin Lymphoma
干预: Biospecimen Collection，Computed Tomography，Decitabine and Cedazuridine，Nivolumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05292664 / NCI-2022-07956

Venetoclax Basket Trial for High Risk Hematologic Malignancies

AI 简述这是一项I期试验，研究Venetoclax联合Azacitidine、Cytarabine、Methotrexate用于高风险血液恶性肿瘤，在美国开展。

?

适用疾病: Myelodysplastic Syndromes, de Novo；Myelodysplastic Syndromes, Secondary；Myelodysplastic Syndromes, Previously Treated
干预: Venetoclax，Azacitidine，Cytarabine，Methotrexate
地点: United States
申办方: Andrew E. Place, MD

正在招募 Phase 1 药物放疗

ClinicalTrials.gov NCT05296304

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

AI 简述这是一项I期试验，研究Bexarotene联合全皮肤电子束治疗用于蕈样肉芽肿，在美国开展。

?

适用疾病: Cutaneous T-cell Lymphoma
干预: Bexarotene，Total Skin Electron Beam (TSEB)
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05312801 / NCI-2022-04030

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

AI 简述这是一项1期试验，在美国研究BAFF CAR-T细胞用于非霍奇金淋巴瘤。

?

适用疾病: Lymphoma, Non-Hodgkin Lymphoma, B-Cell；Refractory Non-Hodgkin Lymphoma；Recurrent Non-Hodgkin Lymphoma
干预: BAFF CAR-T
地点: United States
申办方: Luminary Therapeutics

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05333302

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

AI 简述这是一项1期试验，研究CD19 CAR-T细胞用于儿童/青年CD19+复发/难治性白血病或淋巴瘤，在白俄罗斯开展。

?

适用疾病: B-cell Acute Lymphoblastic Leukemia；Lymphoblastic B-Cell Lymphoma
干预: CD19 CAR-T-cells，Tocilizumab
地点: Belarus
申办方: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05362773 / NCI-2023-00598

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

AI 简述这是一项I期试验，研究MGD024用于复发或难治性血液恶性肿瘤，在美国开展。

?

适用疾病: Leukemia, Acute Myeloid；Myelodysplastic Syndromes；Classical Hodgkin Lymphoma
干预: MGD024
地点: United States
申办方: MacroGenics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05365659 / NCI-2024-06240

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

AI 简述这是一项I期试验，研究IKS03用于晚期B细胞非霍奇金淋巴瘤，在美国、澳大利亚等地开展。

?

适用疾病: B-cell Non-Hodgkin Lymphoma；Diffuse Large B Cell Lymphoma；Follicular Lymphoma
干预: IKS03
地点: United States，Australia，Canada，Italy 等 1 个
申办方: Iksuda Therapeutics Ltd.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05370430 / NCI-2022-07005

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

AI 简述这是一项I期试验，研究BAFFR-CAR T cells用于复发或难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma；Refractory Marginal Zone Lymphoma；Recurrent Follicular Lymphoma
干预: BAFFR-CAR T cells
地点: United States
申办方: PeproMene Bio, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05389423 / NCI-2022-04730

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

AI 简述这是一项I期试验，研究Pomalidomide联合DA-EPOCH±Rituximab用于HIV相关淋巴瘤。

?

适用疾病: Diffuse Large Cell Lymphoma；Non-Hodgkin Lymphoma；Burkitt Lymphoma
干预: Vincristine，Prednisone，Doxorubicin，Etoposide
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05418088 / NCI-2022-02972

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

AI 简述这是一项1期试验，研究抗CD19/CD20/CD22 CAR T细胞用于复发或难治性淋巴系统恶性肿瘤。

?

适用疾病: Recurrent Acute Lymphoblastic Leukemia；Recurrent B Acute Lymphoblastic Leukemia；Recurrent B-Cell Prolymphocytic Leukemia
干预: Anti-CD19/CD20/CD22 CAR T-Cells，Cyclophosphamide，Fludarabine Phosphate，Echocardiography
地点: United States
申办方: Sumithira Vasu

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT05432635 / NCI-2022-04622

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究基因修饰T细胞联合疫苗用于移植后B细胞非霍奇金淋巴瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；Diffuse Large B-Cell Lymphoma；Mantle Cell Lymphoma
干预: Anti-CD19-CAR CMV-specific T-lymphocytes，Autologous Hematopoietic Stem Cell Transplantation，Multi-peptide CMV-Modified Vaccinia Ankara Vaccine，Myeloablative Conditioning
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05476770

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

AI 简述这是一项1期试验，研究Tagraxofusp用于儿童复发或难治CD123阳性血液恶性肿瘤，在美国、澳大利亚等地开展。

?

适用疾病: Hematologic Malignancy；AML；ALL
干预: Tagraxofusp，Fludarabine，Cytarabine，Dexamethasone
地点: United States，Australia
申办方: Therapeutic Advances in Childhood Leukemia Consortium

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05512390 / NCI-2023-03269

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项I期试验，研究ABBV-319用于复发/难治性弥漫大B细胞淋巴瘤、滤泡性淋巴瘤或慢性淋巴细胞白血病，在美国等国家开展。

?

适用疾病: Diffuse Large B-Cell Lymphoma；Chronic Lymphocytic Leukemia；Follicular Lymphoma
干预: ABBV-319
地点: United States，Australia，Canada，Israel 等 2 个
申办方: AbbVie

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05544019

Study of SGR-1505 in Mature B-Cell Neoplasms

AI 简述这是一项I期试验，研究SGR-1505用于成熟B细胞肿瘤，在美国、法国等地开展。

?

适用疾病: Mature B-Cell Neoplasm；Non Hodgkin Lymphoma；DLBCL
干预: SGR-1505
地点: United States，France，Italy，Moldova 等 4 个
申办方: Schrödinger, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05544968

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

AI 简述一项I期试验，研究anti-CD30 biAb-AATC用于复发/难治性CD30阳性血液恶性肿瘤。

?

适用疾病: Hodgkin Disease；CD30-Positive Diffuse Large B-Cell Lymphoma；CD30+ Anaplastic Large Cell Lymphoma
干预: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)，GM-CSF
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05602363 / NCI-2023-06023

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究Docirbrutinib用于既往治疗过的慢性淋巴细胞白血病或非霍奇金淋巴瘤。

?

适用疾病: B-cell Malignancy；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: Docirbrutinib
地点: United States
申办方: Carna Biosciences, Inc.

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05618925

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

AI 简述这是一项I期试验，研究N803、CD19t-haNK、环磷酰胺、氟达拉滨用于复发/难治非霍奇金淋巴瘤。

?

适用疾病: Non Hodgkin's Lymphoma Refractory/Relapsed
干预: N803，CD19t-haNK suspension，Cyclophosphamide，Fludarabine
地点: United States
申办方: ImmunityBio, Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05625594 / NCI-2022-09152

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

AI 简述这是一项I期试验，研究脑室内注射CD19-CAR T细胞用于中枢神经系统淋巴瘤，在美国开展。

?

适用疾病: Central Nervous System Lymphoma；Secondary Central Nervous System Lymphoma；Primary Central Nervous System Lymphoma
干预: Aspiration，Biospecimen Collection，Catheterization，CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05659732

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

AI 简述这是一项I期试验，研究PEP07用于晚期癌症。

?

适用疾病: Acute Myeloid Leukemia；Lymphoma, Mantle-Cell
干预: PEP07
地点: Australia，Taiwan
申办方: PharmaEngine

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05679895

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

AI 简述这是一项I期试验，研究CD1a-CAR T细胞疗法用于复发/难治性T细胞急性淋巴细胞白血病或淋巴母细胞淋巴瘤。在西班牙开展。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；Lymphoblastic T-Cell Lymphoma
干预: CD1a-CAR T
地点: Spain
申办方: OneChain Immunotherapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05685173 / NCI-2023-03084

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

AI 简述这是一项I期试验，研究REGN5837联合Odronextamab用于侵袭性B细胞非霍奇金淋巴瘤。在美国、法国等地开展。

?

适用疾病: B-cell Non-Hodgkins Lymphoma (B-NHL)；Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma；Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
干预: Odronextamab，REGN5837
地点: United States，France，Netherlands，Spain 等 1 个
申办方: Regeneron Pharmaceuticals

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05705570

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

AI 简述这是一项I期试验，研究CAR-T细胞用于复发难治CD19阳性B淋巴恶性肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Acute Lymphoblastic Leukemia Refractory；B-cell Lymphoma Recurrent
干预: Cyclophosphamide，Fludarabine，Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0
地点: Brazil
申办方: Nelson Hamerschlak

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05755087 / NCI-2023-00200

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

AI 简述这是一项I期试验，在美国研究Tegavivint用于复发或难治性大B细胞淋巴瘤。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type；Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type；Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
干预: Biospecimen Collection，Computed Tomography，Positron Emission Tomography，Tegavivint
地点: United States
申办方: Lapo Alinari

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05773040 / NCI-2023-02055

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

AI 简述这是一项I期试验，研究JV-213自体CD79b靶向CAR-T细胞疗法用于复发或难治性B细胞淋巴瘤。

?

适用疾病: Lymphomas；B-cell Lymphomas；Refractory Marginal Zone Lymphoma
干预: JV-213，Leukapheresis
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05794958 / NCI-2023-05593

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

AI 简述这是一项I期试验，研究Axicabtagene Ciloleucel再输注用于标准治疗后复发难治的高危非霍奇金淋巴瘤。

?

适用疾病: Non-Hodgkin Lymphoma；Large B-cell Lymphoma；Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: Axicabtagene Ciloleucel
地点: United States
申办方: Stanford University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05798897 / NCI-2023-03005

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

AI 简述这是一项I期试验，研究MT-601用于复发/难治性淋巴瘤，在美国开展。

?

适用疾病: Non-Hodgkin Lymphoma, Adult；Non-Hodgkin Lymphoma, Refractory；Non-Hodgkin Lymphoma, Relapsed
干预: MT-601
地点: United States
申办方: Marker Therapeutics, Inc.

正在招募 EARLY / Phase 1 生物制剂手术/操作放疗

ClinicalTrials.gov NCT05800405

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

AI 简述这是一项早期I期试验，研究桥接放疗后行CAR-T细胞治疗用于复发/难治性大B细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Refractory Diffuse Large B-Cell Lymphoma
干预: Biospecimen Collection，Chimeric Antigen Receptor T-Cell Therapy，Computed Tomography，External Beam Radiation Therapy
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT05801913 / NCI-2023-02195

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究CMV特异性CD19-CAR T细胞联合疫苗用于复发难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: High Grade B-Cell Non-Hodgkin's Lymphoma；Intermediate Grade B-Cell Non-Hodgkin's Lymphoma；Recurrent B-Cell Non-Hodgkin Lymphoma
干预: Anti-CD19-CAR CMV-specific T-lymphocytes，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 基因治疗

ClinicalTrials.gov NCT05836896

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究BCMA靶向CAR-T细胞用于复发难治性B细胞恶性肿瘤。

?

适用疾病: Neoplasms；Relapsed Diffuse Large B-cell Lymphoma (DLBCL)；Refractory Diffuse Large B-cell Lymphoma (DLBCL)
干预: MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
地点: Germany
申办方: Technische Universität Dresden

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05887167

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

AI 简述这是一项I期试验，研究收集并联合自体造血干细胞与CAR-T细胞疗法用于复发/难治性血液恶性肿瘤。

?

适用疾病: Hematologic Malignancy；Large B-cell Lymphoma；Acute Lymphoblastic Leukemia
干预: autologous hematopoietic stem cells added to planned CAR T
地点: United States
申办方: Joshua Sasine, MD, PhD

正在招募 Phase 1 药物放疗

ClinicalTrials.gov NCT05950802

Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

AI 简述这是一项1期试验，优化淋巴细胞清除方案以改善接受Yescarta细胞治疗患者的结局，在加拿大开展。

?

适用疾病: DLBCL - Diffuse Large B Cell Lymphoma
干预: Cyclophosphamide，TLI
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05963217

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

AI 简述这是一项I期试验，研究TBI-2001（CAR-T）用于复发难治CD19+B细胞淋巴瘤、CLL/SLL。

?

适用疾病: Relapsed or Refractory CD19+ B-cell Lymphoma；Relapsed or Refractory Chronic Lymphocytic Leukemia；Relapsed or Refractory Small Lymphocytic Lymphoma
干预: TBI-2001，Cyclophosphamide，Fludarabine
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 生物制剂放疗

ClinicalTrials.gov / NCI NCT05967416 / NCI-2023-10268

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

AI 简述这是一项I期试验，研究SIRPant-M用于复发难治非霍奇金淋巴瘤。

?

适用疾病: Refractory Non-Hodgkin Lymphoma；Relapsed Non-Hodgkin Lymphoma；Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type
干预: SIRPant-M，External-beam radiotherapy (XRT)
地点: United States
申办方: SIRPant Immunotherapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05984147

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

AI 简述这是一项I期试验，研究AUR108用于复发晚期淋巴瘤，在印度开展。

?

适用疾病: Relapsed Advanced Lymphomas
干预: AUR108
地点: India
申办方: Aurigene Discovery Technologies Limited

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05989204 / NCI-2023-10266

TmCD19-IL18 in CD19+ Cancers

AI 简述这是一项I期试验，研究TmCD19-IL18用于CD19阳性非霍奇金淋巴瘤，在美国开展。

?

适用疾病: Non Hodgkin Lymphoma；Refractory Marginal Zone Lymphoma；Refractory Double-Hit Lymphoma
干预: TmCD19-IL18
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05990465

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究LV20.19 CAR-T细胞联合Pirtobrutinib用于复发难治B细胞淋巴瘤，在美国开展。

?

适用疾病: Non Hodgkin Lymphoma；Diffuse Large B Cell Lymphoma；Follicular Lymphoma
干预: Pirtobrutinib，LV20.19 CAR T cells
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06015880 / NCI-2023-06477

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AI 简述这是一项I期试验，在美国研究Mosunetuzumab、Polatuzumab Vedotin和Lenalidomide联合用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified；High Grade B-Cell Lymphoma；Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
干预: Biospecimen Collection，Computed Tomography，Lenalidomide，Mosunetuzumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06022029

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

AI 简述这是一项I期试验，研究瘤内ONM-501单药或联合cemiplimab用于晚期实体瘤和淋巴瘤。

?

适用疾病: Triple Negative Breast Cancer；Diffuse Large B Cell Lymphoma；Follicular Lymphoma
干预: ONM-501，Cemiplimab
地点: United States，Australia
申办方: OncoNano Medicine, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06026319 / NCI-2023-09089

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究CD79b-19 CAR T细胞用于非霍奇金淋巴瘤。

?

适用疾病: Non-hodgkin Lymphoma；Relapsed Non-Hodgkin Lymphoma；Refractory Non-Hodgkin Lymphoma
干预: CD79b-19 CAR T cells，Cyclophosphamide，Fludarabine
地点: United States
申办方: Marcela V. Maus, M.D.,Ph.D.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06028373 / NCI-2023-09543

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

AI 简述这是一项I期试验，研究ATG-031用于晚期实体瘤或B细胞非霍奇金淋巴瘤。

?

适用疾病: Advanced Solid Tumors；B-cell Non-Hodgkin Lymphomas；Advanced Malignant Solid Tumor
干预: ATG-031
地点: United States
申办方: Antengene Biologics Limited

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06132503

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

AI 简述这是一项I期试验，研究LP-284用于复发或难治性淋巴瘤和晚期实体瘤。

?

适用疾病: Relapsed or Refractory Lymphomas；Advanced Solid Tumor
干预: LP-284
地点: United States
申办方: Lantern Pharma Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06150664 / NCI-2024-04028

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

AI 简述这是一项I期试验，研究CTX-8371用于多种晚期恶性肿瘤。

?

适用疾病: Non Small Cell Lung Cancer；Triple Negative Breast Cancer；Hodgkin Lymphoma
干预: CTX-8371
地点: United States
申办方: Compass Therapeutics

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06173518 / NCI-2024-02788

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

AI 简述这是一项I期试验，研究AUTO1用于复发或难治性B细胞急性淋巴细胞白血病和B细胞非霍奇金淋巴瘤儿童患者。

?

适用疾病: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia；Relapsed or Refractory B Cell Non-Hodgkin Lymphoma；Recurrent B Acute Lymphoblastic Leukemia
干预: AUTO1
地点: United States，Spain，United Kingdom
申办方: Autolus Limited

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06176690 / NCI-2026-00532

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

AI 简述这是一项I期试验，研究C7R修饰的CD30.CAR EBVST细胞用于CD30阳性淋巴瘤。

?

适用疾病: CD30-Positive Diffuse Large B-Cell Lymphoma；Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type；Anaplastic Large Cell Lymphoma, ALK-Positive
干预: C7R.CD30.CAR-EBVST cells
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06191887 / NCI-2023-10077

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

AI 简述这是一项I期试验，研究BAFFR靶向CAR-T细胞用于复发或难治性B细胞血液恶性肿瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；Recurrent Chronic Lymphocytic Leukemia；Recurrent Diffuse Large B-Cell Lymphoma
干预: Autologous BAFFR-targeting CAR T Cells，Bendamustine，Biopsy，Biospecimen Collection
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06208735

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

AI 简述这是一项1期试验，在加拿大研究CLIC-2201用于复发/难治性B细胞恶性肿瘤。

?

适用疾病: B-Cell Leukemia；Non-Hodgkin's Lymphoma；B-cell Acute Lymphoblastic Leukemia
干预: CLIC-2201
地点: Canada
申办方: British Columbia Cancer Agency

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06209619 / NCI-2023-10172

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

AI 简述这是一项1期试验，研究CC-99282联合Rituximab在CAR-T治疗后早期用于复发非霍奇金淋巴瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma-Recurrent；Diffuse Large B-Cell Lymphoma-Recurrent；Follicular Lymphoma-Recurrent
干预: Biopsy，Biospecimen Collection，Computed Tomography，Golcadomide
地点: United States
申办方: Nathan Denlinger

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06223542 / NCI-2022-11194

Studying TAK-243 in Patients With Advanced Cancer

AI 简述这是一项I期试验，研究TAK-243用于晚期实体瘤和淋巴瘤。

?

适用疾病: Advanced Lymphoma；Advanced Malignant Solid Neoplasm；Indolent Non-Hodgkin Lymphoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Echocardiography Test
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06227026 / NCI-2024-00442

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

AI 简述这是一项I期试验，研究抗CD19 CAR-T细胞用于复发/难治性CD19+恶性肿瘤。在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia；Diffuse Large B Cell Lymphoma；Refractory Acute Lymphoblastic Leukemia (ALL)
干预: Anti-CD19 CAR-T cells
地点: United States
申办方: University of Utah

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06326463 / NCI-2024-03240

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

AI 简述这是一项I期试验，研究CD70靶向CAR-T细胞用于儿童血液恶性肿瘤，在美国开展。

?

适用疾病: Hematologic Malignancy；ALL, Childhood；AML, Childhood
干预: Fludarabine，Cyclophosphamide，CD70-CAR T cell infusion (Autologous)，Mesna
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06334991

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究CD19 t-haNK用于复发/难治性非霍奇金淋巴瘤。

?

适用疾病: Non-Hodgkin Lymphoma Refractory/ Relapsed
干预: CD19 t-haNK
地点: South Africa
申办方: ImmunityBio, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06340737 / NCI-2024-03048

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

AI 简述这是一项I期试验，研究自体CD22 CAR-T细胞用于复发/难治性B细胞淋巴瘤，在美国开展。

?

适用疾病: Follicular Lymphoma；Mantle Cell Lymphoma；Hairy Cell Leukemia
干预: CD22CART Infusion
地点: United States
申办方: Stanford University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06392477

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究SAR448501用于复发/难治性B细胞非霍奇金淋巴瘤，在澳大利亚、新加坡等地开展。

?

适用疾病: B-cell Non Hodgkin Lymphoma
干预: SAR448501
地点: Australia，Serbia，Singapore，South Korea 等 1 个
申办方: Sanofi

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06393738 / NCI-2024-06932

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

AI 简述这是一项I期试验，研究ARV-393用于复发/难治性非霍奇金淋巴瘤，在美国、加拿大等地开展。

?

适用疾病: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)；Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)；Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
干预: ARV-393，Glofitamab
地点: United States，Canada，Denmark，Spain
申办方: Arvinas Inc.

正在招募 EARLY / Phase 1 器械药物

ClinicalTrials.gov NCT06398457

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

AI 简述这是一项早期I期试验，研究Daratumumab和透明质酸酶-fihj用于高危原发移植物失败的患者。在美国开展。

?

适用疾病: Hematologic Malignancy；Bone Marrow Transplant Rejection；Acute Myeloid Leukemia (AML)
干预: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)，JH-DSA Semi-Quant Screen and Response Score
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06420089 / NCI-2024-06437

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

AI 简述这是一项I期试验，研究Senza5 CART5用于复发难治性T细胞非霍奇金淋巴瘤。在美国开展。

?

适用疾病: T Cell Non-Hodgkin Lymphoma；Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
干预: Senza5 CART5
地点: United States
申办方: Vittoria Biotherapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06447376

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

AI 简述这是一项I期试验，研究Siltuximab预防和治疗Epcoritamab引起的细胞因子释放综合征用于非霍奇金淋巴瘤。

?

适用疾病: Non-Hodgkin Lymphoma；Cytokine Release Syndrome
干预: Siltuximab，Epcoritamab，Gemcitabine and oxaliplatin
地点: United States
申办方: Taylor Brooks

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06508463 / NCI-2024-09810

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

AI 简述这是一项I期试验，研究静脉注射水疱性口炎病毒用于外周T细胞淋巴瘤。

?

适用疾病: Peripheral T Cell Lymphoma；Relapsed Peripheral T-Cell Lymphoma；Peripheral T-Cell Lymphoma, Not Otherwise Specified
干预: Biopsy，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物基因治疗

ClinicalTrials.gov / NCI NCT06528301 / NCI-2024-09413

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

AI 简述这是一项1期试验，研究UB-VV111联合或不联合雷帕霉素用于复发/难治性CD19阳性B细胞恶性肿瘤，在美国和澳大利亚开展。

?

适用疾病: Lymphoma, B-Cell；Lymphoma, Non-Hodgkin (NHL)；Lymphoma, Large B-Cell, Diffuse (DLBCL)
干预: UB-VV111，rapamycin
地点: United States，Australia
申办方: Umoja Biopharma

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06544265 / NCI-2025-03031

SynKIR-310 for Relapsed/Refractory B-NHL

AI 简述这是一项I期试验，研究SynKIR-310用于复发/难治性B细胞非霍奇金淋巴瘤，在美国开展。

?

适用疾病: B Cell Lymphoma；NHL, Adult；Mantle Cell Lymphoma
干预: SynKIR-310
地点: United States
申办方: Verismo Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06547528

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

AI 简述这是一项I期试验，研究ONO-4685单药用于复发或难治性T细胞淋巴瘤和CLL/SLL。在日本等地开展。

?

适用疾病: Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
干预: ONO-4685
地点: Japan
申办方: Ono Pharmaceutical Co., Ltd.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06593145

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

AI 简述这是一项I期试验，研究FCTX-CL19-1 CAR-T细胞用于难治复发CD19+ B细胞肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia (ALL)；Mantle Cell Lymphoma (MCL)；Large B-cell Lymphoma
干预: FCTX-CL19-1 (Tarcidomgen Kimleucel)
地点: Poland
申办方: FamiCordTx

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06624085 / NCI-2024-09804

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AI 简述这是一项I期试验，研究Glofitamab联合化疗用于复发或难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma；Refractory Diffuse Large B-Cell Lymphoma
干预: Glofitamab，Tocilizumab，Obinutuzumab，Gemcitabine
地点: United States，Puerto Rico
申办方: Hoffmann-La Roche

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06667687

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

AI 简述这是一项I期试验，在美国、澳大利亚、以色列、日本等地研究ABBV-291用于非霍奇金淋巴瘤。

?

适用疾病: Non-Hodgkin's Lymphoma
干预: ABBV-291
地点: United States，Australia，Israel，Japan 等 1 个
申办方: AbbVie

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT06672705 / NCI-2024-08887

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

AI 简述这是一项I期试验，研究Epcoritamab用于复发或难治性移植后淋巴增殖性疾病。

?

适用疾病: Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder；EBV-Related Post-Transplant Lymphoproliferative Disorder；Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder
干预: Biopsy，Biospecimen Collection，Computed Tomography，Epcoritamab
地点: United States
申办方: Timothy Voorhees

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06675123 / NCI-2024-08854

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

AI 简述这是一项I期试验，研究Pacritinib联合BTK抑制剂用于复发或难治性套细胞淋巴瘤。

?

适用疾病: Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: Biopsy，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06699771

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

AI 简述这是一项I期试验，研究GCC2005用于复发/难治性NK和T细胞淋巴瘤。

?

适用疾病: Lymphoma, T-Cell
干预: GCC2005，Cyclophosphamide，Fludarabine
地点: South Korea
申办方: GC Cell Corporation

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06703892

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

AI 简述这是一项I期试验，研究GF-CART01用于复发或难治性B细胞血液恶性肿瘤，在台湾开展。

?

适用疾病: Diffuse Large B Cell Lymphoma Relapsed；Diffuse Large B Cell Lymphoma Refractory；Follicular Lymphoma ( FL)
干预: GF-CART01，GF-CART01，GF-CART01
地点: Taiwan
申办方: GenomeFrontier Therapeutics TW Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06708897 / NCI-2025-01918

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

AI 简述这是一项I期试验，在美国开展，研究ZE50-0134用于复发难治CLL/SLL及低级别淋巴瘤。

?

适用疾病: CLL / SLL；CLL (Chronic Lymphocytic Leukemia)；SLL (Small Lymphocytic Lymphoma)
干预: ZE 50-0134
地点: United States
申办方: Lomond Therapeutics Holdings, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06709469

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

AI 简述这是一项I期试验，在西班牙开展，研究CAR T细胞用于儿童、青少年和年轻成人复发难治急性淋巴细胞白血病。

?

适用疾病: Precursor Cell Lymphoblastic Leukemia-Lymphoma
干预: Autologous CD19/CD22 CAR T cells，Allogeneic CART-NKG2D cells
地点: Spain
申办方: Instituto de Investigación Hospital Universitario La Paz

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06733441 / NCI-2024-10412

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

AI 简述这是一项I期试验，研究TLN-254用于复发或难治性T细胞淋巴瘤。在美国、加拿大开展。

?

适用疾病: Lymphoma；Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Recurrent Follicular T-Cell Lymphoma
干预: TLN-254
地点: United States，Canada
申办方: Treeline Biosciences, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06755450

Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

AI 简述这是一项I期试验，研究AUR112用于复发难治性晚期淋巴瘤，在印度开展。

?

适用疾病: Relapsed Advanced Lymphomas
干预: AUR112
地点: India
申办方: Aurigene Discovery Technologies Limited

正在招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT06765876

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

AI 简述这是一项早期I期试验，研究CART123 T细胞用于复发难治CD123+血液恶性肿瘤。

?

适用疾病: Leukemia, Myeloid, Acute(AML)；Precursor Cell Lymphoblastic Leukemia-Lymphoma；Myelodysplastic Syndromes (MDS)
干预: Autologous CAR123 T lymphocytes
地点: Czechia
申办方: Institute of Hematology and Blood Transfusion, Czech Republic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06789159 / NCI-2024-10500

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

AI 简述这是一项I期试验，研究VK-2019用于复发或难治EB病毒阳性弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma Refractory；Diffuse Large B Cell Lymphoma Relapsed；Epstein-Barr Virus (EBV) Infection
干预: VK-2019
地点: United States
申办方: Pierluigi Porcu

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06792734 / NCI-2025-01322

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

AI 简述这是一项I期试验，研究BTM-3566用于复发/难治性成熟B细胞淋巴瘤。

?

适用疾病: Lymphoma, B-Cell；Recurrent Mature B-Cell Non-Hodgkin Lymphoma；Refractory Mature B-Cell Non-Hodgkin Lymphoma
干预: BTM-3566
地点: United States
申办方: Bantam Pharmaceuticals

正在招募阶段未标明生物制剂

ClinicalTrials.gov NCT06866873

CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

AI 简述这是一项试验，研究CD-19 CAR-T细胞用于儿童B细胞ALL或淋巴瘤。

?

适用疾病: Lymphoma, B-Cell；Acute Lymphoblastic Leukemia, Pediatric
干预: CAR-T
地点: Hong Kong
申办方: Hong Kong Children's Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06879340 / NCI-2025-03905

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

AI 简述这是一项I期试验，研究DuoCAR20.19.22-D95用于复发或难治性B细胞恶性肿瘤，以及氟达拉滨和环磷酰胺作为条件治疗，在美国开展。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma；B-cell Acute Lymphoblastic Leukemia；Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type
干预: DuoCAR20.19.22-D95，Fludarabine (Conditional therapy)，Cyclophosphamide (Conditional therapy)
地点: United States
申办方: University of Kansas Medical Center

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06883604

Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin

AI 简述这是一项研究质子治疗用于霍奇金淋巴瘤的临床试验，在瑞典开展。

?

适用疾病: Hodgkin Lymphoma
干预: Proton therapy.
地点: Sweden
申办方: Uppsala University Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06916767 / NCI-2025-05415

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

AI 简述这是一项I期试验，研究BAFF CAR-T细胞（LMY-920）用于复发难治性CLL/小淋巴细胞淋巴瘤。

?

适用疾病: Relapsed CLL；Refractory CLL；Refractory Lymphoma
干预: BAFF CAR-T，Obinutuzumab，Cyclophosphamide，Fludarabine
地点: United States
申办方: Paolo Caimi, MD

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06934382 / NCI-2025-05470

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

AI 简述这是一项I期试验，研究Anti-CD7 CAR-T细胞用于复发/难治性T细胞急性淋巴细胞白血病或淋巴瘤。

?

适用疾病: T-Cell Acute Lymphoblastic Leukemia/Lymphoma；Recurrent T Acute Lymphoblastic Leukemia；Refractory T Acute Lymphoblastic Leukemia
干预: Allogeneic anti-CD7 CAR-T cells (BEAM-201)
地点: United States
申办方: Stephan Grupp MD PhD

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06977711 / NCI-2025-04162

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

AI 简述这是一项I期试验，研究Loncastuximab和Roflumilast联合R-CHOP用于初治高危弥漫大B细胞淋巴瘤，在美国开展。

?

适用疾病: Diffuse Large B-cell Lymphoma；Large B-Cell Lymphoma with IRF4 Rearrangement；Fibrin-Associated Diffuse Large B-Cell Lymphoma
干预: Loncastuximab，Roflumilast，Rituximab，Cyclophosphamide
地点: United States
申办方: The University of Texas Health Science Center at San Antonio

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06980116

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

AI 简述这是一项I期试验，研究EXS73565用于复发难治B细胞恶性肿瘤，在格鲁吉亚、摩尔多瓦、西班牙、乌克兰开展。

?

适用疾病: Relapsed or Refractory B-cell Malignancies；Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)；Follicular Lymphoma (FL)
干预: EXS73565
地点: Georgia，Moldova，Spain，Ukraine 等 1 个
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07001384 / NCI-2025-05949

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

AI 简述这是一项I期试验，在美国研究Alectinib和Duvelisib用于ALK阳性间变性大细胞淋巴瘤。

?

适用疾病: Anaplastic Lymphoma Kinase；Anaplastic Large Cell Lymphoma；Refractory Anaplastic Large Cell Lymphoma
干预: Alectinib，Duvelisib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07044050

A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

AI 简述这是一项I期试验，研究OT-C001（扩增/活化的同种异体自然杀伤细胞）用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-cell Lymphoma With no Other Specification
干预: allogenic natural killer cells
地点: France
申办方: Emercell SAS

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07047885 / NCI-2025-04854

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

AI 简述这是一项I期试验，研究Ropeginterferon alfa-2b用于皮肤T细胞淋巴瘤，包括蕈样肉芽肿和塞扎里综合征。

?

适用疾病: Cutaneous T Cell Lymphoma；Mycosis Fungoides；Sezary Syndrome
干预: Ropeginterferon alfa-2b
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT07052305 / NCI-2026-00568

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

AI 简述这是一项I期试验，研究NT-I7（Efineptakin Alfa）用于CAR-T细胞治疗后的复发/难治性大B细胞淋巴瘤。

?

适用疾病: Large B-cell Lymphoma；Recurrent High-Grade B-Cell Lymphoma；Refractory High-Grade B-Cell Lymphoma
干预: NT-I7，CAR T-cell therapy
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT07055477 / NCI-2025-05058

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

AI 简述这是一项I期试验，研究CCR4 CAR T细胞用于CCR4阳性T细胞恶性肿瘤。

?

适用疾病: Relapsed and/or Refractory Mature T Cell Malignancy；Peripheral T-Cell Lymphoma；Angioimmunoblastic T-cell Lymphoma
干预: Cyclophosphamide，Fludarabine，Autologous CCR4 CAR T cells
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07082803 / NCI-2025-07427

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

AI 简述这是一项I期试验，研究TLN-121和TLN-254用于复发或难治性非霍奇金淋巴瘤，在美国、澳大利亚、加拿大开展。

?

适用疾病: Lymphoma；Lymphoma, Non Hodgkin；Recurrent High-Grade B-Cell Lymphoma
干预: TLN-121，TLN-254
地点: United States，Australia，Canada
申办方: Treeline Biosciences, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07082868 / NCI-2025-06902

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

AI 简述这是一项I期试验，研究Epcoritamab和ibrutinib用于中枢神经系统淋巴瘤，在美国开展。

?

适用疾病: Primary Central Nervous System Lymphoma (PCNSL)；Primary Central Nervous System Lymphoma；Relapsed Primary Central Nervous System Lymphoma
干预: ibrutinib，Epcoritamab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07108868

A Phase I Dose Finding Study of MB-CART2219.1

AI 简述这是一项I期试验，研究MB-CART2219.1（靶向CD19和CD22的CAR-T细胞）用于淋巴瘤、CLL和急性淋巴细胞白血病。

?

适用疾病: Lymphoma；CLL；Acute Lymphoblastic Leukemia, Pediatric
干预: CAR-T cells targeting CD19 and CD22
地点: Germany
申办方: University Hospital Tuebingen

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07114367

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

AI 简述这是一项I期试验，研究NB02 (Poseltinib)单药用于复发难治性非霍奇金淋巴瘤。在韩国开展。

?

适用疾病: Non Hodgkin Lymphoma (NHL)
干预: NB02 (Poseltinib)
地点: South Korea
申办方: NOBO Medicine

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07121946 / NCI-2025-08847

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究LTZ-301用于复发/难治性非霍奇金淋巴瘤，在美国开展。

?

适用疾病: Non-Hodgkin Lymphoma Refractory/ Relapsed；DLBCL - Diffuse Large B Cell Lymphoma；Mantle Cell Lymphoma (MCL)
干预: LTZ-301
地点: United States
申办方: LTZ Therapeutics, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07137494 / NCI-2025-06306

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

AI 简述这是一项I期试验，在美国开展，研究MB-CART19.1细胞疗法用于中枢神经系统淋巴瘤。

?

适用疾病: Primary Central Nervous System (CNS) Lymphoma；Secondary Central Nervous System Lymphoma；Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
干预: MB-CART19.1 Cellular Therapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07166419 / NCI-2025-05721

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

AI 简述这是一项I期试验，在United States开展，研究抗CD19/20/22 CAR-T细胞用于复发或难治性非霍奇金淋巴瘤和急性淋巴细胞白血病。

?

适用疾病: Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive；Recurrent Acute Lymphoblastic Leukemia；Recurrent Chronic Lymphocytic Leukemia
干预: Autologous Anti-CD19/CD20/CD22 CAR T-cells，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1 基因治疗

ClinicalTrials.gov NCT07220993

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

AI 简述这是一项I期试验，研究CD7靶向CAR-T细胞用于T细胞恶性肿瘤。

?

适用疾病: T-cell Acute Lymphoblastic Lymphoma；T-non-Hodgkin Lymphoma；T-cell Acute Lymphoblastic Leukemia
干预: CD7.CAR/28zeta T Cells
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07226843 / NCI-2025-09711

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

AI 简述这是一项I期试验，研究LY4584180联合Rituximab用于复发血液癌症，在美国、法国、德国、意大利等地开展。

?

适用疾病: Lymphoma, Non-Hodgkin's；Lymphoma, Diffuse Large B-Cell；Follicular Lymphoma
干预: LY4584180，Rituximab
地点: United States，France，Germany，Italy 等 4 个
申办方: Eli Lilly and Company

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07300683

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

AI 简述这是一项I期试验，研究抗CCR9 CAR T细胞用于T细胞白血病/淋巴瘤。在英国开展。

?

适用疾病: T Cell Acute Lymphoblastic Leukemia；T Cell Lymphoblastic Lymphoma
干预: CARCCR9 T cells
地点: United Kingdom
申办方: University College, London

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07308132

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

AI 简述这是一项I期试验，研究JNJ-95566692用于非霍奇金淋巴瘤。

?

适用疾病: Lymphoma, Non-Hodgkin
干预: JNJ-95566692，JNJ-87801493
地点: Australia，Belgium，Turkey (Türkiye)
申办方: Janssen Research & Development, LLC

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07343934

huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma

AI 简述这是一项I期试验，研究huCART19-IL18-eDHFR细胞用于复发/难治性滤泡性淋巴瘤。

?

适用疾病: Relapsed or Refractory Follicular Lymphoma
干预: huCART19-IL18-eDHFR cells，[18F]Fluoropropyl-Trimethoprim
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07444632 / NCI-2026-01395

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

AI 简述这是一项I期试验，研究CAR.70工程化的NK细胞用于复发/难治性淋巴恶性肿瘤。

?

适用疾病: Lymphoid；Hodgkin Lymphoma；Recurrent B Acute Lymphoblastic Leukemia
干预: Fludarabine，TGFBR2 KO CAR27/IL-15 NK cells，Cyclophosphamide
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07451054 / NCI-2026-04589

CD45BE-HSPC + CART-45 Cells

AI 简述这是一项1期试验，研究CD45BE-HSPC联合CART-45细胞用于复发/难治性淋巴瘤，在美国开展。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma (NHL)；Richter's Transformation；T-Cell Non-Hodgkin Lymphoma
干预: CART-45 cells，CD45BE-HSPC
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1 生物制剂药物放疗

ClinicalTrials.gov / NCI NCT07478848 / NCI-2026-04228

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

AI 简述这是一项I期试验，研究放疗、口服万古霉素和CAR-T用于B细胞淋巴瘤。

?

适用疾病: Large B Cell Lymphoma；Non Hodgkin Lymphoma (NHL)；Diffuse Large B Cell Lymphoma (DLBCL)
干预: Vancomycin 125mg，Radiation Therapy，CAR-T
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募阶段未标明生物制剂

ClinicalTrials.gov NCT07509450

Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study

AI 简述这是一项初步研究，评估粪便微生物移植在CAR-T细胞治疗和异基因干细胞移植患者中的作用。

?

适用疾病: Lymphoma Receiving CAR-T Therapy
干预: Fecal Microbial Transplant Enema，Fecal Microbial Transplant Enema
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07513129 / NCI-2026-02416

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

AI 简述这是一项I期试验，研究Venetoclax、Dexamethasone、Bortezomib和Daratumumab用于复发/难治T细胞急性淋巴细胞白血病。

?

适用疾病: T-cell Acute Lymphoblastic Leukemia；Lymphoma；Recurrent T Acute Lymphoblastic Leukemia
干预: Venetoclax，Dexamethasone，Bortezomib，Daratumumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT07528352 / NCI-2026-04042

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

AI 简述这是一项I期试验，研究体外放疗后双特异性抗体治疗用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma；Recurrent Diffuse Large B-Cell Lymphoma；Refractory Diffuse Large B-Cell Lymphoma
干预: Epcoritamab，Glofitamab，External Beam Radiation Therapy
地点: United States
申办方: University of Utah

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT07532525 / NCI-2026-00885

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

AI 简述这是一项I期试验，研究来那度胺用于CAR-T细胞治疗后复发或难治性CD19+ B细胞白血病或淋巴瘤。

?

适用疾病: Recurrent B Acute Lymphoblastic Leukemia；Recurrent B-Cell Non-Hodgkin Lymphoma；Refractory B Acute Lymphoblastic Leukemia
干预: Biospecimen Collection，Pomalidomide
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07586618

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

AI 简述这是一项I期试验，在美国开展，首次在人体中研究新药4A10用于复发难治性急性淋巴细胞白血病或淋巴母细胞淋巴瘤。

?

适用疾病: Lymphoblastic Lymphoma；Acute Lymphoblastic Leukemia ALL
干预: 4A10
地点: United States
申办方: Allterum Therapeutics, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07691606

A Study of ARC-02 in B-cell NHL

AI 简述这是一项I期试验，研究ARC-02联合利妥昔单抗用于B细胞非霍奇金淋巴瘤，在美国等国开展。

?

适用疾病: B-cell Non Hodgkin Lymphoma
干预: ARC-02，Rituximab
地点: United States，Australia，France，Italy 等 2 个
申办方: Taiho Oncology, Inc.

正在招募 Phase 1 器械药物

ClinicalTrials.gov NCT07257419

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

AI 简述这是一项1期试验，研究CD45RA去除的CD19-CAR T细胞用于复发难治CD19+ ALL和淋巴瘤。在美国开展。

?

适用疾病: Relapsed Pediatric ALL；Hematopoietic Cell Transplantation；Hematologic Malignancy
干预: Anti-Thymocyte Globulin (Rabbit)，Cyclophosphamide，Fludarabine，Thiotepa
地点: United States
申办方: St. Jude Children's Research Hospital

即将招募 Phase 3 生物制剂药物

ClinicalTrials.gov NCT05700448

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

AI 简述这是一项III期试验，研究Sugemalimab联合化疗用于结外NK/T细胞淋巴瘤。

?

适用疾病: Extranodal NK/T-cell Lymphoma
干预: Sugemalimab，Placebo，Pegaspargase，Gemcitabine
地点: 未列出
申办方: CStone Pharmaceuticals

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06355401

Maintenance Hormonal Therapy and DLBCL

AI 简述这是一项II/III期试验，研究Tamoxifen维持治疗用于弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma
干预: Tamoxifen 20mg
地点: 未列出
申办方: Sohag University

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06573645

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

AI 简述这是一项III期试验，比较高剂量Rituximab联合CHOP方案用于新诊断的晚期弥漫大B细胞淋巴瘤男性患者。

?

适用疾病: Lymphoma, Large B-Cell, Diffuse
干预: Rituximab
地点: 未列出
申办方: Xia Yi

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07178457

Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

AI 简述这是一项III期试验，研究Brentuximab Vedotin作为异基因移植后维持治疗用于皮肤T细胞淋巴瘤。

?

适用疾病: Cutaneous T Cell Lymphoma (CTCL)；Brentuximab Vedotin
干预: Brentuximab Vedotin (Bv)，Placebo
地点: 未列出
申办方: Assistance Publique - Hôpitaux de Paris

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07516093

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

AI 简述这是一项III期试验，比较NX-5948与Pirtobrutinib用于复发/难治性CLL/SLL。

?

适用疾病: B-cell Lymphoma；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: NX-5948，Pirtobrutinib
地点: 未列出
申办方: Nurix Therapeutics, Inc.

即将招募 Phase 2, Phase 3 生物制剂药物手术/操作

ClinicalTrials.gov NCT07572123

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

AI 简述这是一项II/III期试验，评估在化疗和自体干细胞移植后加入维持免疫治疗用于高风险复发/难治霍奇金淋巴瘤。

?

适用疾病: Recurrent Classic Hodgkin Lymphoma；Refractory Classic Hodgkin Lymphoma
干预: 3-Dimensional Conformal Radiation Therapy，Autologous Hematopoietic Stem Cell Transplantation，Biospecimen Collection，Brentuximab Vedotin
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07647432

HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

AI 简述这是一项2/3期试验，研究Elranatamab用于新诊断浆母细胞淋巴瘤合并或不合并HIV。

?

适用疾病: Plasmablastic Lymphoma；Hiv；Consolidation
干预: Elranatamab (Elra)
地点: 未列出
申办方: University of Illinois at Chicago

暂时不招募 Phase 2

NCI NCT01880567 / NCI-2013-01304

Ibrutinib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or Older Patients with Newly Diagnosed Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Ibrutinib联合Rituximab用于套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma；Recurrent Mantle Cell Lymphoma；Refractory Mantle Cell Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT02117336 / NCI-2014-01869

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

AI 简述这是一项1期试验，研究复发/难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤，在美国开展。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: Piramal Enterprises Limited

暂时不招募 Phase 2

NCI NCT02446457 / NCI-2015-01307

Rituximab and Pembrolizumab with or without Lenalidomide in Treating Patients with Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究Rituximab和Pembrolizumab联合或不联合Lenalidomide用于复发滤泡性淋巴瘤和弥漫大B细胞淋巴瘤。

?

适用疾病: Recurrent Grade 3a Follicular Lymphoma；Recurrent Grade 1 Follicular Lymphoma；Recurrent Grade 2 Follicular Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT02629809 / NCI-2016-00016

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究伊布替尼联合氟达拉滨、环磷酰胺和奥妥珠单抗用于慢性淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT02756897 / NCI-2016-00797

Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Venetoclax和Ibrutinib用于慢性或小淋巴细胞白血病。

?

适用疾病: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia (CLL)；Recurrent Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT03581942 / NCI-2018-02477

Copanlisib and Ibrutinib in Treating Patients with Recurrent or Refractory Primary Central Nervous System Lymphoma

AI 简述这是一项I/II期试验，研究Copanlisib联合Ibrutinib用于复发或难治性原发中枢神经系统淋巴瘤。

?

适用疾病: Recurrent Central Nervous System Lymphoma；Refractory Central Nervous System Lymphoma；Primary Central Nervous System Lymphoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

暂时不招募 Phase 1

NCI NCT04301076 / NCI-2020-01535

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATLL)

AI 简述这是一项I期试验，研究来那度胺联合EPOCH化疗用于成人T细胞白血病淋巴瘤。

?

适用疾病: Adult T-Cell Leukemia/Lymphoma；Acute Adult T-Cell Leukemia/Lymphoma；HTLV-1 Infection
干预: 未列出
地点: United States
申办方: Yale University Cancer Center LAO

暂时不招募 Phase 1

NCI NCT04850495 / NCI-2021-01332

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

AI 简述这是一项I期试验，研究Zanubrutinib联合R-PolaCHP用于新诊断的弥漫大B细胞淋巴瘤。

?

适用疾病: Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma；Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma；Transformed Lymphoplasmacytic Lymphoma to Diffuse Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT04855253 / NCI-2021-03799

E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T for the Treatment of Relapsed/Refractory B-Cell Lymphomas

AI 简述这是一项I/II期试验，研究E7777联合CAR-T用于复发/难治性B细胞淋巴瘤，在美国开展。

?

适用疾病: Recurrent Mediastinal Lymphoma；Refractory Mediastinal Lymphoma；Recurrent High-Grade B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

暂时不招募 Phase 1

NCI NCT05052528 / NCI-2021-07396

Fludarabine and Cyclophosphamide with or without Rituximab before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or CNS Lymphoma

AI 简述这是一项I期试验，研究Fludarabine和Cyclophosphamide联合或不联合Rituximab用于CAR-T治疗前的复发难治弥漫大B细胞淋巴瘤或中枢神经系统淋巴瘤。

?

适用疾病: Recurrent Primary Central Nervous System Lymphoma；Refractory Primary Central Nervous System Lymphoma；Recurrent Secondary Central Nervous System Lymphoma
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

暂时不招募 Phase 2

NCI NCT05202782 / NCI-2021-08866

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin’s Lymphoma or Transformed Indolent B-cell Lymphoma

AI 简述这是一项II期试验，研究Zanubrutinib联合CAR T细胞疗法用于复发或难治性侵袭性B细胞非霍奇金淋巴瘤。

?

适用疾病: Large B-Cell Lymphoma with IRF4 Rearrangement；Recurrent Intravascular Large B-Cell Lymphoma；Refractory Intravascular Large B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: Northwestern University

暂时不招募 Phase 1

NCI NCT05081479 / NCI-2021-14331

Acetylcysteine for the Treatment of Patients with Lymphoma Receiving a CD19 CAR T-cell Therapy

AI 简述这是一项I期试验，研究乙酰半胱氨酸用于接受CD19 CAR-T治疗的淋巴瘤患者。

?

适用疾病: Lymphoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT05138458 / NCI-2022-02450

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

AI 简述这是一项I/II期试验，研究MT-101用于CD5+复发/难治T细胞淋巴瘤，在美国开展。

?

适用疾病: Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8；Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
干预: 未列出
地点: United States
申办方: Myeloid Therapeutics

暂时不招募 Phase 2

NCI NCT05337735 / NCI-2022-02841

Vudalimab for the Treatment of Advanced Rare Cancers

AI 简述这是一项II期试验，研究Vudalimab用于多种晚期罕见癌症。在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT05400122 / NCI-2022-07858

Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers

AI 简述这是一项I期试验，研究通用供者NK细胞联合Aldesleukin和Vactosertib用于局部晚期或转移性结直肠癌、胃癌、食管癌及血液肿瘤。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

暂时不招募 Phase 2

NCI NCT05890352 / NCI-2023-02518

A Phase 2 Study Adding the Drugs Tazemetostat or Zanubrutinib to Usual Treatment for People with Large B-Cell Lymphoma that Returned or Did Not Respond to Earlier Treatment

AI 简述这是一项II期试验，研究Tazemetostat或Zanubrutinib联合常规治疗用于复发/难治性大B细胞淋巴瘤，在美国开展。

?

适用疾病: High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements；Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma；Recurrent High-Grade B-Cell Lymphoma
干预: 未列出
地点: United States
申办方: SWOG

暂时不招募 Phase 2

NCI NCT05821088 / NCI-2023-02612

Tafasitamab and Lenalidomide followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma

AI 简述这是一项II期试验，研究Tafasitamab和Lenalidomide续贯Tafasitamab联合ICE用于复发/难治性大B细胞淋巴瘤。

?

适用疾病: Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma；Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma；Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

暂时不招募 Phase 2

NCI NCT05723055 / NCI-2023-02653

Axatilimab in Combination with Nivolumab for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

AI 简述这是一项II期试验，研究Axatilimab联合Nivolumab用于复发或难治性经典型霍奇金淋巴瘤。

?

适用疾病: Recurrent Classical Hodgkin Lymphoma；Refractory Classical Hodgkin Lymphoma
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

暂时不招募 Phase 1

NCI NCT05377827 / NCI-2023-08553

Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Treating Patients with CD7+ Hematologic Cancers

AI 简述这是一项I期试验，研究抗CD7异体CAR-T细胞（WU-CART-007）用于CD7阳性血液肿瘤。

?

适用疾病: Recurrent Mycosis Fungoides and Sezary Syndrome；Refractory Acute Myeloid Leukemia (AML)；Refractory Mycosis Fungoides and Sezary Syndrome
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

暂时不招募 Phase 2

NCI NCT06108232 / NCI-2023-09268

Obinutuzumab and CC-99282 for the Treatment of Patients with Previously Untreated High Tumor Burden Follicular Lymphoma

AI 简述这是一项II期试验，研究Obinutuzumab联合CC-99282用于滤泡性淋巴瘤。

?

适用疾病: Grade 1 Follicular Lymphoma；Stage IV Follicular Lymphoma；Grade 3a Follicular Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT06692452 / NCI-2024-10764

Tazemetostat in Combination with CHOP for Previously Untreated Peripheral T-Cell Lymphoma

AI 简述这是一项II期试验，研究Tazemetostat联合CHOP用于未经治疗的外周T细胞淋巴瘤，在美国开展。

?

适用疾病: Follicular Helper T-Cell Lymphoma；Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

暂时不招募 Phase 2

NCI NCT06557330 / NCI-2025-05198

Measurable Residual Disease Guided De-Intensification of Bendamustine and Rituximab for the Treatment of Indolent Non-Hodgkin Lymphoma

AI 简述这是一项II期试验，研究MRD指导的苯达莫司汀和利妥昔单抗减量用于惰性非霍奇金淋巴瘤。在美国开展。

?

适用疾病: Refractory Marginal Zone Lymphoma；Recurrent Grade 3a Follicular Lymphoma；Refractory Grade 1 Follicular Lymphoma
干预: 未列出
地点: United States
申办方: Fox Chase Cancer Center

暂时不招募 Phase 2

NCI NCT07030699 / NCI-2025-06141

Epcoritamab with Lenalidomide and Tafasitamab for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, ECLAT Trial

AI 简述这是一项2期试验，研究Epcoritamab联合来那度胺及Tafasitamab用于复发或难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Recurrent High-Grade B-Cell Lymphoma；Refractory High-Grade B-Cell Lymphoma；Refractory Grade 3b Follicular Lymphoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

暂时不招募 Phase 1

NCI NCT07285668 / NCI-2025-09022

TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion after Donor Stem Cell Transplant for the Prevention of Relapse in Patients with High-Risk Blood Cancers

AI 简述这是一项I期试验，研究TCRαβ+和CD19+去除的供体淋巴细胞输注用于预防血液癌症复发。

?

适用疾病: Refractory Lymphoma；Recurrent Lymphoma；Refractory Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

暂时不招募 Phase 1

NCI NCT07388563 / NCI-2026-01195

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

AI 简述这是一项I期试验，研究阿扎胞苷和阿巴西普用于复发/难治性T细胞淋巴瘤。在美国开展。

?

适用疾病: Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma；Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified；Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
干预: 未列出
地点: United States
申办方: National Cancer Institute

暂时不招募 Phase 2

NCI NCT07566364 / NCI-2026-03445

Mosunetuzumab in Combination with BTK Inhibitor Therapy for the Treatment of Measurable Residual Disease Positive Chronic Lymphocytic Leukemia

AI 简述这是一项II期试验，研究Mosunetuzumab用于慢性淋巴细胞白血病MRD阳性患者。

?

适用疾病: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma；Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

即将招募 Phase 1 药物

ClinicalTrials.gov NCT04419909

Retreatment With CTL019/CTL119

AI 简述这是一项I期试验，研究CD19靶向自体T细胞(CTL019/CTL119)再治疗用于B细胞淋巴瘤。

?

适用疾病: Lymphoma, B-Cell
干预: CD19 redirected autologous T cells (CTL019 or CTL119 cells)
地点: United States
申办方: University of Pennsylvania

即将招募 EARLY / Phase 1 联合产品

ClinicalTrials.gov NCT05728879

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

AI 简述这是一项早期1期试验，研究APR-TD011喷雾用于皮肤T细胞淋巴瘤，在美国开展。

?

适用疾病: Cutaneous T Cell Lymphoma
干预: APR-TD011 (RLF-TD011)
地点: United States
申办方: Northwestern University

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05779930 / NCI-2026-04623

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

AI 简述这是一项早期I期试验，研究CD19 CAR-T细胞用于复发/难治性CD19阳性急性淋巴细胞白血病和非霍奇金淋巴瘤。在美国开展。

?

适用疾病: Acute Lymphoblastic Leukemia, in Relapse；Non-Hodgkin's Lymphoma, Relapsed；Non-Hodgkin's Lymphoma Refractory
干预: CD19 specific Chimeric Antigen Receptor T Cell
地点: United States
申办方: Nationwide Children's Hospital

即将招募 EARLY / Phase 1 基因治疗

ClinicalTrials.gov NCT06097455

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

AI 简述这是一项早期I期试验，在西班牙研究ARI0003细胞输注用于复发/难治性B细胞侵袭性淋巴瘤。

?

适用疾病: Refractory Non-Hodgkin Lymphoma；Relapsed Non-Hodgkin Lymphoma
干预: ARI0003
地点: Spain
申办方: Fundacion Clinic per a la Recerca Biomédica

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07101328

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

AI 简述这是一项I期试验，研究LY4152199用于既往治疗过的B细胞恶性肿瘤，在美国、澳大利亚等地开展。

?

适用疾病: Lymphoma, Non-Hodgkin；B-cell Lymphoma；Lymphoma, Large B-Cell, Diffuse
干预: LY4152199 - IV
地点: United States，Australia，Canada，Denmark 等 8 个
申办方: Eli Lilly and Company

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07166549

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

AI 简述这是一项I期试验，在Switzerland开展，研究双特异性CAR T细胞用于B细胞恶性肿瘤。

?

适用疾病: B Cell Malignancies；B-cell Leukemia；B Cell Lymphoma
干预: Experimental Intervention
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07225439

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

AI 简述这是一项I期试验，研究Rituximab联合Tafasitamab及异体NK细胞用于复发/难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Non Hodgkin Lymphoma；B-cell Non Hodgkin Lymphoma；Diffuse Large B Cell Lymphoma
干预: Allogeneic NK cells，Rituximab，Tafasitamab，Interleukin-2
地点: United States
申办方: Paolo Caimi, MD

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07297160

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

AI 简述这是一项I期试验，研究CAR-T细胞疗法用于CD70阳性淋巴瘤、骨髓瘤及实体瘤。

?

适用疾病: Lymphoma；Myeloma；Solid Tumors
干预: Dose Level -1，Dose Level 1 (starting dose level)，Dose Level 2，Dose Level 3
地点: United States
申办方: Baylor College of Medicine

即将招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT07332507 / NCI-2025-09714

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

AI 简述这是一项I期试验，研究Teclistamab用于复发性浆母细胞淋巴瘤。

?

适用疾病: Recurrent Plasmablastic Lymphoma；Refractory Plasmablastic Lymphoma
干预: Biospecimen Collection，Computed Tomography，Positron Emission Tomography，Teclistamab
地点: United States
申办方: National Cancer Institute (NCI)

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07335328

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

AI 简述这是一项I期试验，研究双特异性抗CD20/CD19 CAR-T细胞用于复发/难治B细胞非霍奇金淋巴瘤。

?

适用疾病: B-cell Non Hodgkin Lymphoma
干预: 1 X 10^6 cells/kg，2.5 X 10^6 cells/kg，Dose expansion: The maximum tolerated dose of CAR-T cells
地点: United States
申办方: Medical College of Wisconsin

即将招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07443137 / NCI-2026-03512

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

AI 简述这是一项I期试验，研究Rapcabtagene autoleucel用于大B细胞淋巴瘤，在美国开展。

?

适用疾病: Large-cell Lymphoma；Double-Hit Lymphoma；Triple-Hit Lymphoma
干预: Rapcabtagene autoleucel (YTB323)
地点: United States
申办方: Stanford University

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07518329

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

AI 简述这是一项I期试验，研究ALA-101用于CD19阳性非霍奇金淋巴瘤和白血病，在澳大利亚开展。

?

适用疾病: Non Hodgkin Lymphoma (NHL)；Leukaemia
干预: ALA-101
地点: Australia
申办方: Arovella Therapeutics Ltd

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07608731

Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas

AI 简述这是一项I期试验，研究Golcadomide联合培美曲塞、利妥昔单抗和地塞米松用于复发难治性中枢神经系统淋巴瘤。在美国开展。

?

适用疾病: Large B-cell Lymphoma；Central Nervous System Lymphoma
干预: Golcadomide，Pemetrexed，Rituximab，Dexamethasone
地点: United States
申办方: Allison Winter

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07638982

Axatilimab + CAR-T for High-Risk Lymphoma

AI 简述这是一项I期试验，研究Axatilimab联合CAR-T用于高危淋巴瘤，在美国开展。

?

适用疾病: Diffuse Large B Cell Lymphoma (DLBCL)；Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma；High-grade B-cell Lymphoma (HGBCL)
干预: Axatilimab
地点: United States
申办方: Northside Hospital, Inc.

即将招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov NCT07676877

Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

AI 简述这是一项1期试验，在美国研究低剂量全身照射联合Tisagenlecleucel用于复发难治大B细胞淋巴瘤。

?

适用疾病: Recurrent Diffuse Large B-Cell Lymphoma；Refractory Diffuse Large B-Cell Lymphoma
干预: Biospecimen Collection，Computed Tomography，Cyclophosphamide，Fludarabine
地点: United States
申办方: Nathan Denlinger

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07679919

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

AI 简述这是一项I期试验，研究BAFF CAR-T细胞用于难治性血液恶性肿瘤。在美国开展。

?

适用疾病: Non-Hodgkin Lymphoma；Chronic Lymphocytic Leukemia；Hairy Cell Leukemia
干预: LMY-922
地点: United States
申办方: Luminary Therapeutics

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04856137

A Phase I/II Study of Diffuse Large B-cell Lymphoma

AI 简述这是一项I/II期试验，研究Rituximab、Paclitaxel和Ruxolitinib用于难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Refractory Diffuse Large B-cell Lymphoma
干预: Rituximab Paclitaxel Ruxolitinib
地点: 未列出
申办方: National Health Research Institutes, Taiwan

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05055791

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

AI 简述这是一项I/II期试验，研究SYHX1903用于复发难治血液系统恶性肿瘤。

?

适用疾病: Acute Myeloid Leukemia；Lymphoma；Multiple Myeloma
干预: SYHX1903
地点: 未列出
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05280626

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

AI 简述这是一项II期试验，研究信迪利单抗联合R-CHOP用于p53突变且PD-L1表达的弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma
干预: Sintilimab，Rituximab
地点: 未列出
申办方: Innovent Biologics (Suzhou) Co. Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05627115

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

AI 简述这是一项II期试验，研究Tislelizumab联合AVD和放疗用于老年霍奇金淋巴瘤一线治疗。

?

适用疾病: Hodgkin Lymphoma
干预: Tislelizumab, AVD, Radiotherapy
地点: 未列出
申办方: University College, London

即将招募 Phase 4 药物

ClinicalTrials.gov NCT05814848

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

AI 简述这是一项IV期试验，研究Relmacabtagene Autoleucel再次输注用于复发/难治性B细胞淋巴瘤。

?

适用疾病: Relapsed or Refractory B-cell Lymphoma
干预: Relmacabtagene Autoleucel Injection
地点: 未列出
申办方: Changhai Hospital

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT05979857

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

AI 简述这是一项早期I期试验，研究SP-3164用于复发或难治性非霍奇金淋巴瘤。

?

适用疾病: Lymphoma, Non-Hodgkin's, Adult
干预: SP-3164
地点: 未列出
申办方: Salarius Pharmaceuticals, LLC

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06385522

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

AI 简述这是一项I期试验，研究BITR2101用于非霍奇金淋巴瘤，特别是皮肤T细胞淋巴瘤。

?

适用疾病: NHL；Cutaneous T Cell Lymphoma；Peripheral T-cell Lymphoma
干预: BITR2101
地点: 未列出
申办方: Boston Immune Technologies and Therapeutics

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06441097

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

AI 简述这是一项II期试验，比较Pola-RCHP-X与Pola-RCHP用于未经治疗的弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma
干预: Polatuzumab vedotin，Rituximab，Cyclophosphamide，Doxorubicin
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06573138

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

AI 简述这是一项II期试验，研究Selinexor、抗PD-1抗体联合Golidocitinib用于复发/难治性结外NK/T细胞淋巴瘤。

?

适用疾病: Lymphoma, Extranodal NK-T-Cell
干预: Selinexor, anti-PD-1 antibody plus Golidocitinib
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06573151

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

AI 简述这是一项II期试验，研究Selinexor、抗PD-1抗体联合P-GemOx方案用于复发/难治性NK/T细胞淋巴瘤。

?

适用疾病: Lymphoma
干预: Selinexor, anti-PD-1 antibody and P-GemOx
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06652139

Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive

AI 简述这是一项II期试验，研究塞利尼索联合BEAM方案用于自体干细胞移植治疗MYC阳性复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma
干预: selinexor combined with BEAM regimen，BEAM regimen
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06652165

Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

AI 简述这是一项II期试验，研究zanubrutinib联合BEAM用于复发难治性弥漫大B细胞淋巴瘤的自体干细胞移植。

?

适用疾病: DLBCL
干预: zanubrutinib combined with BEAM，BEAM
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06656221

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

AI 简述这是一项II期试验，研究Glofitamab联合Orelabrutinib和Bortezomib用于高危套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma
干预: Obinutuzumab，Glofitamab，Bortezomib，Orelabrutinib
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06669143

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

AI 简述这是一项II期试验，研究Zanubrutinib联合Lenalidomide维持治疗初治弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma
干预: Zanubrutinib，Lenalidomide
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06701344

Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

AI 简述这是一项II期试验，研究Go-CHOP方案用于初治肠病相关T细胞淋巴瘤。

?

适用疾病: Enteropathy Associated T Cell Lymphoma
干预: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)，Golidocitinib
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06702605

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

AI 简述这是一项II期试验，研究XNW5004片用于复发/难治性外周T细胞淋巴瘤。

?

适用疾病: Relapsed/Refractory Peripheral T Cell Lymphoma
干预: XNW5004 tablets
地点: 未列出
申办方: Evopoint Biosciences Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06748521

Dynamic CtDNA-guided Targeted Therapy in DLBCL

AI 简述这是一项II期试验，研究动态ctDNA指导下靶向治疗用于弥漫大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B Cell Lymphoma (DLBCL)
干预: R-CHOP + X
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 4 药物

ClinicalTrials.gov NCT06761911

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

AI 简述这是一项IV期试验，研究Brentuximab Vedotin联合其他药物治疗复发/难治霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma (Category)
干预: Brentuximab Vedotin (Bv)，Sintilimab，Tislelizumab，Bendamustine
地点: 未列出
申办方: Xiuhua Sun

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06901999

Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients

AI 简述这是一项II期试验，研究甲氨蝶呤或塞替派联合R-CHOP和奥布替尼用于中枢神经系统淋巴瘤。

?

适用疾病: CNS Lymphoma
干预: Orelabrutinib，RCHOP+MTX or Thiotepa
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06916416

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

AI 简述这是一项II期试验，研究帕博利珠单抗联合放疗用于早期经典霍奇金淋巴瘤。

?

适用疾病: Classical Hodgkin Lymphoma
干预: Pembrolizumab
地点: 未列出
申办方: University of Cologne

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06919679

Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma

AI 简述这是一项II期试验，研究BrECADD用于HIV阳性的晚期经典霍奇金淋巴瘤。

?

适用疾病: Hodgkin Lymphoma (Category)
干预: BrECADD
地点: 未列出
申办方: University of Cologne

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06921044

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

AI 简述这是一项II期试验，研究R-mini-MCOP用于老年初治弥漫性大B细胞淋巴瘤。

?

适用疾病: Diffuse Large B-Cell Lymphoma
干预: R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone
地点: 未列出
申办方: Xiaohui He

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06979076

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

AI 简述这是一项I/II期试验，研究选择性PKC-β抑制剂MS-553用于复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

?

适用疾病: CLL (Chronic Lymphocytic Leukemia)；SLL (Small Lymphocytic Lymphoma)
干预: MS-553, DS1，MS-553, DS2
地点: 未列出
申办方: MingSight Pharmaceuticals, Inc

即将招募阶段未标明生物制剂

ClinicalTrials.gov NCT07008872

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

AI 简述这是一项试验，研究CD7 CAR-T细胞疗法用于CD7阳性复发/难治T细胞淋巴瘤/急性白血病。

?

适用疾病: CD7+ Lymphoma；CD7+ Acute Leukemia
干预: CD7 CART
地点: 未列出
申办方: Qi deng

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07081607

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

AI 简述这是一项II期试验，研究golidocitinib联合azacitidine和chidamide用于外周T细胞淋巴瘤。

?

适用疾病: Peripheral T-Cell Lymphoma, Not Classified
干预: golidocitinib with azacytidine and chidamide
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07107204

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

AI 简述这是一项I/II期试验，研究BT02用于复发难治血液恶性肿瘤（白血病、淋巴瘤等）。

?

适用疾病: Relapsed or Refractory Hematologic Malignancies；Leukemia；Lymphoma
干预: BT02
地点: 未列出
申办方: Biotroy Therapeutics

即将招募 Phase 1, Phase 2 器械药物

ClinicalTrials.gov NCT07175415

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

AI 简述这是一项I/II期试验，研究Capivasertib联合Venetoclax和地塞米松用于复发难治儿童血液肿瘤。

?

适用疾病: Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
干预: Capivasertib，Venetoclax，Dexamethasone，Intrathecal chemotherapy
地点: 未列出
申办方: Princess Maxima Center for Pediatric Oncology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07180771

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

AI 简述这是一项II期试验，研究Bosmolisib (BR101801)用于复发/难治性外周T细胞淋巴瘤。

?

适用疾病: Peripheral T Cell Lymphoma
干预: BR101801
地点: 未列出
申办方: Boryung Pharmaceutical Co., Ltd

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07191249

A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

AI 简述这是一项II期试验，研究皮下注射Mosunetuzumab用于既往未经治疗的低肿瘤负荷滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphoma
干预: Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.
地点: 未列出
申办方: Tel-Aviv Sourasky Medical Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07209163

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

AI 简述这是一项I/II期试验，研究Tazemetostat联合方案用于复发/难治外周T细胞淋巴瘤。

?

适用疾病: Peripheral T Cell Lymphoma
干预: Tazemetostat，Linperlisib，Golidocitinib
地点: 未列出
申办方: Ruijin Hospital

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07213882

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

AI 简述这是一项早期I期试验，研究DT-7012用于复发难治性皮肤T细胞淋巴瘤。

?

适用疾病: Cutaneous T Cell Lymphoma (CTCL)；Mycosis Fungoides；Sezary Syndrome
干预: DT-7012
地点: 未列出
申办方: Assistance Publique - Hôpitaux de Paris

即将招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07244380

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

AI 简述这是一项2期试验，研究S101自体抗CD7 CAR-T细胞用于复发难治T淋巴母细胞白血病/淋巴瘤。

?

适用疾病: T Lymphoblastic Leukemia/Lymphoma
干预: Autologous CD7-targeting CAR T cells
地点: 未列出
申办方: Hebei Senlang Biotechnology Inc., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07279584

Golidocitinib Combined With GemOx in RR PTCL

AI 简述这是一项2期试验，研究戈利昔替尼联合GemOx用于复发难治外周T细胞淋巴瘤。

?

适用疾病: Peripheral T-cell Lymphomas (PTCL)
干预: golidocitinib，GEMOX
地点: 未列出
申办方: Ruijin Hospital

即将招募阶段未标明药物

ClinicalTrials.gov NCT07299331

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

AI 简述这是一项试验，研究泽布替尼、利妥昔单抗和来那度胺一线用于边缘区淋巴瘤。

?

适用疾病: Marginal Zone Lymphoma(MZL)
干预: Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma，Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma
地点: 未列出
申办方: Zhengzhou University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07326371

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

AI 简述这是一项II期试验，研究Glofitamab联合CAR-T治疗用于复发/难治性弥漫大B细胞淋巴瘤。

?

适用疾病: DLBCL - Diffuse Large B Cell Lymphoma
干预: Glofitamab，Obinutuzumab，Axicabtagene Ciloleucel，Relmacabtagene autoleucel (relma-cel)
地点: 未列出
申办方: Ruijin Hospital

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT07335094

A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy

AI 简述这是一项早期I期试验，研究人源化CD19 CAR-T细胞联合TLR2用于初治B细胞急性淋巴细胞白血病/淋巴瘤。

?

适用疾病: B Lymphoblastic Leukemia/Lymphoma
干预: humanized CD19 CAR-T Cells with TLR2
地点: 未列出
申办方: Zhujiang Hospital

即将招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07360288

Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma

AI 简述这是一项II期试验，研究TC011用于复发或难治性滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphoma (FL)
干预: TC011 single-arm
地点: 未列出
申办方: TICAROS Co., Ltd.

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07383233

CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma

AI 简述这是一项I期试验，研究CD19/BAFF-R体内CAR-T细胞疗法用于复发/难治性B细胞急性白血病或恶性淋巴瘤。

?

适用疾病: Lymphoma；CAR T Cell Therapy；Acute Leukemia
干预: CD19/BAFF-R in vivo CAR-T cell intravenous infusion
地点: 未列出
申办方: Qi deng

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07385989

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

AI 简述这是一项II期试验，研究Golidocitinib联合P-GEMOX和PD-1抑制剂用于初治晚期结外NK/T细胞淋巴瘤。

?

适用疾病: Extranodal NK/T-cell Lymphoma
干预: Golidocitinib in combination with P-GEMOX and PD-1 inhibitor，PD-1 inhibitor in combination with P-GEMOX
地点: 未列出
申办方: WEI XU

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07387848

Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas

AI 简述这是一项II期试验，研究Glofitamab用于复发B细胞淋巴瘤的自体干细胞移植桥接或巩固治疗。

?

适用疾病: Diffuse Large B Cell Lymphoma Refractory
干预: Glofitamab
地点: 未列出
申办方: American University of Beirut Medical Center

即将招募阶段未标明生物制剂

ClinicalTrials.gov NCT07412405

This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R

AI 简述这是一项试验，研究自体抗CD19 CAR-T细胞（ARI-0001）用于复发/难治性CD19+血液恶性肿瘤。

?

适用疾病: Adult B-cell Acute Lymphoblastic Leukemia；Follicular Lymphoma (FL)；Mantle Cell Lymphoma (MCL)
干预: ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T)
地点: 未列出
申办方: GUSTAVO SALGUERO

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07457177

Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

AI 简述这是一项II期试验，研究Golidocitinib联合培门冬酶和PD-1抗体用于晚期结外NK/T细胞淋巴瘤。

?

适用疾病: NK T-Cell Lymphoma
干预: Golidocitinib + Pegaspargase + Anti-PD-1 mAb
地点: 未列出
申办方: LIANG WANG

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT07477366

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

AI 简述这是一项II期试验，研究CD19 t-haNK和N-803联合利妥昔单抗用于复发B细胞非霍奇金淋巴瘤。

?

适用疾病: Relapsed B-Cell Non-Hodgkin Lymphoma
干预: CD19 t-haNK- IV Administration，N-803，rituximab
地点: 未列出
申办方: ImmunityBio, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07505849

ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma

AI 简述这是一项II期试验，比较Zanubrutinib联合R2与R2方案用于新诊断滤泡性淋巴瘤。

?

适用疾病: Follicular Lymphomas
干预: Zanubrutinib+R2，R2
地点: 未列出
申办方: KeshuZhou

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07506668

RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

AI 简述这是一项I/II期试验，研究RN1701注射剂用于复发/难治性B细胞淋巴瘤。

?

适用疾病: Relapsed/Refractory B-cell Lymphoma
干预: RN1701 injection
地点: 未列出
申办方: Affiliated Hospital of Nantong University

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07520006

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

AI 简述这是一项I/II期试验，研究NX-5948联合其他药物用于B细胞恶性肿瘤。

?

适用疾病: B-cell Lymphoma；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预: NX-5948，venetoclax，rituximab，obinutuzumab
地点: 未列出
申办方: Nurix Therapeutics, Inc.

即将招募 EARLY / Phase 1 基因治疗

ClinicalTrials.gov NCT07546630

Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma

AI 简述这是一项早期I期试验，研究CD19/CD20串联双靶CAR-T细胞用于复发难治B细胞淋巴瘤。

?

适用疾病: Relapsed/Refractory B-Cell Lymphoma
干预: CD19/CD20 Tandem Dual CAR-T
地点: 未列出
申办方: Affiliated Hospital to Academy of Military Medical Sciences

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07552324

Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP

AI 简述这是一项II期试验，研究Chidamide和Lisaftoclax联合Pola-R-CHP方案用于双/三打击弥漫大B细胞淋巴瘤。

?

适用疾病: DHL；THL；DLBCL - Diffuse Large B Cell Lymphoma
干预: CL-Pola-R-CHP
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT07569965

Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

AI 简述这是一项II期试验，研究zamtocabtagene autoleucel用于高危套细胞淋巴瘤。

?

适用疾病: Mantle Cell Lymphoma (MCL)
干预: zamtocabtagene autoleucel (MB-CART2019.1)，Cyclophosphamide，Fludarabine
地点: 未列出
申办方: Miltenyi Biomedicine GmbH

即将招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07575893

CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma

AI 简述这是一项I期试验，研究CD30 CAR-T细胞用于低风险复发经典型霍奇金淋巴瘤。

?

适用疾病: Classical Hodgkin Lymphoma
干预: CD30+ CAR T-cells，Bendamustin，Fludarabine
地点: 未列出
申办方: New York Medical College

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT07584850

Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

AI 简述这是一项早期I期试验，研究GI001用于复发或难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: B-Cell Non-Hodgkin Lymphoma
干预: GI001 Injection
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07603479

A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究JL19001单药或联合标准治疗用于晚期实体瘤或复发/难治性B细胞非霍奇金淋巴瘤。

?

适用疾病: Malignancies；Solid Malignant Tumor；NHL (Non-Hodgkin Lymphoma)
干预: JL19001, subcutaneous injection, 1 μg/kg，JL19001, subcutaneous injection, 5 μg/kg，JL19001, subcutaneous injection,10 μg/kg，JL19001, subcutaneous injection,15 μg/kg
地点: 未列出
申办方: Jecho Biopharmaceuticals Co., Ltd.

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07192471

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

AI 简述这是一项I期试验，研究KK2223用于复发或难治性T细胞非霍奇金淋巴瘤。

?

适用疾病: T-cell NHL (PTCL or CTCL)
干预: KK2223
地点: United States，Italy，Spain
申办方: Kyowa Kirin, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06486337

CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma

AI 简述这是一项II期试验，研究CMOP±R用于初治非霍奇金淋巴瘤。

?

适用疾病: NHL
干预: CMOP±R
地点: 未列出
申办方: The First Affiliated Hospital of Soochow University

术语	中文意思	对找临床试验有什么用
DLBCL	弥漫大 B 细胞淋巴瘤，是常见非霍奇金淋巴瘤类型。	很多 CAR-T、双抗和新药试验会专门招 DLBCL。
滤泡性淋巴瘤 / Follicular lymphoma	一种常见惰性 B 细胞淋巴瘤。	搜索时要和 DLBCL 分开，试验条件不同。
霍奇金淋巴瘤 / Hodgkin lymphoma	与非霍奇金淋巴瘤不同的一大类淋巴瘤。	可以找 PD-1、CD30、复发难治相关试验。
Relapsed / refractory	复发或难治，指治疗后复发或对治疗反应不理想。	很多海外血液肿瘤试验会限定 R/R 患者。
CAR-T	一种细胞治疗方式，常见靶点包括 CD19 等。	可以找 CAR-T、cell therapy、CD19 相关试验。
Bispecific antibody	双特异性抗体，常见方向包括 CD20xCD3 等。	复发难治淋巴瘤中常见研究方向。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

淋巴瘤

当前同步到的治疗类试验